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ABSTRACT
DNA gyrase is a lethal bacterial enzyme that is a target of the fluoroquinolones, one
of the best antibiotic classes used in chemotherapy, the only reliable postinfection
option to fight against bacterial infections. However, emergence of resistance has
been being found inevitably leading to more difficulty in the treatment of infections
caused by higher resistance each year. It is therefore important to study further how
some clinical bacteria develop their resistance, especially those with very high
resistance, in order to establish more effective and appropriate ways of preventing
bacterial resistance. Several bacterial isolates from Malaysia and Thailand were
found and tested for their MIC of ciprofloxacin (Cip). Some had very to extremely
high resistance including three Acinetobacter baumanii (MIC of 128 mg/L). GyrA
and parC are homologous genes and are subunits of enzyme gyrase and
topoisomerase IV, respectively. By using the whole cell-directed PCR technique,
magnetic biotin-streptavidin separation (Dynabeads®M-280 Streptavidin) and direct
DNA sequencing, sequence analysis showed that: three Escherichia coli (MIC of 128
mg/L) had two mutations in gyrA (Ser-83-Leu and Asp-87-Tyr) and one mutation in
parC (Ser-83-Ile). Another E. coli (MIC of 32 mg/L) had the same three mutations
except at gyrA 87 the mutation was Asp-87-Asn. Thus Tyr substitution seems to
enhance resistance more than any other mutations. One Citrobacter freundii (MIC of
128 mg/L) had Thr-83-Ile and Asp-87-Tyr; and no mutation in parCs QRDR.
Enterobacter sakazakii (MIC of 32 mg/L) had two mutations in gyrA 's QRDR: Ser-
83-Tyr and Asp-87-Asn, and one mutation in parCs QRDR: Ser-83-Ile. Moreover,
one Moraxella catarrhalis (found in Edinburgh) with high Cip resistant at MIC of
4.0 mg/L had one mutation in gyrA's QRDR: Gly-87-Asn, and its parC s QRDR was
not to be revealed. Mutations in both gyrA's and parCs QRDR at amino acid
residues 83 and 87 are probably the main mechanism of Cip resistance of those
isolates tested. (Amino acid positions appeared above are these equivalent to E.
colVs gyrA.) gyrA's and parC s QRDR of Citrobacter freundii and Enterobacter
sakazakii, and also gyrA's QRDR of Moraxella catarrhalis were revealed perhaps
for the first time. Unique gyrA silent-nucleotide alterations of eight E. coli from
Malaysia and Thailand were found to be common to both sensitive and resistant
isolates at position 438, 456, 483 and 516, which differed from all E. coli published
sequences in GENBANK.
Mutual antagonism between chloramphenicol (Cm) and rifampicin (Rif) against Cip
was examined on E. coli NCTC10418. In response to Cip, E. coli KL16 showed a
convex curve, not the commonly found biphasic. Cip bactericidal activity was much
reduced when the E. coli was exposed to Cm, regardless of how long (0 to 120 min)
the bacteria were subjected to Cm. Cip regained its strongly bactericidal effect on the
cells after Cm had been removed. Rif did not antagonise Cip activity when the cells
were challenged with both Rif and Cip at the same time after a previous 30-min
exposure of the cells to Rif.
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1. INTRODUCTION
Fluoroquinolones are highly potent members of a class of antibacterial agents called
quinolones, new totally synthetic broad-spectrum antibacterial agents developed for
treatment of infections in humans ranging from urinary tract infections to life-
threatening septicaemia. It is the drugs' s remarkable potency and novel mode of
action against many bacterial species that leads to an optimistic view of the potential
for resistance development. Nine to 13 years of clinical use in almost every country
in the world demonstrates the universal acceptance of these drugs, however it also
raises concerns about the development and incidence of resistant strains inevitably
leading to difficulty in the treatment of infections.
In the fight against bacterial diseases, antibiotic therapy is the only reliable
postinfection option. However, the use of antibacterial therapy has almost always led
to the development of bacterial resistance. Fortunately, resistance to 4-quinolones is
still rare in common pathogens with 97 to 100% of strains remaining susceptible
(Acar et. al., 1993). Resistance has been reported in methicillin-susceptible
Staphylococcus aureus, Campylobacter jejuni/coli, Salmonella spp., Shigella spp.
and Escherichia coli (Acar et. al., 1993). The highest incidence of resistance is
observed in Serratia and Acinetobacter spp., and particularly in methicillin-resistant
S. aureus (Acar et. al., 1993).
Wide-scale resistance to 4-quinolones has developed in both non- and pathogens
with the wide and careless use of quinolones; resistance is now a problem and is set
to become a major problem soon. In order to reduce the inevitable emergence of 4-
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quinolone resistance, treatment with these drugs should be carefully controlled. It is
imperative that we use these drugs to their maximum potential so that the
development of resistance is minimized. This means that further studies should be
performed to establish more effective and appropriate ways of preventing bacterial
resistance. The purpose of this thesis is to understand further the action of the
fluoroquinolones, the mechanisms involved in the development of resistance and
then to devise strategies to use these drugs more effectively.
QUINOLONES
4-Quinolones are synthetic antibacterial drugs whose chemical structures are never
found in nature. They are a new class of totally synthetic broad-spectrum
antibacterial agents. They are not strictly-speaking antibiotics but they are now
usually referred to as such. On the basis of their structures and antimicrobial spectra,
quinolones can be separated into two groups (Chu & Shen, 1995): first-generation
quinolones and newer second-generation quinolones.
1. First-generation quinolones include nalidixic acid, oxolinic acid, pipemidic acid,
piromidic acid and cinoxacin. Nalidixic acid, discovered in 1962, was the first
member of the antibacterial quinolones and was found to be active against Gram-
negative bacteria. Nalidixic acid and other members of the first-generation
quinolones are widely considered unattractive for extensive clinical use for a
number of important reasons:(l) moderate activity against Gram-negative
bacteria; (2) lack of activity against Gram-positives and pseudomonads, as well as
anaerobes; (3) low blood levels for the treatment of systemic infections and skin
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infections; (4) side effects produced on the central nervous system, and
gastrointestinal intolerance often found when they are given at high doses to some
patients; (5) bacterial resistance developed fairly rapidly resulting in frequent
failure in the treatment of urinary tract infections either because of the rapid
development of bacterial resistance or because of superinfection with intrinsically
resistant species (Chu & Shen, 1995).
2. Second-generation quinolones (fluoroquinolones) include all those currently in
clinical use: norfloxacin (Koga et. al., 1980), pefloxacin (Gouefforn et. al., 1981),
ciprofloxacin (Wise, Andrews & Edwards, 1983), enoxacin (Matsumoto et. al.,
1984), ofloxacin (Sato et. al., 1982), fleroxacin (Chin, Brittain & Neu, 1986),
lomefloxacin (Hokuriku Pharmaceutical Co., 1986), tosufloxacin (Chu et. al.,
1986; Soejima & Shimada, 1989) and sparfloxacin (Miyamoto et. al., 1990).
The second-generation quinolones are extremely important in present medical
treatment of bacterial infections as these drugs have a far more extensive
antimicrobial spectrum, much higher potency, and more superior pharmacokinetic
profile than the first-generation quinolones. Basically, the difference between these
two quinolones is the addition of fluorine in the second-generation quinolone
chemical structure and, as such, it is widely known as "fluoroquinolone".
Fluoroquinolones are by far the drugs of choice for treatment of infectious diseases
with many advantages over other drugs. (1) There is the apparent lack of plasmid-
borne resistance to the fluoroquinolones. (2) There is no evidence of hydrolysis of
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fluoroquinolones by any bacterial enzymes found so far. (3) Superinfection with
drug-resistant microorganisms has been rare. (4) Few side effects have been reported.
(This is especially true with ciprofloxacin, the use ofwhich has been associated with
mild gastrointestinal side effects.). (5) They possess superior pharmacokinetic
profiles over the first-generation quinolones (for example, higher oral bioavailability,
quick distribution to the tissues and penetration into cells and body fluids, and more
rapid and relatively longer serum half-life over other antibacterial agents.), and they
can be administered both orally and parenterally. Because of their high potency and
efficacy in oral mode of administration, peak serum concentrations are normally
achieved within two hours after oral dosing. With a clinical dosage regimen of 1-2
times daily, their concentrations in serum and tissues are generally sufficiently high
enough above the MIC90 for many Gram-negative and Gram-positive aerobes, giving
good clinical efficacy against simple, serious and chronic bacterial systemic
infections. Thus, fluoroquinolones compare favourably with the third- and fourth-
generation cephalosporins. (6) Furthermore, the majority of resistance mechanisms
found to date are through chromosomal mutation that are less likely to have a major
clinical impact. For these reasons, the fluoroquinolones are accepted in clinical
practice as one of the most useful antibacterial drugs ever used against a good
number ofbacterial infections (Chu & Shen, 1995).
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CHEMICAL STRUCTURE
Quinolones generally consist of a 1-substituted-l,4-dihydro-4-oxopyridine-3-
carboxylic acid moiety combined with an aromatic or heteroaromatic ring fused at 5-
and 6-positions. Four-Quinolone is used as a generic name for the 4-oxo-l,4-
dihydro-quinolone skeleton (Figure 1) (Chu & Shen, 1995). Thus, nalidixic acid is a
8-aza-4-quinolone (Figure 2). Related compounds are oxalic acid and pipemidic acid.
Figure 3 illustrates the use of the Smith method in naming these nine ring skeletons
(Smith, 1984a). Derivatives with an extra ring or rings attached to the basic skeleton
at positions other than two and three are also considered as 4-quinolones (which refer
to both first- and second-generation quinolones). Many clinicians and
microbiologists, however, would prefer to name all of them as quinolones. Because
the newer very potent quinolones possess a fluorine atom at the 6-position, they may
also be referred to as fluoroquinolones : norfloxacin, pefloxacin and ciprofloxacin
etc. (Figure 4) (Chu & Shen, 1995).
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Figure 3 Different ring skeletons of quinolones. An example of an antibacterial











Figure 4 Second-generation quinolones.
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DNA TOPOISOMERASE
Cell division requires topological changes are imposed upon cellular DNA prior to
and during replication and segregation of chromosomes. Interconversion of different
topological forms of DNA is catalysed by (DNA) topoisomerases, a family of
enzymes classified according by their catalytic mechanism of action. The two
predominant topoisomerases have been considered to be I and II. Type I enzymes
introduce transient single stranded breaks into DNA, pass an intact single strand of
DNA through the broken strand, and then re-ligate the break. Type II enzymes, in
contrast, make transient double-stranded breaks into one segment of DNA and pass
an intact duplex through the broken DNA, before resealing the break.
Topoisomerases are ubiquitious enzymes charged with the task of resolving
topological problems which arise during the various processes ofDNA metabolism,
including transcription, recombination, replication and chromosome partitioning
during cell division (Austin & Fisher, 1990; Gasser et. al., 1992; Osheroff et. al.,
1991; Sternglanz, 1989; Wang, 1985). As a result of performing this vital role,
topoisomerase action is necessary for the viability of all organisms from unicellular
bacteria to humans.
Cellular functions i.e. DNA replication, transcription from many promoters,
transposition, and several types of recombination all depend on the appropriate level
of supercoiling being maintained in the cell: the degree of DNA supercoiling is a
major determinant of cellular functions. At the simplest level, supercoiling is a
means of packaging DNA into the relatively small environment of the cell. Negative
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supercoiling may be detrimental to the cell if not properly regulated by
topoisomerases.
The supercoiled state ofDNA is regulated by topoisomerases; therefore the enzymes
are vital to function and viability ofbacterial cells.
E. coli and probably most bacteria contain two type I and two type II topoisomerases.
The two type I enzymes are topoisomerase I and topoisomerase III and they are not
essential for viability (Austin & Fisher, 1990; Sternglanz, 1989; Wang, 1985). The
two essential type II enzymes are DNA gyrase and topoisomerase IV (DiNardo et.
al., 1982; Oram & Fisher, 1992; Pruss et. al., 1982; Raji et. al., 1985).
DNA gyrase, an essential type II DNA topoisomerase found only in bacteria, is the
primary target for quinolone action with DNA topoisomerase IV as the secondary
target in many bacteria (Chu & Shen; 1995; Cozzarelli, 1980; Gellert, 1981; Reece &
Maxwell, 1991). Using a gel-filtration method, the binding of [3H]enoxacin to the
complex formed between pBR322 DNA and serveral mutant gyrase preparations has
been studied recently (Yoshida et. al., 1993). This technique measured tightly-bound
ligands that were not dissociated during the filtration step. The results of this study
favoured the view that quinolone binds tightly only to the enzyme-DNA complex,
and that both A- and B-subunits were involved with the binding (Chu & Shen. 1995).
Fluoroquinolones are relatively more potent against DNA gyrase than topoisomerase
IV, especially in bacterial cells (Zechiedrich et. al., 1994); fluoroquinolones inhibit
the activity of gyrase at concentrations lower than those inhibiting topoisomerase IV
(Hooper, 1995).
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In S. aureus, DNA topoisomerase IV has been proposed as a primary target of
fluoroquinolones according to the result that mutations in QRDR of gyrA were not
present in eight low quinolone-resistant S. aureus while parC mutations Ser-80-Phe
or Ser-80-Tyr had been found in both high and low quinolone-resistant S. aureus
(Ferrero et. al., 1994). This is in agreement with Hooper (1995). Similarly, Campa et.
al. (1997) have proposed that topoisomerase IV is the primary target of ciprofloxacin
in Streptococcus pneumoniae, and DNA gyrase being a secondary one.
Chen et. al.{ 1996) and Heisig (1996) confirmed that GyrA is a specific primary
target of quinolones and topoisomerase IV is a secondary, less sensitive target in E.
coli. This is based on an experiment that mutant CR1 of E. coli with mutations at
gyrA and parC (gene for topoisomerase IV) was able to grow in medium containing
0.5 mg/L ciprofloxacin while mutant GP201 ofE. coli with only gyrA mutation died.
The wildtype died even more quickly (Chen et. al., 1996).
DNA GYRASE
DNA gyrase almost certainly has a general role both in removing supercoils and in
the introduction of negative supercoils into DNA, together with a more specialized
role in removing knots and unlinking catenates generated by recombination (Adams
et. al., 1992).
Several studies indicate that the effects of changes in DNA supercoiling on gene
expression are pervasive. DNA supercoiling can increase, decrease, or leave
unaffected the expression of specific genes. Basically, in the eubacteria, negative
superhelical turns (supercoiling) are introduced into DNA (relaxed and positively
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supercoiled DNA) (Hooper & Wolfson, 1989) by DNA gyrase, and can be removed
by one or more DNA-relaxing topoiosomerases. The enzyme carries out successive
rounds of supercoiling until enough negative supercoils have been introduced to
cause its dissociation. There is thus an upper limit to the degree of supercoiling
which gyrase can achieve. The balance of these activities, possibly modulated also
by the effects of transcription, is responsible for keeping superhelicity in an
acceptable range (Menzel & Gellert, 1994). Gyrase also catalyzes the interconversion
ofmore complex topological forms ofDNA.
DNA gyrase is capable of altering the topological state of DNA in several ways:
DNA replication, recombination, and transcription. Gyrase can supercoil, relax,
unknot, and decatenate closed circular DNA (and reverse these latter two reactions).
The enzyme's unique function is to introduce as well as remove negative
superhelical turns to and from relaxed closed circular DNA. This is achieved at the
expense of ATP hydrolysis (Gellert et. al., 1976a). The gyrase enzyme is associated
with replication forks (Drlica et. al., 1980) and has access to most of the
chromosome (Franco & Drlica, 1988), presumably to maintain appropriate levels of
superhelical tension. These enzymes are believed to operate through a mechanism by
which DNA suffers a double-strand break, and another duplex segment is passed
through the break before it is resealed. Supercoiling tends to be processive, although
the affinity of gyrase for DNA decreases as the negative superhelicity rises. Without
ATP, gyrase relaxes negatively supercoiled DNA, but this reaction is at least 20-fold
slower than supercoiling (Gellert et. al., 1979; Higgnins et. al., 1978). Specific amino
acid changes in the gyrase subunits which are frequently associated with drug
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resistance have been identified (See MECHANISMS OF RESISTANCE TO
QUINOLONES, p.39).
DNA gyrase has a tetrameric structure (A2B2, MW 374,000) composed of two
homodimers of subunits A (MW 97,000) encoded by the gyrA gene, and B (MW
90,000) encoded by the gyrB gene. The enzyme exists in a heart-shaped form, with
the upper portion of the heart formed by the A2 dimer and the B subunit attached
below the A subunit (Drlica, 1984; Kirchtausen, Want & Harrison, 1985). Both
genes are located far apart on the E. coli chromosome; gyrA is at 48 minutes on the
standard E. coli map and gyrB is at 82 minutes. The two genes must therefore be
separately controlled. In many other bacterial species the two genes are nearest
neighbours (Reece & Maxwell, 1991), so close that they are presumably co-
transcribed. To date, the complete nucleotide sequences of these two genes have
been determined in five organisms, namely, E. coli, Neisseria gonorrhoeae, Bacillus
subtilis, Staphylococcus aureus and Borrelia burgdorferi (Drlica & Kreiswirth,
1994).
GvrA subunit
The A subunit is responsible for breaking (cutting) and rejoining (resealing) of
both strands of duplex DNA. Before rejoining, a DNA segment has passed
through the transient breaks. Under the control of gyrase, these reactions occur
throughout relaxed or positive supercoiled DNA, which act as a substrate and
become negative supercoiled DNA- a necessary form of the molecule.
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As an intermediate of the reaction, the 5'-ends of the transiently broken DNA are
covalently linked to a tyrosyl residue on the gyrA protein. The site of covalent
attachment to DNA is Tyr-122 of the A chain (Horowitz & Wang, 1987), and the
quinolone antibiotics that act on GyrA interfere with all reactions involving DNA
strand passage (See MECHANISM OF QUINOLONES : DNA, RNA and protein
syntheses, page 16).
In E. coli it has been shown that the full length protein can be divided into two
separable domains: the C-terminal 300 amino acids is a DNA-binding protein,
whereas the N-terminus is the cutting-rejoining domain. The N-terminal region
alone is sufficient to retain DNA supercoiling activity when it is complexed with
the GyrB protein (Reece & Maxwell, 1991). All sequenced gyrA gene
homologues are 800-900 amino acids long. The highest homology is located
within the N-terminal 400 amino acids, where resistant mutations usually take
place.
GvrB subunit
The B subunit is the site of ATP hydrolysis to drive the process and
conformational changes in the complete enzyme to allow DNA strand passage as
new molecules (Mizuuchi et. al., 1978; Neu, 1994). The B subunit processes




Cozzarelli and his co-workers (Brown & Cozzarelli, 1979; Morrison & Cozzarelli,
1981) proposed a DNA supercoiling model consisting of the following four steps; (i)
binding of gyrase to DNA substrate to stablize a positive DNA node; (ii) cleavage of
DNA at 4-base pair staggered sites at the node, forming covalent linkages between a
tyrosine group on the gyrase A-subunit and the 5'-end of the DNA chain; (iii)
passage of the intact DNA segment at the node through the opened DNA gate, thus
inverting the sign of the node; and (iv) resealing the DNA break and completing a
supercoiling run.
DNA TOPOISOMERASE IV: A POTENTIAL SECONDARY
TARGET
Besides DNA gyrase, there are two other enzymes that share control of bacterial
DNA topology. As DNA gyrase introduces negative supercoiling into chromosomal
DNA (Drlica & Snyder, 1978; Gellert et. al., 1976a, b): DNA topoisomerase I
counters the action of gyrase to prevent the accumulation of excess supercoiling
(DiNardo et. al., 1982; Pruss et. al., 1982): and DNA topoisomerase IV plays a
central role resolving the catenation generated by DNA replication (Adams et. al.,
1992; Peng & Marians, 1993a, b). DNA topoisomerase may be membrane bound
(Kato et. al., 1992); thus, it may differ in their accessibility to the quinolones
(Howard et. al., 1993a; Urios et. al., 1991).
Topoisomerase IV probably plays a very different role in chromosome topology from
gyrase (Chen et. al., 1996). Genetic studies indicate that topoisomerase IV is
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required at the terminal stages ofDNA replication, and mutants in topoisomerase IV
genes are deficient in chromosomal partitioning (Adams et. al., 1992; Peng &
Marians, 1993b).
DNA gyrase and topoisomerase IV have amino acid sequence similarity and similar
double strand passage modes of action. Both are type II enzymes and they share
some similarity in their structures and functions; for example, the active form of the
topoisomerase IV has a tetrameric (ParC)2(ParE)2 structure similar to the A2B2
structure ofDNAgyrase (Peng & Marians, 1993b).
The bacterial topoisomerase IV gene has been found to be highly homologous to the
classic type II gyrase genes: the ParE protein (601 amino acids) is homologous to the
GyrB protein (52% identity), and the ParC protein (730 amino acids) is homologous
to the GyrA protein (41% identity). In both cases amino acid similarities are
scattered throughout the length of the proteins. The homologies, supported by
biochemical evidence, leave no doubt that the ParE and ParC proteins form a
complex that has topo II activity; this activity has been named topo IV (Kato et. al.,
1990). It is interesting to note that in the E. coli parE and parC genes, the amino
acids thought to be responsible for the sensitivity of gyrase to coumarin and
fluoroquinolone antibiotics are conserved in topoisomerase IV. This suggests that the
ParE and ParC proteins might be sensitive to inactivation by these drugs (Huang,
1994). The DNA relaxation activity of purified E. coli topoisomerase IV is indeed
sensitive to novobiocin and oxolinic acid inhibition, confirming the sequence
predictions (Kato et. al., 1992).
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DNA topoisomerase IV as well as DNA gyrase are essential for cell viability and
sensitive to both types of gyrase inhibitors, the coumerins and quinolones (Gellert et.
al., 1977; Hoshino et. al., 1994; Kato & Ikeda, 1993; Peng & Marians, 1993b; Sugino
et. al., 1977).
Ciprofloxacin was able to kill a gyrase (gyrA) mutant resistant to the prototype
quinolone, nalidixic acid, and created complexes on DNA detected by DNA
fragmentation. This lethal effect of ciprofloxacin was eliminated by additional
mutations mapping in parC, one of the two genes encoding topoisomerase IV. Thus,
the fluoroquinolone compounds have another intracellular target DNA topoisomerase
IV. In the absence of the gyrA mutation; however, the parC (CipR) allele did not by
itself confer resistance to ciprofloxacin, indicating that gyrase is the major quinolone
target in E. coli (Chen et. al., 1996).
MECHANISM OF QUINOLONES : DNA, RNA and protein
syntheses
All quinolones rapidly inhibit DNA synthesis (replication) and begin to inhibit RNA
synthesis at a single most bactericidal concentration (See KILLING MECHANISM
OF QUINOLONE, page 22; ANTIBACTERIAL ACTIVITY, page 56). Some
quinolones require RNA synthesis in order to kill bacteria (See MUTUAL
ANTAGONISM, page 19). Protein synthesis is required by all quinolones to kill
bacteria (see below).
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Trapping topoisomerases on DNA has several consequences, the most striking of
which is rapid inhibition of DNA replication (Goss, Deitz & Cook, 1964). In
bacteria, gyrase is clustered along the chromosome and distributed at 100 kbp
intervals. When quinolones are present, complexes of quinolone-gyrase-DNA form
quickly resulting in duplex DNA breakage and no functioning gyrase (Drlica et. ah,
1980; Engle et. ah, 1982). As such, DNA synthesis is inhibited in proportion to the
number of complexes formed and it begins where application forks reach the
complex with fork-associated gyrase. Within a few minutes after the presence of
quinolone, DNA synthesis rates drop below 5% of that observed in untreated
controls. Inhibition is rapid even at low drug concentrations at which inhibition is
only partial and few complexes form (Snyder & Drlica, 1979).
For several quinolone compounds, inhibition of DNA synthesis occurs at the
minimum inhibitory concentration for growth, which has been thought to equal
minimum bactericidal concentration (Chow et. ah, 1988). A study demonstrated that
inhibition ofDNA synthesis is not by itself responsible for the bactericidal effect of
oxolinic acid. Because the drug concentration sufficient to inhibit DNA synthesis by
90% in ten minutes had little effect on survival during a 2.5 hour treatment (Chen et.
ah, 1996).
Quinolone-gyrase-DNA complex formation is not sufficient to kill cells. This result
came from the study by Chen et. ah, (1996): no difference was observed in the size
of DNA fragments generated by treatment of cells with oxolinic acid at 1 mg/L
(sufficient to inhibit DNA synthesis) and 30 mg/L (sufficient to kill) when followed
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by protein denaturation to release DNA ends/breaks constrained in drug-gyrase-DNA
complexes, whose formation parallels inhibition of DNA synthesis with
chromosomal DNA. In the other words, the same number of complexes form at both
concentrations.
Neither complex fomation nor inhibition of DNA synthesis are themselves lethal,
because suppression of protein or RNA synthesis during treatment with bactericidal
concentrations of nalidixic acid prevents loss of colony-forming ability on agar
lacking the drugs (Deitz, Cook & Gross, 1966). Collectively, these observations
indicate that cell death is a consequence ofcellular function(s) induced in response to
the DNA-gyrase-drug interaction (Chen et. al., 1996). There are some data to support
the idea that intracellular release ofDNA ends, not simply formation of quinolone-
gyrase-DNA complexes, accounts for the lethal effect of oxolinic acid. Chen et. al.
(1996) proved that cell death parallels the freedom ofDNA strands to rotate, which is
presumably is due to dissociation of the complexes, causing release of DNA breaks
from constraint by gyrase. Examination of chromosomal DNA extracted from E. coli
indicated that bacteriostatic concentrations of oxolinic acid trap gyrase and block
DNA synthesis without releasing broken DNA from drug-gyrase-DNA complexes.
Release occurred only at high, bactericidal oxolinic acid concentrations (Chen et. al.,
1996). DNA strand breakage may be the more specific cause that triggers some
unknown process that kills cells [See KILLING MECHANISM OF QUINOLONE,
page 22].
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Release of DNA breaks and cell death were both blocked by chloramphenicol,
suggesting that synthesis of additional protein activity is required to free the DNA
ends (Chu & Shen, 1995). Moreover, protein synthesis-independent killing is also
believed to involve in cell death caused by quinolones since rifampicin completely
blocks the lethal effect of ciprofloxacin on a gyrA (NalR) mutant.
The more recently discovered fluoroquinolone compounds, such as ciprofloxacin,
possess an additional mode of killing that does not require ongoing protein synthesis
(Howard et. ah, 1993a, b). Ciprofloxacin at low concentration behaves much like the
less potent oxolinic acid at high concentration, since chloramphenicol was very
effective at blocking the bactericidal action at low concentrations of ciprofloxacin.
Thus, increasing the concentration or potency of a quinolone appears to shift its
mode of action from one requiring protein synthesis to one that does not. It seemed
possible that the second mode of ciprofloxacin action might involve direct
dissociation ofquinolone-gyrase-DNA complexes.
MUTUTAL ANTAGONISM
The use of quinolones drugs together with other drugs of different antimicrobial
classes does not necessarily mean that an improvement will be found in curing
bacterial infections. In fact, some of these drugs antagonise the action of quinolones
and so must not be used clinically together. Considerable attention should therefore
be paid to the possibility of mutual antagonism between some antibacterials and 4-
quinolones. Early studies showed that the activity of nalidixic acid (Smith & Lewin,
1988) and oxolinic acid (Chen et. al., 1996) were antagonized by rifampicin and by
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chloramphenicol. However, the lethal effect of the potent fluoroquinolone
ciprofloxacin is only partially blocked by either rifampicin or the presence of a
nalidixic acid resistance (NalR) allele ofgyrA (Lewin et. al., 1991).
The 4-quinolones that are antagonised to the greatest extent by rifampicin or
chloramphenicol are norfloxacin, oxolinic acid, acrosoxacin, flumequine, pipemidic
acid, cinoxacin, nalidixic acid and piromidic acid. This finding came from the
experiment that employed the RNA synthesis inhibitor, rifampicin which was added,
to produce a final concentration of 160 mg/1, 20 min after the bacteria had been
treated in nutrient broth with each 4-quinolone at its most bactericidal concentration.
It completely abolished their bactericidal effects and changed the response to
bacteriostasis (Smith, 1984a).
The results with ciprofloxacin and ofloxacin were in striking contrast because
rifampicin addition only partially slowed their bactericidal effects. Moreover,
ciprofloxacin and ofloxacin at their most bactericidal concentration more rapidly
killed E. coli (90%, in 19 min) than any of the other 4-quinolones tested (90%, 59
mins in mean) (Smith, 1984b). Rifampicin also has no significant effect on the
activity of the newer fluoquinolone temafloxacin and sparfloxacin, (Smith & Lewin,
1988; Neu, 1991).
Therefore, 4-quinolones can be divided into two groups according their susceptibility
to antagonism by RNA synthesis inhibition.
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1. Group A. Rifampicin-sensitive 4-quinolones: norfloxacin, oxolinic acid,
acrosoxacin, flumequine, pipemidic acid, cinoxacin, nalidixic acid and piromidic
acid.
2. Group B. Rifampicin-insensitive 4-quinolones: ciprofloxacin, ofloxacin,
temafloxacin and sparfloxacin
Group A can cause a secondary inhibition ofRNA synthesis which has mechanism A
(common to all 4-quinolones) which can be abolished by rifampicin addition. Group
B has not only A but mechanism B (unique to ofloxacin and ciprofloxacin) which is
completely resistant to rifampicin antagonism. In other words, group B was not able
to, more or less, cause the secondary inhibition or its bactericidal activity is not as
susceptible to antagonism by RNA synthesis inhibition.
Group B drugs appear to have an additional mode of action. They can kill non-
growing cells, cells in stationary phase, and cells treated with inhibitors of protein
and RNA syntheses (Zeiler, 1985; Lewin et. al., 1990; Eng et. al., 1991). Non-
induced lethality requires higher concentrations of drug than does the induced form
(Lewin et. al., 1991), and it is not exerted by all compounds against all bacteria; for
example, ciprofloxacin, which exhibits non-induced killing of E. coli, does not kill
staphylococci in the presence of chloramphenicol, while ofloxacin does (Lewin &
Smith, 1988). The mechanism of non-induced killing of bacteria is not understood at
present (Drlica & Kreiswirth, 1994).
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Synergy has been noted infrequently; for example for a combination of anti-
Pseudomonas penicillins, anti-Pseudomonas cephalosporins, and imipenem with the
fluoroquinolones against P. aeruginosa (Neu, 1991). Synergy is rarely seen with
aminogylcosides. Combination of fluoroquinolones with clindamycin, erythromycin,
metronidazole, and vancomycin does not affect the activity against aerobic or
anaerobic Gram-positive or Gram-negative bacteria. The activity of the
fluoroquinolones against Enterobacteriaceae is decreased in the presence of
chloramphenicol (Smith & Lewin, 1988).
KILLING MECHANISM OF QUINOLONE
Mechanisms of4-quinolones have been divided into three (Howard, Pinney & Smith,
1994):
Mechanism A: The only mechanism, possessed by the original 4-quinolone nalidixic
acid, requires cellular replication and RNA and protein syntheses, what may result
from the induction of SOS processing. Since mechanism A requires RNA synthesis,
it is inhibited by rifampicin, and since it requires cell division , it is inactive in
washed bacteria suspended in phosphate-buffered saline (PBS), in which cell
division is inhibited.
Mechanism B: It is possessed by ciprofloxacin and ofloxacin, and requires neither
RNA nor protein synthesis and is active against non-dividing bacteria. Mechanism B
is not inhibited by rifampicin, and is effective on cells suspended in PBS (Zeiler &
Grohe, 1984).
22
Mechanism C: It is possesed by ciprofloxacin, ofloxacin and norfloxacin, and kills
non-dividing bacteria, but requires protein and RNA syntheses. Therefore it will
occur in cells suspended in PBS, but is inhibited by rifampicin (Ratcliffe & Smith,
1985).
The presently available information offers only partial insight of the underlying
causes of cell death caused by the topoisomerase-targeting drugs. High-affinity
gyrase-quinolone interaction sites on the chromosome are poorly understood (Drlica
& Kreiswirth, 1994). A major determinant of their cytotoxicity is the conversion of a
latent single- or double-stranded break in a drug-topoisomerase-DNA ternary
complex into an irreversible double stranded DNA break. It is beleived to lead to
DNA relaxation, activation of the SOS response and degradation of DNA. (Herrero
& Moreno, 1986).
Quinolones (at bacteriostatic concentrations and above) trap DNA gyrase on broken
chromosomal DNA and act as a catalytic intermediate. This results in stabilised
DNA-drug-gyrase complexes containing DNA breaks and thus prevents enzyme
turnover, DNA synthesis and cell growth (Gellert et. al., 1977; Sugino et. al., 1977).
Consequently, supercoiling, relaxation, catenation, and decatenation are all inhibited,
but ATP hydrolysis is not appreciably affected. Saturating concentrations of
quinolone result in cleavage of the chromosome into about 50-100 pieces (Bejar &
Bouche, 1984; Snyder & Drlica, 1979), although only a small fraction of the DNA is
cleaved at the 50-100 high-frequency interaction sites (toposites) detected by pulsed-
field gel electrophoresis (Condemine & Smith, 1990).
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The stabilized complex, termed a 'cleavable complex', is believed to trigger a
cellular process leading to cell death (Drlica, 1984; Kreuzer & Cozzarelli, 1990).
This complex has both DNA strands cleaved with a 4-bp stagger and the 5' ends
protruding (Gellert et. al., 1977; Sugino et. al., 1977; Morrison & Cozzarelli, 1979).
The 5'-phosphoryl end at the break is covalently bound to the A subunit (Morrison &
Cozzarelli, 1979). As such, the specific target of the antibacterial quinolone is the A-
subunit ofDNA gyrase (Chu & Shen, 1995).
When purified DNA gyrase and DNA are treated with oxolinic acid and then with
detergents, such as sodium dodecyl sulfate, site-specific breakage of duplex DNA is
observed with one gyrase A subunit attached to the 5' end of each of the two severed
DNA strands. Incubation ofgyrase and DNA in the presence of a quinolone drug and
termination of the reaction with SDS leads to double-stranded cleavage of the DNA
and covalent attachment of the A subunits to the 5'-phosphate groups at the break
sites (Drlica, 1984; Hooper et. al., 1986; Gellert et. al., 1977; Sugino et. al., 1977;
Morrison & Cozzarelli, 1979). Specifically, a phosphate ester is formed between
Tyrl22 of GyrA and the 5'-end of the DNA (Horowitz & Wang, 1987). Thus, it is
thought that quinolones lead to the interruption of the supercoiling cycle at the DNA
breakage-rejoining step.
Although the A sub-unit does appear to bind DNA in the absence of the B sub-unit
(Kirchhausen, Wang & Harrison, 1985), and the B sub-unit is found to have a weak
ATPase activity, the ATPase activity of the gyrase B protein is only fully stimulated
in the presence of the A protein and DNA (Maxwell & Gellert, 1984). Whereas the A
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protein is the target of quinolone drugs, the B protein seems to be the target of both
4-quinolone and coumarin drugs such as novobiocin. Further evidence has been
shown by Yamagishi et. al. (1986) that two quinolone-resistant mutations in the E.
coli gyrB gene have been identified at the DNA sequence level suggesting that both
subunits of gyrase may be a target for quinolone attack. A more specific target of
action of 4-quino tones has been shown to be the A subunits. However, mutations in
gyrB have secondary effects on quinolone interaction mediated via protein-protein
contacts. Other resistant mutations have also been mapped, for example norB, norC,
nficB and cjxB which decrease the expression of the porin outer membrane protein
OmpF (Hirai et. al., 1986; Hooper et. al., 1986, 1989).
The mechanism of inhibition by quinolone on DNA gyrase at the molecular level has
not been elucidated completely. In 1989 Shen and his coworkers proposed the
cooperative quinotone-DNA binding model as illustrated in Figure 5 (Shen et. al.,
1989). This model proposed that the drug binding site is induced during the gate-
opening step of the supercoiling process. The separated short DNA strands between
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Figure 5 Quinolone-DNA co-operative binding model for the inhibition of DNA
gyrase. Quinolone molecules (filled and slashed rectangles at the
centre of the diagram) bind to a gyrase-induced DNA site during the
intermediate gate-opening step of the DNA supercoiling process.
Binding of the drug is through hydrogen-bonding (indicated by dotted
lines) to the unpaired bases. The stacking of the rectangles mimics the
mode of drug self-association shown at the right. The tyrosine-122
residues of the gyraseA-subunits are covalently linked transiently to
the 5'-end of the DNA chain (Horowitz & Wang, 1987) during the
supercoiling catalysis. Subsequent opening of the DNA chains,
between the four-base-pair staggered cuts, results in a locally
denatured DNA bubble which is proposed to be the site for drug
binding. The binding of the drug molecules thus stabilizes the enzyme-
DNA intermediate. When relaxed DNA substrate (represented by the
short DNA segment in the diagram) is used, ATP is required for the
induction of the drug binding site. Dashed curves denote the shape of
the DNA gyrase, a tertrameric toposiomerase composed of two A-
subunits and two B-subunits, as revealed by the electron microscopic
image of theMycobacterium luteus enzyme (Shen et al., 1989).
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the 4-base-pair staggered cuts may form a denatured DNA bubble that is a preferred
site for the drug to bind in a multi-dimensional fashion. Quinolones, with their
simple molecular structure and few functional binding groups, acquire high-binding
affinity via self-association of the drug molecules. Two types of interactions have
been proposed on the basis of nalidixic acid crystal structures: the 71-71 stacking
between the quinolone rings and the tail-to-tail hydrophobic interactions between the
N-l substitution groups (Figure 5, right panel). Such interactions not only enhance
the binding strength but also provide flexible adjustment in fitting the receptor
conformation in the binding pocket.
Quinolones are essentially DNA-targeted drugs. They possess two unique
characteristics at the molecular level: they do not bind to the isolated target enzyme,
and they bind preferentially to single-stranded rather than double-stranded DNA.
Participation of the DNA-bound enzyme in creating the binding site and the
capability of the drug to saturate the binding pocket in a co-operative manner account
for the drug's specficity and superior potency.
It is likely that gyrase A subunit as a primary target to ciprofloxacin is not sensitive
to inhibition of protein synthesis but topoisomerase IV ParC subunit is (Chen et.
al., 1996). This was based on the evidence that, in the presence of 0.5 mg/L
ciprofloxacin, mutant GP201 (gyrA (NalR) mutation) became fully resistant on
treatment with chloramphenicol, and the wildtype was partially protected by
chloramphenicol. Since there was a distinct lag before killing, by ciprofloxacin,
commenced with the gyrA (NalR) mutant strain GP201, the lethal effects associated
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with topoisomerase IV were manifested slowly (Chen et. al., 1996). Introduction of
the lexA-3 allele, which prevents induction of the SOS response, eliminated the lag:
thus, one or more components of the SOS response retard the lethal effects of
ciprofloxacin-topoisomerase IV interactions (Chen et. al., 1996).
Chu and Shen (1995) found that ten fluoroquinolones had MIC values that are
normally one or two orders of magnitude lower than the inhibitory activities against
the purified enzyme. In their experiments, the antibacterial activity and the DNA
gyrase inhibition activity of ten fluoroquinolones had good correlation, with the
antibacterial concentrations on the average about 20-fold lower than the anti-gyrase
concentrations. As such, they concluded that at least three factors may contribute to
this phenomenon: (1) the drug is concentrated in the cell by an active transport
process, (2) a small signal produced at sub-ICso concentration is sufficient and can be
amplified by some unknown cellular process leading to the cell killing, and (3) there
are secondary targets in the cell responsible for the lethality. For each quinolone, one
or more of the above factors may contribute to its bactericidal action against different
bacterial species including resistance mutants (Chu & Shen, 1995).
Factor (1) is unlikely as it would require a specific quinolone concentration
mechanism, which would be paradoxical for a completely synthetic compound.
Factor (2) is more likely-the I50 is an arbitary figure and it is much more likely that
the concentration to inhibit the cell is going to be far lower than the I50, when half the
action of the enzyme is annihilated.
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SELECTIVITY FOR BACTERIA, NOT FOR HUMANS
Quinolones have toxic effects on bacterial DNA gyrase and topoisomerase IV, but
not on human DNA topoisomerases. This selectively is because there are
fundamental differences as to how their DNA is organized. Bacterial chromosome is
not bounded by a nuclear envelope as is the case in humans. In the human cell, the
eucaryotic nucleus has 46 separate chromosomes. Each chromosome is composed of
chromatin, half of which is small basic proteins, termed histones, which are firmly
associated with an equal weight of DNA. In contrast, bacteria have no histones and
only one chromosome, which is very different in structure from that in humans.
Human cells possess a topoisomerase II which, like bacterial DNA gyrase, can
transiently cut and seal ds DNA by introducing two nicks staggered apart by four
base pairs with the 5' end protruding (Miller, Liu & Englund, 1981; Liu et. al., 1983).
This enzyme, unlike bacterial DNA gyrase, is composed of two subunits (rather than
four) each ofMW 172k. Even more significantly, the mammalian enzyme does not
possess any negative supercoiling activity. Therefore, it is not surprising that the
human enzyme is insusceptible to inhibition by the 4-quinolone antibacterials (Miller
et. al., 1981): quinolones drugs are generally toxic to only bacteria, not to humans.
CLINICAL USE
Fluoroquinolones are found to be highly effective for the treatment of both
complicated and uncomplicated urinary tract infections, as well as for acute and
chronic prostatitis, bacterial gastroenteritis, enteric fevers and selected respiratory
infection (Turnidge, 1995). They are considered as the drug of choice for the
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management of gastrointestinal tract infections. Moreover, they are very effective for
the treatment of acute pyelonephritis due to the fact that high concentrations can be
achieved in both the kidney and urine. They have also been demonstrated to be
highly efficacious for the treatment of sexually-transmitted diseases, Gram-negative
bacillary osteomyelitis, bone and joint and skin and skin-structure infections, and can
be used in the single-dose treatment of uncomplicated gonococcal urethritis and
cervicitis. Multiple doses are needed for the effective treatment of genital infections
with Chlamydia trachomatis or Ureaplasma urealyticum and single-dose treatment
for these infections is not recommended. The clinical and bacteriological cure rates
for fluoroquinolone therapy of respiratory tract infections are as high as 90% (Chu &
Shen, 1995).
Pneumonia caused by Streptococcus pneumoniae, and infections caused by
enterococci are not effectively treated with fluoroquinolones with the exception of
sparfloxacin and tosufloxacin, owing to their less potent activity in vitro against these
bacteria. Furthermore, fluoroquinolone have limited activities against a number of
clinically-important Gram-positive bacteria such as Streptoccocus pyogenes and,
particularly, methicillin-resistant S. aureus and P. aeruginosa (Blumberg et. al.,
1991; Parry et. al., 1989). For pelvic inflammatory disease, fluoroquinolones (with
the possible exception of tosufloxacin and sparfloxacin) should not be used as a
single agent for the treament of this kind of infection (Chu & Shen, 1995).
Among fluoroquinolones, ciprofloxacin was shown by Smith (1986) that it stands out
clearly as the most active antibiotic not only because of its average minimum
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inhibitory concentration (MIC) against 21 mutants which was as little as 0.22 mg/L,
but also because the mutant most resistant to it was inhibited by 0.5 mg/L which is
well within its peak serum level of about 3 mg/L following a 0.5 g oral dose (Hooper
& Wolfson, 1985).
Nalidixic acid and similar first-generation quinolones are clinically used principally
for the treatment of two types of infection: in developed countries, treatment of lower
urinary tract infection; in developing countries, treatment of bacterial diarrhoeas
(Turnidge, 1995).
ANTIMICROBIAL SPECTRUM
Fluoroquinolones are highly effective in curing many types of bacterial infections.
Therefore, many bacterial diseases that were difficult to treat with the first-
generation quinolones, and even other classes of antibacterial drugs, have been easily
controlled with fluoroquinolones.
Among the commercially-available quinolones whose in vitro activity are various,
ciprofloxacin is the most active agent (Barry, 1990). Tosufloxacin has activity which
is quite similar to that of ciprofloxacin, and a compound which does not yet have a
name, OPC-17116, has activity very similar to that of ciprofloxacin against the
Enterobacteriaceae (Espinoza et. al., 1988; Neu et. al., 1992). Among the quinolones
used clinically, only tosufloxacin and sparfloxacin possess reasonable activity
against anaerobes. In general, norfloxacin, ofloxacin, lomefloxacin, and fleroxacin
have bery similar antimicrobial profiles, whereas sparfloxacin, tosufloxacin, and
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ciprofloxacin are more active agents (Chin et. al., 1991). Susceptibility for
enterobacterial organisms usually differs little from one agent to another by, at most,
one- or two-fold dilutions.
All of the commercially available fluoroquinolones have excellent activity in vitro
encompassing not only Gram-negative aerobes but also many Gram-positive aerobes
as well as some anaerobes. Inherently, fluoroquinolone-sensitive bacteria comprise
the majority of the Enterobacteriaceae causing not only urinary or gastrointestinal
diseases but also respiratory, skin structure, and bone and joint infections. These
organisms are Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Serratia
marcescens, Salmonella spp., Shigella spp., and Campylobacter spp. The antibiotics
also have superior activity against fastidious Gram-negative species such as
Haemophilus influenzae and other Haemophilus species, Neisseria gonorrhoeae,
Neisseria meningitidis, and Moraxella (Branhamella) catarrhalis (Barry, 1990;
Eliopoulos & Eliopoulos, 1989; Neu, 1989).
In 1988 it would have been possible to state that virtually 99% of members of the
aforementioned organisms would have been susceptible to <2 mg/L. However, by
1991 resistance was seen among Klebsiella species, Enterobacter species, Serratia
marcescens, and occasional Providencia species. Nonetheless, currently 90% of
community isolates of Enterobacteriaceae would be inhibited by concentrations of >
2 mg/L (Neu, 1994).
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Fluoroquinolones have good activity against Gram-positive bacteria: Staphylococcus
aureus and many of the coagulase-negative staphylococci (Barry, 1990; Eliopoulos
& Eliopoulos, 1989; Neu, 1992). These include Staphylococcus epidermidis,
Staphylococcus haemolyticus, and the urinary pathogen Staphylococcus
saprophyticus. In the 1980s the MICs of fluoroquinolones against staphylococci,
including methicillin-resistant staphylococci, ranged between 0.25 and 2 mg/L.
Unfortunately, since 1989 methicillin-resistant S. aureus resistant to
fluoroquinolones have been encountered throughout the world (Blumberg et. al.,
1991; Kaatz et. al., 1991; Isaacs et. al., 1988; Maple et. al., 1989; Schaeffer, 1989;
Shalit et. al., 1989). These strains have minimum inhibitory concentrations (MICs) in
the range of 4-32 mg/L. Compounds such as tosufloxacin and sparfloxacin inhibit
staphylococci at lower concentrations (i.e., 0.12 mg/L) and will inhibit a number of
the methicillin-resistant S. aureus (MRSA) resistant to ciprofloxacin at
concentrations of 1 mg/L (Chin et. al., 1991). Although many streptococci have high
MICs, most staphylococci, including methicillin-resistant isolates, are susceptible. In
addition, fluoroquinolones are able to kill beta-lactamase-containing bacteria, and
those resistant to aminoglycosides. Fluoroquinolones are also active against
Mycobacterium tuberculosis with sparfloxacin the most active agent (Neu et. al.,
1992). Fluoroquinolones, in general, inhibit P. aeruginosa at concentrations that are
achievable in urine. Ciprofloxacin has been the most active agent, and prior to 1988
it inhibited 90% ofP. aeruginosa at concentrations of <1 mg/L. In recent years many
P. aeruginosa isolates have ciprofloxacin MICs in the range of 2-8 mg/L (Neu,
1994). Of the common genital pathogens, fluoroquinolones are very active against
Neisseria gonorrhoeae and Haemophilus ducreyi, but are only moderately active
33
against mycoplasmas, ureaplasmas and chlamydiae. They are found to have activity
against Rickettsia conovic, M. tuberculosis and M. leprae, as well as M. avium (Neu,
1994).
Ciprofloxacin is a new fluoroquinolones that is highly active against a broad array of
microbial pathogens. MICs of ciprofloxacin are generally below 0.5 mg/L for
Hemophilus, Neisseria, and Enterobacteriaceae and are 1.0 mg/L or less for many
non-fermentative Gram-negative bacteria. Most staphylococci, including strains
resistant to methicillin, are inhibitied by 1.0 mg/L or less of ciprofloxacin, whereas
streptococci are somewhat less susceptible. Obligate anaerobes are generally not
susceptible to ciprofloxacin at concentrations below 1.0 mg/L. Factors diminishing
the in vitro activity of ciprofloxacin include acidic pH, high levels of magnesium
ions, and an inoculum size of 107 CFU/ml or greater. Table 1 shows the in vitro
activities ofciprofloxacin against Gram-positive bacteria.
34
Table 1 The in vitro activities of ciprofloxacin against Gram-positive bacteria.
Bacteria (Numbers of strains) MIC (mg/L)
Staph, epidermidis 20) 0.03-0.5
Staph, aureus 20) 0.12-1.0
Strep, pyogenes 20) 0.25-2.0
Strep, pneumoniae 20) 0.5-16
Group B streptococci 10) 0.5-2.0
Viridans streptococci 30) 1.0-16.0
Enterococci 20) 0.25-2.0
H. influenzae 20) <0.007-0.03
N. meningitidis 20) <0.007-0.03
N. gonorrhoeae 20) <0.007-0.03
E. coli 10) <0.007-0.05
Shigella spp. 10) <0.007-0.06
Salmonella spp 10) <0.007-0.015
Klebsiella spp. 10) 0.03-0.25
Proteus mirabilis 10) <0.007-0.12
Enterobacter spp. 10) <0.007-0.06
Citrobacter spp. 10) <0.007-0.25
Serratia spp. 10) <0.007-0.12
Providencia stuartii 20) <0.007-0.5
Morganella morganii 30) <0.007-0.015
P. aeruginosa 20) 0.06-8.0
Other non-fermenters 27) <0.007-1.0
Other non-fermenters (3) 2.0-4.0
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CLINICAL DEVELOPMENT OF RESISTANCE
Resistance is only rarely encountered among common pathogens. In most studies, 97
to 100% of all pathogens are fully susceptible to fluoroquinolones (Goldstein &
Acar, 1995). Nevertheless, a clinical resistant clone may be selected during therapy
and cause clinical failure. It may or may not disseminate, depending on
epidemiological conditions (Goldstein & Acar, 1995). However, with the extensive
general use worldwide of the fluoroquinolones, resistance is now being seen in
Enterobacteriaceae, including E. coli and Klebsiella species. Resistance to
fluoroquinolones in the clinical setting has been seen principally with methicillin-
resistant S. aureus and P. aeruginosa (Blumberg et. al., 1991; Parry et. al., 1989;
Wolfson & Hooper, 1989). Fluoroquinolone resistance has followed treatment of
cutaneous infections, osteomyelitis, and respiratory infections, particularly in cystic
fibrosis patients (Bosso, 1989; Peterson et. al., 1989; Scully et. al., 1987). In urinary
tract infections resistance has been seen in Serratia marcescens, Ent. spp., and E. coli
as well (Fujimaki et. al., 1989). Ciprofloxacin-resistant MRSA have been noted in
Europe, the United States, and Japan. Studies have indicated that within a short
period up to 80% of MRSA in an institution may be resistant to all of the
fluoroquinolones (Maple et. al., 1989; Soussy et. al., 1991). In 1991, the New York
City Department of Health Phage Typing Laboratory received more than 4000
MRSA isolates from more than 30 different New York City health care facilities.
Almost 90% were ciprofloxacin resistant (Drlica & Kreiswirth, 1994). Some
investigators have reported 95 to 100% fluoroquinolone resistance among MRSA
(Goldstein & Acar, 1995). In addition, methicillin-susceptible S. aureus resistance
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has been increasing. Soussy et. al. (1991) noted that 92% of MRSA had by 1990
developed resistance to pefloxacin, and 22% of methicillin-susceptible S. aureus.
Most reports of the incidence of fluoroquinolone-resistant S. aureus do not
distinguish between methicillin-resistant S. aureus (MRSA) and methicillin-sensitive
S. aureus (MSSA), or indicate the origin of the strain. More than 96% of MRSA
isolated from community-acquired infections are susceptible to fluoroquinolones
(Acar & Francoual, 1990; Acar et. al., 1993; Hoban & Jones, 1993; Jones, 1992;
Jones et.al., 1992; Thornsberry, Brown & Bouchillon, 1992). 38% of P. aeruginosa
and 54% of S. marcescens were found to be resistant to pefloxacin. High-level
resistance to fluoroquinolones (i.e., MIC of ciprofloxacin [Cip] greater than 1 mg/L)
is rarely found among clinical isolates of E. coli (Barry et. al., 1990). In Japan there
has been a 20-30% increase in fluoroquinolone resistance in Gram-negative species
such as P. aeruginosa (Tabuko, 1992). However, a longitudinal study over 5 years in
the United Kingdom reported that 91% of P. aeruginosa remained sensitive to Cip
(Tillotson, Culshaw and O'Keefe, 1992) and in Germany, ofloxacin resistance
amongst Gram-negative species as a whole totalled less than 4% after 7 years's use
(Focht, Kraus & Noser, 1992). Further, despite the free availability of both ethical
and "bootleg" preparations of norfloxacin and ciprofloxacin in South India, where
most of the population harbour trimethoprim-ampicillin- and chloramphenicol-
resistant commensals, there was no cross-resistance to fluoroquinolones amongst
nalidixic acid-resistant aerobic faecal flora (Amyes et. al., 1991).
The most common mechanisms of resistance to fluoroquinolones appears to be
alterations in the DNA gyrase A subunit and, in the case of Gram-negatives,
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alteration of outer membrance proteins and lipopolysaccharide (Cohen et. al., 1989;
Daikos et. al., 1988; Hirai et. al., 1987). It is also the alterations of parC of
topoisomerase IV that is responsible for low and high resistance to fluoroquinolones
in some bacteria (Heisig, 1996).
Studies with E. coli have implicated several genes in resistance to the quinolones.
Those in the gyrase genes are the best studied. The gyrA (nalA) gene encodes the A
subunit of gyrase. Mutations in gyrA are commonly associated with quinolone
resistance in clinical isolates (Nakamura et. al., 1989; Reece & Maxwell, 1991) and
are responsible for high levels of drug resistance (Hane & Wood, 1969; Gellert et.
al., 1977; Sugino et. al., 1977). In E. coli these mutations cluster around Ser-83 in
the N-terminal portion of gyrA gene (Yoshida et. al., 1990a). Such mutants can be
found clinically. In general, changes in the gyrA gene produce an eight- to 16-fold
increase in the concentration of a fluoroquinolone required to inhibit or kill bacteria
(Yoshida et. al., 1990a). In Gram-negative organisms the gyrA gene which confers
susceptibility to fluoroquinolones appears to be dominant over gyrA resistance genes
so that resistance does not occur through genetic transfer of plasmids carrying gyrA
gene (Weidemann, 1990). It does if the recipient becomes a gyrA homozygote by
Hfr-like transfer.
Examination of amino acid changes conferring resistance indicated that in S. aureus
resistance arises from mutation ofgyrA, as it does in E. coli (Sreedharn et. al., 1990),
with amino acid changes occurring in equivalent positions in the proteins. The
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staphylococci probably also exert resistance through restricted uptake of the
quinolones, as has been found with E. coli (nalB and nalD).
Resistance to quinolones can also be caused by changes in permeability. Aoyoma et.
al. (1988) described decreased expression of OmpF due to changes in the nfxB and
cfxB genes which prevented accumulation of fluoroquinolones in cells, as normally
occurs in an energy-dependent fashion. Permeation and DNA gyrase mutations have
been described in P. aeruginosa and Citrobacter freundii (Aoyama et. al., 1988;
Celesk & Robillard, 1989). Two additional loci appear to affect the cell permeability
the quinolones. One is nalB (E. coli map position, 57 minuties), which provides low-
level resistance (Hane & Wood, 1969), and the other is nalD (E. coli map position,
89.8 minutes), which confers a higher level of resistance (Hrebenda et. al., 1985).
The latter locus is sometimes confused with another called nalD, that was
subsequently mapped to gyrB (Yamagishi et. al., 1981, 1986).
Of particular concern is the use of fluoroquinolones in veterinary medicine;
enrofloxacin is used in most European countries in virtually all animals. In Japan, up
to 6 different fluoroquinolones are very widely used in veterinary practice. The US
Food and Drug Adminstration (FDA) is currently preparing some very restrictive
measures for governing the use of fluoroquinolones in animals (FDA, 1994).
MECHANISMS OF RESISTANCE TO QUINOLONES
It was an unusual finding and rather surprising that the frequency of clinical
resistance to the quinolones is much less than that seen with the other major groups
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of antibiotics and chemotherapeutic agents. This mainly results from the fact that no
plasmids have been found to be involved in the 4-quinolone resistance and this
contrasts markedly with resistance to almost all other antibacterial drugs (Turnidge,
1995). Furthermore, fluoroquinolones inhibit transfer of large plasmids (Weiser &
Weidemann, 1987). However, a Japaneses group proposed a plasmid mediated
quinolone resistance in MRSA. Another report confirmed that resistance does not
occur through genetic transfer as to the finding that the gyrA gene which confers
susceptibility to fluoroquinolones appears to be dominant over gyrA resistance genes
in Gram-negative organisms (Weidemann, 1990). Thus, only chromosomal mutation
is responsible for clinical resistance and even that is unusual in the clinical situation;
indeed it is rarely found, because the spontaneous mutation rate is low at 10"9 to 10"12.
Unfortunately, with the extensive general use worldwide of the fluoroquinolones,
resistance has been found clinically, particularly with methicillin-resistant S. aureus
and P. aeruginosa (Blumberg et. al., 1991; Parry, Pazer & Yokna, 1989) and in
Enterobacteriaceae for which these agents had been considered to be a major
breakthrough. An example of careless use of quinolones is the extensive use of
enoxacin, ofloxacin, and lomefloxacin for pneumonia or bacterial bronchitis when S.
pneumoniae is the aetiological agent. This organism responds poorly and continuous
challenge will certainly increase the development of quinolone-resistant strains.
Strains resistant to nalidixic acid are significantly more resistant to the new
fluoroquinolones than are nalidixic acid-susceptible strains. However, most of these
strains remain within the range of susceptibility to fluoroquinolones (Bryskier, 1993;
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Wolfson & Hooper, 1989). In Gram-negative bacilli, fluoroquinolones resistance is
most often a two-stage process, with resistance to previous generations of quinolones
such as nalidixic acid emerging first, conferring higher minimum inhibitory
concentrations for the fluoroquinolones, but usually staying in the susceptible range.
This is followed by further mutations to generate full resistance to the
fluoroquinolones. It is possible that widespread resistance to nalidixic acid was
already established in developing countries, which facilitated the subsequent
emergence of resistance to fluoroquinolones (Hooper & Wolfson, 1990). There is
evidence showing such a trend in the increasing proportion of nalidixic acid-resistant
E. coli that are becoming fluoroquinolone resistant in the Western Pacific region
(Turnidge, 1995).
The mechanisms of quinolone resistance mediated via chromosomal mutations
include (1) alteration of outer membrane proteins and/or changes in
lipopolysaccharide in case of Gram-negatives (Cohen et. al., 1989; Daikos et. al.,
1988; Hirai et. al., 1987), (2) increased efflux of quinolones, (3) changes in
permeability and (4) a decreased affinity ofDNA gyrase (Daniel & Shen, 1995). The
latter is indeed the major cause of resistance giving altered amino acids mostly in a
specific region ofgyrA or parC genes.
GyrA protein is the main target of inactivation by quinolone antibiotics. A change in
a single amino acid in the protein due to mutation in the gyrA gene has been shown
to be associated with resistance (Cullen et. al., 1989; Dimri & Das, 1990; Hopewell
et. ah, 1990; Korten, Wai & Murray, 1994; Tankovic et. al., 1996). These mutations
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are clustered within a narrow region between E. coli nucleotides 382 (Ala-67) and
501 (Gln-106) (Swanberg & Wang, 1987; Yoshida et. al., 1990a, b and c; Hallett &
Maxwell, 1991). Therefore, this region, which is highly conserved in various
bacteria, is designated as the quinolone resistance-determining region (QRDR) of the
gyrA gene (Yoshida et. al., 1990a). This region is in the vicinity of the active site of
the gyrase A subunit, Tyr-122.
Genetic characterisation by determining the DNA sequences of the respective gyrA
genes coding for the A subunit of DNA gyrase of several strains with low-level
resistance to fluoroquinolones (MIC of Cip <1 mg/L) revealed 10 different point
mutations within QRDR at residues Ala-67, Gly-81, Ser-83, Ala-84, Asp-87 and
Gln-106, that can confer fluoroquinolone drug resistance in E. coli (Cullen et. al.,
1989; Hallett & Maxwell, 1991; Oram & Fisher, 1991; Yoshida et. al., 1988;
Yoshida et. al., 1990a). The most critical amino acid changes associated with high
levels of fluoroquinolone resistance are located in residues Ser-83 to Asp-87 of the
E. coli protein (Hallett & Maxwell, 1991; Oram & Fisher, 1991; Yoshida et. al.,
1990a, b and c).
MUTATION AT 83 AND 87
Many mutants isolated from patients have had changes in the E. colVs Ser-83 and
Asp-87 residues in the gyrA gene associated with a significant increase in the
resistance towards all quinolones (Oram & Fisher, 1991; Ruiz et. al., 1995; Yoshida
et. al., 1990a). In general, the changes produce an eight- to 16-fold increase in the
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concentration of a fluoroquinolone required to inhibit or kill bacteria (Yoshida et. al.,
1990a).
In E. coli it has been demonstrated that a single mutation of Ser-83-Ala in the gyrA
gene is sufficient to render the DNA gyrase activity resistant to ciprofloxacin and
nalidixic acid in vitro when the mutant GyrA protein is reconstituted with the wild-
type GyrB protein (Hallett & Maxwell, 1991). The high-level quinolone resistance of
gyrA's Ser-83 E. coli mutants and the weaker binding of quinolone to the complex
formed between DNA and the mutant gyrase compared with that between DNA and
the wild-type gyrase, have prompted the proposal that Ser-83 is a direct quinolone-
binding site mediated through a hydrogen bond (Maxwell, 1992). The commonest
mutation at this position is Ser-83-Leu which is responsible for low-level resistance
to fluoroquinolones (i.e., MIC of ciprofloxacin < 1 mg/L) in both laboratory mutants
and clinical isolates of E. coli (Cullen, 1989; Fisher et. al., 1989; Oram & Fisher,
1991; Piddock, 1995; Yoshida et. al. 1988). Table 2 summarizes reported single
mutations at several position in gyrA's and parCs QRDR ofE. coli, associated with
Cip resistance.
The importance of Ser-83 was more in its position rather than amino acid Ser itself.
The position 83 was proposed by Yonezawa et. al. (1995a), that it is the most
important for the 83rd amino acid residue to be hydrophobic in expressing the
phenotype of quinolone resistance. The researchers also suggested that the hydroxyl
group of Ser does not play a major role in the quinolone-gyrase interaction as to their
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result that Ser-83-Gly, -Asn, -Asp, and -Lys mutations in gyrA expressed sensitivity
to quinolones and the Ser-83-Tyr mutation conferred resistance to quinolone.
Table 2 Single mutations in gyrA's and parC's QRDR of some£ coli with MIC
ofCip (mg/L), and E. colVs gyrA homologous position.
Bacteria Position in E.
coli's gyrAa
Mutationsb MICof Cip Reference
E. coli — GyrA: none 0.0125 Yoshida el. al. (1988)
E. coli 67 GyrA: Ala-67-Ser 0.05 Yoshida el. al. (1988)
E. coli 67 GyrA: Ala-67-Ser 0.2 Yoshida el. al. (1990a)
E. coli 81 GyrA: Gly-81-Cys 0.1 Yoshida el. al. (1990a)
E. coli 81 GyrA: Gly-81-Asp 16 Cambau et. al. (1992)
E. coli 83 GyrA: Ser-83-Trp 0.25 Cullen et. al. (1989)
E. coli 83 GyrA: Ser-83-Trp 0.25 Oram & Fisher (1991)
E. coli 83 GyrA: Ser-83-Trp 0.5 Yoshida et. al. (1990a)
E. coli 83 GyrA: Ser-83-Trp 16 Yoshida el. al. (1990a)
E. coli 83 GyrA: Ser-83-Leu 16 Yoshida el. al. (1988)
E. coli 83 GyrA: Ser-83-Leu 0.5 Yoshida el. al. (1990a)
E. coli 83 GyrA: Ser-83-Leu 0.25 Oram & Fisher (1991)
E. coli 83 GyrA: Ser-83-Ala 4.0 Hallett & Maxwell (1991)
E. coli 84 GyrA: Ala-84-Pro 0.1 Yoshida el. al. (1990a)
E. coli 84 GyrA: Ala-84-Pro 4.0 Yoshida el. al. (1990a)
E. coli 87 GyrA: Asp-87-Asn 0.25 Yoshida el. al. (1990a)
E. coli 87 GyrA: Asp-87-Asn 4.0 Yoshida el. al. (1990a)
E. coli 87 GyrA: Asp-87-Val 0.05 Oram & Fisher (1991)
E. coli 87 GyrA: Asp-87-Tyr 8.0 Heisig el. al. (1993)
E. coli 106 GyrA: Gln-106-His 0.05 Yoshida et. al.( 1988)
E. coli 106 GyrA : Gln-106-Arg 0.05 Hallett & Maxwell (1991)
E. coli - ParC: none 0.39 Kumagai el. al. (1996)
E. coli 81 ParC: Gly-78-Asp 25 Kumagai et. al. (1996)
E. coli 83 ParC: Ser-80-Ile 12.5 Kumagai et. al. (1996)
E. coli 83 ParC: Ser-80-Arg 3.13-12.5 Kumagai el. al. (1996)
E. coli 87 ParC: Glu-84-Lys 12.5 -25 Kumagai el. al. (1996)
3
k Homologous amino acid position in gyrA ofE. coli, where a mutation has occurred.
"GyrA: Ser-83-Leu" indicates amino acid Ser at position 83 ofgyrA is changed to
Leu.
(Note that none of all isolates had both their gyrA and parC QRDR sequenced)
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Asp-87 is the second-most common of the resistance mutations ofE. coli gyrA gene.
The Asp-87-Gly mutation is a novel mutation leading to the loss of a negatively
charged residue in the QRDR of the gyrase A protein. In this respect, it resembles the
Asp-87-Val mutation found in a clinical isolate ofE. coli (Oram & Fisher, 1991) and
on Asp-87-Thr mutation identified in a one-step mutant of E. coli K-12 JM83
selected in vitro. The latter resulted in an increase in the MIC of Cip from 0.015 to
0.25 mg/L. Glu-87-Gly was associated with high-level resistance to Cip (MICs, 8
and 16 mg/L) in Coxiella burnetii (Musso, et. al., 1996).
Yonezawa et. al., (1995b) reported that Asp-87-Ala, -Val, -Phe, -Ser, -Asn and -Lys
mutations in gyrA gene of E. coli conferred resistance to quinolones and observed
that Asp-87-val and Asp-87-Asn were discovered in clinical isolates and laboratory
mutants. The researchers suggested that the carboxyl group of Asp-87 may interact
with the quinolone drug. Table 3 summarises some more examples of bacteria and
their single mutations at 83 and 87 associated with Cip resistance.
Recently, mutations at both Ser-83 and Asp-87 have been shown to occur together
giving rise to a higher MIC of 64 mg/L of ciprofloxacin than in strains with only 1
mutation. Mutations at Ser-83 and Asp-87 is responsible for high-level resistance to
fluoroquinolones (Heisig et. al., 1993; Huang, 1992).
45
Tahle 3 Single mutations in gyrA's QRDR of some bacteria with MIC of








E. faecalis — GyrA: none 8 Tankovic et. at. (1996)
E. faecalis 83 GyrA: Ser-83-Arg 64 Tankovic et. al. (1996)
E. faecalis 83 GyrA: Ser-83-Ile 32-64 Tankovic et. al. (1996)
E. faecalis 87 GyrA: Glu-87-Gly 32-64 Tankovic et. al. (1996)
E. faecalis - GyrA: none 8-16 Korten, Wai & Murray (1994)
E. faecalis 83 GyrA: Ser-83-Arg/Ile 32-128 Korten, Wai & Murray (1994)
E. faecalis 87 GyrA: Glu-87-Lys 32-128 Korten, Wai & Murray (1994)
E. faecium - GyrA: none 32 Korten, Wai & Murray (1994)
E. faecium 83 GyrA: Ser-83-Arg/Ile 32-128 Korten, Wai & Murray (1994)
E. faecium 87 GyrA: Glu-87-Lys 32-128 Korten, Wai & Murray (1994)







Ouabdesselam et. al. (1996)
Ouabdesselam et. a/.(1996)
S. enteritidis 83 GyrA: Ser-80-Phe 0.25-1 Ouabdesselam et. a/.(1996)
S. hadar — GyrA: none 0.03-0.06 Ouabdesselam et. a/.(1996)
S. hadar 83 GyrA: Ser-80-Phe 0.25-1 Ouabdesselam et. al. (1996)
A. baumannii — GyrA: none 1 Vila et. al. (1995)
A. baumannii 83 GyrA: Ser-83-Leu >4 Vila et. al. (1995)
8t
Full name of bacteria: Enterococcus faecalis, Enterococcus faecium,
Salmonella typhimurium, Salmonella enteritidis, Salmonella hadar,
k Acinetobacter baumannii,
Homologous amino acid position in gyrA ofE. coli, where mutations occurred.
"GyrA: Ser-83-Leu" indicates amino acid Ser at position 83 ofgyrA is changed to
Leu.
(Note that none of all isolates had both their gyrA and parC QRDR sequenced.)
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The typical current resistant situation due to chromosomal mutation in gyrA and
parC of E. coli is likely to be that found by Heisig (1996) who stated that "In fifteen
strains of E. coli with MICs of ciprofloxacin (Cip) between 0.015 and 256 mg/L
examined for the presence ofmutations in the QRDR of the gyrA and parC genes, no
mutation was found in a susceptible isolate (MIC of Cip, 0.015 mg/L). Four
moderately resistant strains (MIC of Cip 0.06 to 4 mg/L) carried one gyrA mutation
affecting Ser-83, but in only one of these strains was an additional parC mutation
(Gly-78-Asp) detected. All ten highly resistant strains (MIC of Cip, >4 mg/L)
examined carried two gyrA mutations affecting residues Ser-83 and Asp-87, and at
least one parC mutation. These parC mutations included alterations of Ser-80 to Arg
or lie and Glu-84 to Gly or Lys."
Table 4 summarises double and more mutations at gyrA and parC 83 and 87
detected in E. coli. In the table there were two E. coli with highest ever-reported Cip
MIC of 128 mg/L. One of them was a clinical isolate found in Spain by Vila et. al.
(1996) and had mutations at gyrA and parC 83 and 87. The other E. coli was a
laboratory-produced strain by Heisig et. al. (1993) and had mutations at gyrA 83 and
87 and no report onparC sequence.
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Table 4 Double or more mutations at 83 and 87 in gyrA's andparC's QRDR of








E. coli — GyrA : none 0.007-0.25 Vila et. al., (1996)








































































128 Vila et. al., (1996)
ct
k Homologous amino acid position in gyrA ofE. coli, where a mutation has occurred.
"GyrA: Ser-83-Leu" indicates amino acid Ser at position 83 ofgyrA is changed to
Leu.
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Mutations at Ser-91-Phe in GyrA gene and Ser-87-Ile in parC gene conferred
clinically significant resistance to fluoroquinolones (MIC of ofloxacin, 8.0 mg/L;
MIC of ciprofloxacin, 1.0 mg/L) in N. gonorrhoeae. In wild-type bacteria, amino
acid numbering ofGyrA protein can vary from one bacterium to another and so as to
the type of corresponding amino acid within QRDR; for example, Ala-84 and Asp-
87 in E. coli are Ser-85 and Glu-88, respectively, inS1. aureus.
Huang (1992) reported that there was a correlation between fluoroquinolone
susceptibility and different amino acids at GyrA positions 83, 84, and 87 in wild-type
bacteria of different species. Organisms whose gyrA gene has Ser at position 83, Ala
at position 84, and Asp at position 87 are most sensitive to fluoroquinolone (as is the
case with E. coli). This level can be modulated by different amino acids at these three
positions. The drug sensitivity is increased one order of magnitude by having
residues of Ser at 84 and Glu at 87, as in S. aureus (Huang, 1994). The like amino
acid Thr at position 83 instead of Ser may be sufficient to raise the drug sensitivity
by an order of magnitude, as in the cases of Klebsiella pneumoniae and
Campylobacter jejuni. The intrinsic resistances of C. jejuni and K. pneumoniae are
high at MIC90 of 0.25-0.5 mg/L. The presence of amino acids other than Ser or Thr
at the 83 position appears to render bacteria resistance to fluoroquinolone drugs at
even higher levels (Huang, 1992). The drug resistance to one or two orders of
magnitude above the intrinsic level is again conferred if the wild-type amino acid at
the position equivalent to E. coli GyrA 83 in S. aureus and C. jejuni is changed to a
different amino acid, namely, Ser-83-Ala and Thr-83-Ile, respectively (Sreedharan et.
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al., 1990). In B. burgdorferi Gln(Q) is present at Ser-83, and its MIC90 for Cip is
about 1 mg/L (Huang, 1994). Some other bacteria and mutations at position 83 and
87 assosiated with Cip resistance are summarised in Table 5 and with norfloxacin or
ofloxacin resistance in Table 6.
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Table 5 Mutations in gyrA's and parCs QRDR of some bacteria with MIC of
Cip (mg/L), and E. coifs gyrA homologous position.
Bacteria i
Position





E. cloacae - GyrA: none,
ParC: none
<0.025 Deguchi et. al. (1997b)
E. cloacae 83 GyrA: Ser-83,ParC: none 0.39-3.13 Deguchi et. al. (1997b)
E. cloacae 83 GyrA: Ser-83,ParC: Glu-84 3.13 Deguchi et. al. (1997b)
E. cloacae 83 & 87 GyrA . Ser-83 & Asp-87
- ParC: none
25 Deguchi et. al. (1997b)



































— GyrA : none,
ParC: none <0.015 Deguchi et. al. (1997a)
N. gonorrhoeae 87 GyrA: Asp-95-Asn,ParC: none 0.126 Deguchi et. al. (1997a)
N. gonorrhoeae 83 GyrA: Ser-91-Tyr,ParC: none 0.126 Deguchi et. al. (1997a)
























8.0 Deguchi et. al. (1997a)
ci
k Homologous amino acid position in gyrA ofE. coli, where a mutation is occurred.
"GyrA: Ser-83-Leu" indicates amino acid Ser at position 83 ofgyrA is changed to
Leu.
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Table 6 Mutations in gyrA's QRDR of some bacteria with MIC of norfloxacin



























Tanaka et. al. (1996)
Revel et. al. (1994)
Revel et. al. (1994)
Revel et. al. (1994)
Revel et. al. (1994)
M. smegmatis
83
87 Ofic: 32-64 Revel et. al. (1994)
MRSA — GyrA: none Ofx: <12.5 Tanaka et. al. (1995)
MRSA 83 GyrA: Ser-84-Leu Ofx: 12.5- >50 Tanaka et. al. (1995)
MRSA 87 GyrA: Glu-88-Lys Ofx: 12.5->50 Tanaka et. al. (1995)
MSSA — GyrA: none ON: <12.5 Tanaka et. al. (1995)
MSSA 87 GyrA: Glu-88-Lys Ofx: <12.5 Tanaka et. al. (1995)
Bacteria: Mycobacterium smegmatis,
methicillin-resistant Staphylococcus aureus (MRSA),
k methicillin-susceptible Staphylococcus aureus (MSSA).
Homologous amino acid position in gyrA ofE. coli, where a mutation has
occurred.
Q
"GyrA: Ser-83-Leu" indicates amino acid Ser at position 83 ofgyrA is changed to
^Leu.
MICs ofnorfloxacin (Nor) or ofloxacin (Ofx), mg/L.
MUTATION AT OTHER POSITIONS
Two different one-step mutations in the gyrB gene of gyrase were detected in E. coli
KL16:Asp-426-Asn resulting in a decrease in the susceptibilities to acidic quinolones
but an increase in those to amphoteric quinolones, while Lys-447-Glu resulted in a
decrease of the susceptibilities to all quinolones (Yamagishi et. al., 1986; Yoshida et.
al., 1991). Some mutations map in gyrB which are not of much account (Yamagishi
et. al., 1986).
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HOMOLOGOUS AMINO ACIDS AND THEIR POSITIONS IN
gyrA ANDparC
DNA gyrase and topoisomerase IV are homologous. However, there is variation in
size of these two enzymes in different bacteria. Therefore, an amino acid can have a
different position number and that causes confusion. For example, Glu-88 in GyrA of
S. aureus can be assigned as position 87 according to its homologous position in E.
coli and the latter position is mentioned by several authors. It is also more
communicable to refer position in ParC protein to its homologous in E. coifs GyrA
protein when their functions are considered; one number is refered to. Moreover, in
case a complete sequence of gyrA or parC is not obtained as in this study, it is
impossible to number positions according to individual bacterium. It is accordingly
advisable to observe the homologous comparison of these amino acid residues
between different bacteria and the two genes.
Table 7 shows some homologous positions of bacteria that are different in number
and type of amino acids. (In the results and discussions of this study, gyrA and parC
positions are numbered according to its E. col homologous positions.)
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Table 7 Homologous comparision of some amino acids and their positions in
gyrA and parC of some bacteria.
Bacteria Gene Homologous







Ala-67 Ser-83 Asp-87 Ser-97
Ala-68 Ser-84 Glu-88 Asn-98







Ala-64 Ser-80 Glu-84 Ser-94
Ala-64 Ser-80 Glu-84 Lys-94
Ala-71 Ser-87 Glu-91 Thr-101
TOPOISOMERASE IV
Topoisomerase IV is a secondary, less sensitive target for quinolone action in E. coli
and that the development of high-level fluoroquinolone resistance in E. coli requires
at least one parC mutation in addition to the gyrA mutation (see MUTATION AT 83
AND 87, page 42) (Heisig, 1996).
EPIDEMIOLOGY OF QUINOLONE RESISTANCE
Overall, fluoroquinolone resistance levels in both non-pathogens and pathogens are
highest in developing countries and lowest in developed countries, with transitional
countries undergoing rapid economic improvement showing intermediate levels of
resistance (Turnidge, 1995). In developed countries, levels of resistance to
fluoroquinolones exceeded 10% for only Pseudomonas aeruginosa, Staphylococcus
aureus, and Acinetobacter baumannii and Providencia species. Turnidge (1995)
found that resistance levels of 25% or more in Escherichia coli were noted in three
countries in 1993. In contrast, resistant strains of S. typhi and S. paratyphi A were
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rare or nonexistent in any country, and only low levels of resistance were detected in
Shigella species.
According to Turnidge (1995), fluroquinolone resistance rates are higest in the
developing countries (Thailand, China, Fiji, the Philippines, Vietnam), moderate in
transitional countries (Hong Kong, Singapore, Malasia, Korea, Breunei), and lowest
in developed countries (Japan, New Zealand and Australia). Levels of resistance in
many common pathogens has occurred: such as E. coli, hospital-acquired Gram-
negative bacilli, such as Enterobacter and Acinetobacter spp. already at worrying
levels in China, Korea, the Philippines and Singapore; invasive salmonellae (S. typhi
and S. paratyphi A) at present very low, with the exception of S. paratyphi A in the
Philippines in 1993. Low levels of resistance to fluoroquinolones are now being
detected in Shigella spp. in a number of countries. Resistance in Staphylococccus
aureus is now becoming an obvious problem in many countries. As suggested by
previous experience in the United States, this is strongly associated with strains that
are multiresistant to many antimicrobial agents, including methicillin/oxacillin.
Similar resistance levels are being seen in coagulase-negative staphylococci. At
present, only one country (Australia) has noted resistance in Neisseria gonorrhoeae,
and this is at a low level.
Ciprofloxacin-resistant MRSA have been noted in Europe, the United States, and
Japan. Studies have indicated that within a short period up to 80% ofMRSA in an
institution may be resistant to all of the fluoroquinolones (Maple et. al., 1989; Soussy
et. al., 1991). In addition, methicillin susceptible S. aureus resistance has been
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increasing. Soussey et. al. (1991) noted that 92% ofMRSA had by 1990 developed
resistance to perfloxacin, and 22% of methicillin-susceptible S. aureus. They also
found that 38% of P. aeruginosa and 54% of S. marcescens were resistant to
pefloxacin.
ANTIBACTERIAL ACTIVITY
Interestingly, one feature of all 4-quinolones is that they always give a biphasic
bacterial survival curve when a given bacterium had been treated with 4-quinolones
over a range of concentrations during a single time interval. The drugs usually
display a single most bactericidal concentration, the exact value of which varies
depending on types of bacteria tested, the 4-quinolones used and other conditional
factors. On either side of this concentration, greater or smaller, there is less bacterial
death. Thus even as the concentration increases above the most bactericidal
concentration, the ability of the drug to kill the bacterium deteriorates. It was
revealed that this second phase of the 4-quinolone's activity, where the drugs become
gradually less bactericidal, exists because they begin to inhibit RNA synthesis.
It was generally concluded that; among four 4-quinolones, the most efficient 4-
quinolone drug to kill bacteria is ciprofloxacin; the next most efficient are ofloxacin
and norfloxacin and the least is nalidixic acid. Among these drugs, the most
bactericidal concentration of only nalidixic acid far exceeds its serum concentration -
that of ciprofloxacin, ofloxacin and norfloxacin are readily attainable in the serum
during therapy (Hooper & Wolfson, 1985). As a result, no resistant mutant was
encountered that was resistant to peak serum concentrations of ciprofloxacin,
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norfloxacin or ofloxacin, or resistant to attainable urine concentrations of these
bactericidal agents (Smith, 1986).
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2. MATERIALS AND METHODS
2.1 Reagents




2.6 Determination of the Minimum Inhibitory Concentration (MIC)
2.7 Identification ofClinical Bacterial Isolates
2.8 Genetic characterisation ofMutation in the QRDR ofgyrA and parC Genes of
Clinical Cip-Resistant Bacteria
2.8.1 Preparation ofChromosomal DNA by Enzyme Lysis plus Solvent
Extraction
2.8.2 Prepartion ofChromosomal DNA by Boiling
2.8.3 Verification ofDNA Product by Agarose Gel Electrophoresis
2.8.4 DNA Amplification by Polymerase Chain Reaction (PCR)
2.8.5 DNA-Strand Separation
1. Preparation ofDynabeads
2. Immobilization of the PCR Product
3. Melting the DNA Duplex
4. Separating the DNA Strands
2.8.6 DNA Sequencing
2.8.7 DNA Sequencing-Gel Electrophoresis and Autoradiography
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2. MATERIALS AND METHODS
2.1 REAGENTS
Most chemicals and reagents were supplied by Sigma Chemicals (Poole, Dorset). All
antimicrobial agents were freshly prepared before use with the appropriate solvent
listed below along with their abbreviations and the manufacturers. Others were
shown and described in the appropriate context.






Chloramphenico 1 Cm Ethanol Sigma
Ciprofloxacin Cip Water Byer
Enoxacin Eno 0.1 MHC1 Sigma
Nalidixic acid Nal Water Sigma
Norfloxacin Nfx 0.1 MHC1 Merck, Sharp and Dohme
Ofloxacin Ofx 0.5 M NaOH Roussel Laboratories Ltd
Oxolinic acid Oxl 0.5 M NaOH Sigma
Rifampicin Rif Water Ciba Laboratories
2.2 GROWTH MEDIA AND BUFFERS
1) Columbia Base Agar (Oxoid, Basingstoke, Hants.) was used routinely to grow all
bacteria overnight except where stated.
2) Iso-Sensitest (1ST) Broth/Agar (Oxoid, Basingstoke, Hants.) with antimicrobial
agents if required, was used routinely to grow bacteria for viable counts in
determination of MIC of all bacteria except Neisseria spp. and Moraxella spp.
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that required Columbia Base Agar (Oxoid, Basingstoke, Hants.) with 5.% (v/v)
defribrinateted horse blood.
3) CLED media (Amersham pic., UK).
4) 0.85 % NaCl in distilled water was used for bacterial dilution.
5) 10X TAE buffer pH7.6 (40 mM Tris-acetate, 1 mM EDTA).
6) Binding & Washing Buffer (10 mM Tris-HCl, pH7.5, 1 mM EDTA and 2.0 M
NaCl (final concentration: 1.0 M)).
7) TE Buffer (10 mM Tris-HCl, pH7.5 and 1 mM EDTA).
2.3 BACTERIA
1) Escherichia coli NCTC10418.
2) Escherichia coli KL16 obtained from Dr RJ.Pinney, School of Pharmacy,
University of London.
3) Escherichia coli clinical isolate obtained from Edinburgh Royal Infirmary
Hospital.
4) Staphylococcus aureus NCTC6571.
5) Pseudomonas aeruginosa NCTC10662.
6) Clinical Quinolone-resistant isolates from Malaysia (10 isolates) and Thailand (13
isolates).
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2.4 STORAGE OF BACTERIA
For long-term storage, all bacteria were grown to log phase of growth and then were
put in tight-sealed polystyrene tubes (maximum volume of 1.5 ml) containing 1 ml
nutrient medium and 20 % (v/v) glycerol, and stored in the deep freezer at a constant
temperature of -70°C. To revive the culture, cells were transferred by inoculation
loop and placed on agar to check for purity. If there was difficulty in reviving the
culture, it was grown overnight in broth before any further test.
2.5 GROWTH OF BACTERIA
A single colony from recently streaked agar plates was routinely inoculated into
sterile liquid medium and grown overnight under sterile conditions before passing to
the next stage. In the preparation of logarithmic phase cultures, the bacteria were
regularly grown overnight at 37°C and 130 rpm in a rotary shaker to ensure good,
even growth. Subsequently, 0.1 ml was subcultured into a new universal tube
containing 9.9 ml Iso-Sensitest broth and incubated overnight at 37°C and 130 rpm in
orbital shaker.
When a viable count was performed a liquid culture, 100 pi was serially diluted in
0.85% NaCl solution. 100 pi of suitable dilution were spread on Columbia Base
Agar plate and incubated at 37°C. When the bacteria under test were Neisseria spp.
or Moraxella spp., a CO2 incubator was required in order to provide a precise
temperature of 37°C.
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2.6 DETERMINATION OF THE MINIMUM INHIBITORY
CONCENTRATION (MIC)
Minimum Inhibitory Concentrations (MICs) were performed on Columbia Base Agar
following the British Society for Antimicrobial Chemotherapy (BSAC) guidelines
for susceptibility testing where applicable (Phillips, 1991). MICs were determined by
agar double-dilution plate method. The procedure is as shown below.
1. Inoculum preparation: One fresh single colony of the bacterium to be tested
was put into a Mc Cartney bottle containing 9.9 ml Iso-Sensitest broth and then
incubated by shaking overnight at 37°C. 0.1 ml of the culture was then
inoculated to another 9.9 ml Iso-Sensitest broth and incubated for 16 hours at
37°C before dilution in 0.85% sterile saline to give an inoculum of lxlO4
colony forming units (cfu/spot). The concentration of bacteria was estimated
by measuring its optical density at 550 nm carried out in a spectrophotometer.
The calculation was based on each bacterial standard curve of optical density
and viable cell count. The range of optical density chosen was from the straight
part of the curve only, in order to give accurate numbers of viable cells.
2. MIC plate preparation: A series of 12.5 ml Iso-Sensitest agar plates with
doubling concentrations ofan antibiotic were prepared.
2.1 A correct amount of 10 and/or 1000 mg/1 antibiotic solution was added to
empty plates with appropriate label and identification marks, to produce
the final concentration needed for each set of experiments.
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2.2 An amount of 12.5 ml of 50°C Iso-Sensitest agar was added to each plate.
2.3 To make a good homogeneous distribution of antibiotic added, the plates
were rotated and any bubbles were removed with a quick exposure of
flame from a Bunsen burner. After solidification the plates were dried in
55°C incubator for about 30 minutes with the lids opened.
3. Inoculation: The labelled agar plates were aseptically inoculated with a 2 pi
spot of each fresh-prepared inoculum, delivered from a multipoint inoculator
(Denley, Billinghurst, Surrey).
4. Incubation and result observation: Inoculated agar plates were incubated at
37°C, and the result was observed the next day when the control showed a
correct result: for Cip, MIC of Escherichia coli NCTC10418 was 0.016 mg/L;
Pseudomonas aeruginosa NCTC10662, 0.12 mg/L; Staphylococcus, aureus
NCTC6571, 0.12 mg/L.
Note: In the case of inoculum preparation of Neisseria spp. and Moraxella spp.
that require addition ofblood and precise temperature for growth, cells were
grown on Columbia Base Chocolate agar at precisly 37°C in CO2 incubator,
and one loopful of fresh culture was diluted and mixed well in 0.85% NaCl
to give the same standard cell number of inoculum. MIC blood agar plate
and precise 37°C were also required in incubation step.
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2.7 IDENTIFICATION OF CLINICAL BACTERIAL ISOLATES
Some clinical quinolone-resistant isolates from Malaysia and Thailand was identified
by the use of API20e (Bio Merieux SA, France) for those isolates of
Enterobacteriaceae and other Gram-negative rods, API20Ne (Bio Merieux SA,
France) for those ofnon-enteric Gram-negative rods.
2.8 GENETIC CHARACTERISATION OF MUTATION IN THE
QRDR OF GYRA AND PARC GENES
2.8.1 Preparation of chromosomal DNA by enzyme lysis plus
solvent extraction
Bacterial chromosomal DNA was separated from cells by using the modified
protocol of Zyskind and Bernstein (1989) with no ether extraction step. A single
colony was inoculated into 5 ml of appropriate nutrient broth and grown overnight in
a 37°C incubator. A 1.2 ml volume of this culture was spun in a microcentrifuge
(Microcentaur MSE) at 3000 rpm for about 15 seconds. The broth was discarded and
the cell pellet resuspended in a volume of 0.31 ml HTE buffer (50 mM Tris-HCl, pH
8.0, 20 mM EDTA) by briefly vortexing to give no cell clumps and then 0.35 ml of
2% solution sarcosyl (A-lauroylsarcosine) was added with brief inversion of the tube,
followed by 5 pi RNAase (10 mg/ml in TE buffer) (lOmM Tris-HCl, pH8.0, 10 mM
NaCl, 0.1 mM EDTA) and incubated at 37°C for 15 minutes. A volume of 35 pi of
pronase solution (10 mg/ml pronase in 10 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.1
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mM EDTA buffer, 87°C for 15 minutes to digest any DNases present) was added and
the tubes incubated in a 50°C waterbath until lysis had occurred (30-90 minutes). The
DNA molecular weight was lowered to around 20 kb by vortexing the lysate for 2
minutes to shear the DNA. This decreased the viscosity and made it easier to extract
the lysate with phenokchloroform and ether. Three rounds of phenokchloroform
extraction were carried out by addition of an equal volume (0.70 ml) of
phenokchloroform 1:1, followed by brief vortex for few seconds. The samples were
centrifuged at 13,000 rpm for 3 minutes and the top layer was carefully removed
with a sterile Pasteur pipette and added to a new microcentrifuge tube. The white
flocculent interphase must not be taken across and the phenokchloroform waste was
disposed of in an approved waste receptacle. The resulting lysate was treated with 70
pi of 0.3 M sodium acetate with good mixing, and an equal volume 0.7 ml of
isopropanol. After adding the isopropanol, the tube was inverted five or six times.
The sample was then frozen at -70°C for 15 minutes. DNA precipitation was
achieved after centrifugation at 13,000 rpm for 20 minutes and then the supernatant
was poured off. The resulting pellet was washed three times by the addition of 70%
ethanol, brief vortexing and centrifugation at 13,000 rpm for 5 minutes and then the
supernatant was poured off. After being left to dry at room temperature, the dry
pellet was resuspended in 50 pi of TE buffer, and stored at -20°C for up to 1 month.
The DNA suspension was ready to use as template for DNA amplification by PCR.
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2.8.2 Preparation of chromosomal DNA by boiling
Another way used to prepare chromosomal DNA was by lysing cells in a hypotonic
solution at high temperature (100°C) usually in a boiling water bath. This was a
quick and effective method of preparing DNA for PCR. The main limitation is that
only a few cells usually 104 or less, can be used; otherwise, the accumulation of
cellular debris will begin to inhibit the reaction. This preparation was done by
pelleting 102-104 cells in a 15-ml conical tube in a benchtop centrifuge at 1200-1500
g for about 10 minutes. The cells were resuspended in 5 ml of phosphate-buffered
saline and repelleted by centrifugation. (If necessary, this step was repeated to
remove residual amounts of the original suspension buffer). The washed cells were
resuspended again in 25-50 pi distilled water and transferred to a 0.5 microcentrifuge
tube, followed by boiling in water for 3-5 minutes. The clear lysate was transferred
to a new tube and was ready to use as template for PCR or kept at -20°C for up to 1
month.
Another modified preparation was made by growing cells on an agar medium plate
overnight and then suspending tiny amount of cells in 50-100 pi of sterile water and
boiling for 3-5 minutes. The clear lysate was then ready for DNA amplification by
PCR: 1 pi per 100 pi ofPCR reaction; however, 3-5 pi when amplifying the QRDR
ofMoraxella catarrhalis or Neisseria gonorrhoea.
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2.8.3 Verification ofDNA Product by Agarose Gel Electrophoresis
DNA preparations were examined for their purity, quantity and size by conventional
agarose gel elctrophoresis. Agarose gel electrophoretic analysis of DNA was
performed with TAE (10X TAE pH7.6: 40 mM Tris-acetate, 1 mM EDTA) buffer.
The gels (1% agarose) were made up by melting the appropriate amount of agarose
(GibcoBRL, Montgomery, Maryland) in lx TAE in a microwave oven. Gels were
cast in an appropriate casting tray and, once set, placed in a gel electrophoresis tank
(Bethesda Research Laboratories Horizon 20.25 gel tank, Life Technologies,
Petersburg, Florida or a Pharmacia GNA-100 minitank) and immersed in IX TAE
buffer. Six pi of each PCR sample with 1 pi of tracking dye (30% glycerol, 0.25%
bromophenol blue, 0.25% xylene cyanol) were loaded in a well at one end of the tray
along with standard markers that were either "A, Hindlll digest" (Sigma D-9780) or
"lOObp DNA ladder" (GibcoBRL, Montgomery, Maryland) for molecular weight
reference. Electrophoresis at 100V was then performed for 20-30 minutes depending
on the size of the DNA fragments concerned. After completion of electrophoresis,
gels were stained in water containing 50 pg/L ethidium bromide for about half an
hour. Samples were examined for their purity, quantity and size of bands by UV
visualization on UV transillumination (UV Products, Cambridge). DNA preparations
with good purity must show only one band. Their quantity and size can be estimated
by comparison with that of standard DNA markers on the same gel.
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2.8.4 DNA Amplification by Polymerase Chain Reaction (PCR)
Polymerase chain reaction (PCR) amplification of a specified fragment ofDNA was
carried out in a total volume of 100 or 50 pi prepared in a 0.5 ml polypropylene
microcentrifuge tube (Alpha Laboratories) with a Techne PHC-2 Dri-Block Cycler
(Cambridge, Cambs). The method used is based on Gibco basic PCR protocol and
the hot start method in the protocol was used to ensure high specificity of the
products synthesized. A volume of 100 pi PCR reaction consisted of the following
components sitting on ice: -10 ng DNA template (1-10 pi of the chromosomal DNA
solution), lx PCR buffer (GibcoBRL, Montgomery, Maryland), 1.5 mM MgCfi
(GibcoBRL). 0.2 mM each dNTP (Boehringer, Mannheim), 0.5 pM of one biotin-
labelled primer, and 1.5 pM of another primer without biotin (Oswel DNA Service
Lab, University of Southampton), 2.5 pi of 1% W-l, 2-2.5 units of Taq DNA
Polymerase (GibcoBRL, Montgomery, Maryland) and autoclaved distilled water to
100 pi. One positive and two negative controls were always rim along with the
samples to ensure that only the expected product was constructed. One negative
control had water instead of two primers of the same volume; the other control had,
instead of template, water to the same volume.
Four sets of primers were used; their sequences are shown below (Table 9) together
with the gene and bacteria they were used for. All primer sets were used to amplify
the region including QRDR.
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Table 9 Four sets of primers used in PCR to amplify gyrA's and parCs QRDR.
Name1 Sequence2 Reference RegionAmplified
la) gyrA-E-3' primer atgagcgaccttgcgagagaaattacaccg G6083 gyrA
lb) gyrA-E-5' primer ttccatcagcccttcaatgctgatgtcttc* G6085 gyrA
2a) gyrA-n-3' primer cgccataccgacggcgatacc T1447 gyrA
2b) gyr/t-N-5' primer gacggcctaaagccggtgcac * T1446 gyrA
3a)parC-E-3' primer aggtagcattttcggctcct* V4640 parC
3b) parC-E-5' primer aatgagcgatatggcagagc V4641 parC
4a) parC-N-V primer tgagcaacaccataggcaag V4643 parC
4b) parC-N-5' primer tcccataccgattccaacac* V4642 parC
1 Primer names with "E" is for E. coli, Enterobacter sakazakii and Citrobacter
freundii; with "N" for Neisseria gonorrhoeae and Moraxella spp.
2
Sequence with * is with 5-biotin labelled so subsequent strand separation could be
performed with magnetic biotin-streptavidin separation (Dynabeads®M-280
Streptavidin). Primer set 1) and 3) was designed on inspection of the gyrA
sequence ofE. coli KL16 (Yoshida et. al, 1988); primer set 2) and 4), ofparC
sequence ofN. gonorrhoeae (Belland et. al., 1994).
Reaction mixtures were overlaid with one or two drops of mineral oil to reduce
evaporation, and at the tips of the tubes to improve thermal contact with the heating
block. Thermal cycler condition used is shown below.
1) 96°C for 30 seconds
2) 80°C for until Taq DNA Polymerase was loaded
3) 96°C for 15 seconds
4) 60°C for 30 seconds (in case ofparC, 53°C for 1 min.)
5) 70°C for 90 seconds (repeat step 3, 4 and 5 for 25-30 times)
6) 70°C for 5 minutes
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After completion of the PCR reaction, the biotin-labelled product were taken to a
new tube without oil and placed on ice to quench any further reaction, or stored at -
20°C for up to 1 month for verification of PCR products by agarose gel
electrophoresis and later DNA strand separation. Verification of PCR product by
agarose gel electroporesis was done in the same way as for chromosomal DNA
preparation in 2.8.3.
2.8.5 DNA-STRAND SEPARATION
The double-stranded PCR product with biotin labelled to one strand allows possible
separation by magnetic biotin-streptavidin separation, which is accomplished by the
use of Dynabeads®M-280 Streptavidin (Dynal A.S., Norway). The use of
Dynabeads, as a magnetizable solid phase, for the capture and purification of the
PCR product, allows simple, rapid and efficient preparation of immobilized single-
stranded template for sequencing. The principle of the method is that end labelling of
PCR product with biotin is achieved simply by using a biotinylated primer. Capture
• • • • (ft)
and purification are then accomplished by incubation with Dynabeads M-280
Streptavidin and separation using a Dynal MPC (Magnetic Particle Concentrator).
Once immobilized, the DNA is converted to a single-stranded template by elution
with alkali and another magnetic separation. Immobilized single-stranded template
prepared in this manner are suitable for manual and automated solid-phase DNA
sequencing by the dideoxynucleotide chain termination method, where magnetic
properties of the beads are used further to improve the quality of results. A 100%
single-stranded template can be produced, without interference from primers, free
nucleotides or the complementary strand. The benefit of the method is that PCR
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reaction components (buffer, dNTP's) are removed at the same time as the single-
stranded template is generated.
This DNA strand separation used in the course of this thesis followed the protocol
recommended by Dynal with some changes. The modified method is shown below.
1. Preparation ofDynabeads
1.1 The Dynabeads®M-280 Streptavidin were resuspended by gently shaking the
vial to obtain a homogeneous suspension.
1.2 An amount of 20 jj.1 of the homogeneous Dynabeads for each template
preparation was added to a 1 ml centrifuge tube.
1.3 The tube was placed in the Dynal MPC for at least 30 seconds so that all the
beads were magnetically attracted to one small area of the tube. (The tube
must not be removed during the separation process)
1.4 The supernatant was simply removed by aspiration with a pipette while the
tube remained in the Dynal MPC. (The pipette tip must not touch the inside
wall of the tube, where the Dynabeads were attracted to the magnet)
1.5 The tube was then removed from the Dynal MPC. The same amount as in
step 1.2 of 2X concentrated B&W buffer (lOmM Tris-HCl (pH 7.5), 1 mM
EDTA and 2.0 M NaCl) was added along the inside of the tube where the
Dynabeads were held. The beads were resuspended full but gently by pipette
aspiration.
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1.6 Steps 1.3, 1.4 and 1.5 were repeated twice.
2. Immobilization of the PCR product
2.1 Steps 1.3, 1.4 & 1.5 were repeated but the volume of 2X (concentrated)
B&W was twice that in step 1.5.
2.2 To 40 pi of the amplified product, 40 pi of the washed beads were added.
2.3 The vial was incubated for 15 minutes at room temperature keeping the
beads suspended by gentle rotation of the tube.
3. Melting the DNA duplex
3.1 The beads were washed by repeating steps 1.3, 1.4 and 1.5, and the pellet was
resuspended in 40 pl/reaction of 2X B&W. (Note: The immobilized product
could then be stored at 4°C for several weeks)
3.2 The beads were washed again and the pellet was resuspended in 8 pi of a
freshly prepared 0.1 M NaOH. It was then incubated at room temperature for
10 minutes.
4. Separating the DNA strands
4.1 By using the Dynal MPC to collect the Dynabeads on the side of the tube, the
NaOH supernatant containing the non-biotinylated DNA strands, was
transferred to a clean tube for step 4.4.
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4.2 The Dynabeads with the immobilized biotinylated DNA strands were washed
once with 50 pi 0.1 M NaOH, once with 50 jal IX B&W buffer, and once
with 50 pi TE buffer.
4.3 The supernatant was removed and 13 pi of sterile MilliQ water was added.
This final solution contained biotinylated DNA strands ready for sequencing.
4.4 To determine the nucleotide sequence of the complementary DNA template in
the alkali supernatant, the NaOH supernatant from step 4.1 was added and
mixed well with 4 pi 0.2 M HC1 and immediately with 1 pi 1.0 M Tris-HCl
(pH 7.5) without water added. This complementary DNA template was ready
for sequencing.
Note: The same pipette was used for both NaOH and HC1, as small differences in
calibration between different pipettes can cause neutralization problems. To save
time and cost 0.1 M NaOH was prepared by diluting 1 M NaOH prepared in bulk
which was stored in -70°C up to 3 months.
2.8.6 DNA Sequencing
A 7 pi volume of the single-stranded DNA template either from step 4.3 or 4.4 in
DNA-strand separation, was used routinely in the sequencing reaction which was
carried out with a T7 Sequenase version 2.0 DNA Sequencing kit (US 70770)
according to the manufacturer's protocol with [35S] dATP (Amersham Life
Sciences, UK) radiolabel and pyrophosphatase. Sequencing primers used were
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the same as those used in Amplification ofDNA by PCR. This sequencing is based
on the chain-termination method to synthesis complementary DNA strands from
single strand-DNA template amplified by PCR. When proper mixtures of dNTPs and
one of the four ddNTPs were used, the DNA polymerase produced a fraction of the
population of chains at each site where the ddNTP was incorporated. Four separate
reactions, each with a different ddNTP gave the complete sequence information. A
radioactively labelled nucleotide also was included in the synthesis, so the labelled
DNA chains of various lengths were visualised by autoradiography after separation
by high-resolution electrophoresis producing information of complementary
sequence of the template. The protocol is as followed.
1. Annealing template and primer. Four ingredients were combined into a tube as
followed:
Primer 1 pi (final concentration 0.5 pmoFpl)
DNA template (from step 4.3 or 4.4) 7 pi
T7 Sequenase reaction buffer 2 pi
Total 10 pi
2. The capped tube was warmed to 65°C for 2 minutes, then allowed to cool slowly
to room temperature over a period of about 30 minutes. Then it was chilled on ice.
3. One pi T7 Sequenase enzyme was combined with 6.5 pi Enzyme Dilution Buffer
and 0.5 pi pyrophosphatase.




Labelling mix (diluted (1:5)
[35S] dATP




3.25 units (2 pi of 1:8 dilution)
This mixture was mixed thoroughly and incubated for 3 minutes at room
temperature or cooler (4-20°C).
Note: [35S] dATP should have specific activity of 1,000-1,200 Ci/mmol and the
concentration about 10 pCi/pl.
5. Termination reactions.
5.1 Four tubes each labelled G, A, T and C were filled each with 2.5 pi of the
appropriate dideoxy termination mix, and were then prewarmed to 37-45°C
(45°C was preferable). It must not be below 37°C.
5.2 When the labelling reaction was completed, 3.5 pi of it was transferred to
each of the four pre-warmed tubes labelled G, A, T and C.
5.3 After 3 minute incubation at 37°C, 4 pi of stop solution was added to each
termination reaction, mixed and stored on ice. These terminated sequencing
mixtures were ready for sequencing gel electrophoresis and were be stored at
-20°C for less than 7 days.
(Note: Except the enzyme, each of the kit components was thawn on ice, mixed by
pumping and down several times with a micropipette. Whenever necessary,
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the reaction tubes were briefly spun a microcentrifuge to collect the
contents in the bottom of the tube.)
2.8.7 DNA Sequencing-Gel Electrophoresis and Autoradiography
DNA sequencing gel electrophoresis was performed with a Nucleic Acid Sequencing
Cell (BioRad, Watford, Herts). The glass sequencing gel plates were thoroughly
cleaned on one side each: once with water; twice with cleaning solution, twice with
double distilled water, twice with ethanol; and three times with propanol or acetone
(scrub hard and work a small area at a time on the second propanol/acetone wash).
The cleaner the plates, the easier it was to pour a gel without bubbles. The two plates
were then assembled together with 0.2 mm cleaned spacers separating the two plates.
The top plate was siliconized with Gel Slick (AT Biochem, Malvern, Pennsylvania),
in order to let the gel stick onto the unsiliconized glass plate when the apparatus was
disassembled.
The best sequencing gel employed through the course was of 8%, which was
prepared from 40% Accugel 19:l™(acrylamide:bis-acrylamide) gel solution
(National Diaganostics, USA, Order No. EC-850, sequencing grade, gas stabilized).
To make a sequencing gel 8 M urea and IX TBE buffer were combined with 8% gel
(19:1 = acrylamide:bis-acrylamide). It was heated briefly by heating in a microwave
oven and then was swirled to dissolve urea in gel solution. The cool gel solution was
then purified by millipore filtration. The gel solution was then ready for the plug: 30
ml of the gel solution was polymerised by the addition of 150 pi 25% ammonium
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persulphate solution and 150 pi TEMED. Immediately, this was poured into the gel
casting tray to form a plug. Next, the rest of the gel solution was cooled down to
about 4°C as recommended by the manufacturer so that the solution is not set at the
time of pouring. For each ml of remaining gel solution, 1 pi of 25% ammonium
persulphate solution and 1 pi of TEMED was added and the solution poured
carefully between the two plates of the gel apparatus. The flat edge of a shark
toothed comb was pushed between the plates to layer the top of the gel. The gels
should be prepare 2-20 hours prior to use. Once set, the comb was removed and the
top of the gel was thoroughly flushed with distilled water. The sharktooth comb was
then replaced with the points downwards just touching the surface of the gel. The gel
was clamped into the sequencing apparatus and IX TBE solution poured into the top
and bottom reservoirs. The gel was then pre-run at 50 W for an hour and then at
higher (70-100) wattage so that the gel temperature was at 55-60°C. The gel was
ready to be loaded with the extended sequencing mixtures. The samples were loaded
in the order G, A, T and C immediately after denaturing the DNA by heating the
samples to 85°C for 3 minutes. Immediately after this incubation, 2-3 pi of each
sample were loaded onto the gel after the wells were rinsed out with buffer, being
sure to rinse out all the urea-containing buffer from each well. The gel was then
electrophoresed at 55°C and maintained at this temperature regardless of the wattage
for 5-8 hours, depending on which part of the sequence was to be read. Once
electrophoresis was complete, the glass plates were removed from the apparatus and
the top plate very carefully removed. The bottom plate with the gel attached was then
placed in a fixing bath containing 15% methanol and 5% acetic acid in water for 20
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minutes. The plate and gel were then removed and a sheet of Whatman 3MM paper
placed on top of the gel. Even pressure was then applied and the paper peeled off
taking the gel with it. The gel attached to the paper was covered in Saran Wrap and
dried in a vacuum gel drier for 2-3 hours at 80°C. When dry, the gel was placed in an
autoradiography cassette (Amersham Life Sciences, UK) and exposed to Kodak
Biomax MR-1 film at room temperature for about 10-20 hours after which the film
was developed at the X-ray department, Royal Infirmary ofEdinburgh.
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3. INVESTIGATION OF CIPROFLOXACIN
RESISTANCE IN CLINICAL BACTERIAL ISOLATES
3.1 INTRODUCTION
This section seeks to demonstrate whether there were any unusually high levels of
ciprofloxacin (Cip) resistant bacteria amongst clinical isolates from Malaysia and
Thailand. The results could lead to support the report of Turnidge (1995) that
developing countries shows high antibiotic resistance and is lesser in countries with
better welfare. If there was any unusually high level of resistance, their gyrA and
parC genes responsible for high Cip resistance would be studied further. It was
hoped that at the end of the study a solution to fluoroquinolone-resistance might be
found. It was also decided to include Moraxella catarrhalis isolates from Edinburgh.
Urinary tract bacterial isolates from Malaysia (Kathiravel et. al., (1994), Thailand
and Moraxella isolates from Edinburgh were examined for their antibiotic sensitivity
to Cip. If high Cip-resistant isolates were found they would be used for further study
on gyrA orparC mutations, a common cause ofCip resistant mechanism.
Although, in general, fluoroquinolone resistance was the purpose of this
investigation, Cip alone was used primarily as a representative because it was the
most powerful fluoroquinolone. It is anticipated that resistance found to
ciprofloxacin also commonly conferred potent to every other fluoroquinolones;
however, despite this presumption, some other fluoroquinolones: ofloxacin,
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norfloxacin and enoxacin, were also tested for their activities against some isolates
(Table 13).
3.2 METHODS
Antibiotic sensitivity testing of Cip for those three groups of bacterial isolates was
determined by double dilution-plate method (full details in 2.6) and their minimum
inhibitory concentrations (MICs) were shown (Table 10). Some isolates with high
resistance were then identified by API 20e or 20 Ne(full details in 2.7).
3.3 RESULTS
3.3.1 MALAYSIAN ISOLATES
Among 163 Malaysian urinary tract isolates collected by Kathiravel et. al., (1994),
22% (36/163) had MIC ofCip >0.08 mg/L, and 6% > 1 mg/L. The ten most resistant
isolates were from four bacterial species: E. coli, Acinetobacter baumanii, P.
aeruginosa and Klebsiella sp. Their MICs are displayed in Table 10. Some had
remarkably high level of Cip resistantnce: two E. coli; 32, 128 mg/L and six A.
baumanii, 4-128 mg/L. As E. coli is very common and widespread, it is regarded
very serious and unusual that the two E. coli had such an unusually high resistance
and so they were to be examined further in the next experiment. The rest of the Cip-
resistant bacteria had intermediate resistance and they were P. aeruginosa KP174
(MIC of2 mg/L) and Klebsiella sp. KP 50 (MIC of 4 mg/L).
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Table 10 Minimum inhibitory concentrations (MIC) against Cip of the
Malaysian clinical urinary-tract isolates.
COUNTRY NAME MIC of Cip
(mg/L)
Malaysia E. coli KP 88 128
Malaysia E.coli KP 115 32
Malaysia Acinetobacter baumanii KP 7 64
Malaysia Acinetobacter baumanii KP 23 128
Malaysia Acinetobacter baumanii KP 24 64
Malaysia Acinetobacter baumanii KP 29 64
Malaysia Acinetobacter baumanii KP 47 8
Malaysia Acinetobacter baumanii KP 66 4
Malaysia P. aeruginosa KP174 2
Malaysia Klebsiella sp. KP 50 4
Malaysia E. coli KP 42,62,90,126,147 <0.031
(reference strain) E. coli NCTC10418 0.016
(reference strain) P. aeruginosa NCTC10662 0.12
(reference strain) S. aureus NCTC 6571 0.12
Malaysia Acinetobacter baumanii KP 31,32,33 <0.031
Malaysia P. aeruginosa KP 15,21,22 <0.12
Malaysia K. pneumoniae KP 3 & 5 0.06
3.3.2 THAILAND ISOLATES
Some urinary-tract bacteria were isolated from patients in Thailand and screened for
high fluoroquinolone resistance. Thirteen isolates from Thailand were found to be
highly resistant to Cip. After their antibiotic sensitivity to Cip was rechecked, all
isolates were identified by API 20e or 20 Ne(full details in 2.7). Their identity and
their MIC results are displayed in Table 11. Six isolates showed the same remarkably
high MIC of 128 mg/L which was considered seriously high and it therefore implied
possible failure in fluoroquinolone chemotherapy. Those six isolates were two E. coli
(T281 & T295), three Acinetobacter baumanii (T76, T78 and T537) and one
Citrobacterfreundii (T1510).
The second highest value ofMIC under this investigation was 32 mg/L shared by
four isolates of Enterobacter spp.: Ent. amnigenus (T75), Ent. cloacae (T400 and
T401) and Ent. sakazakii (T77). Some other isolates showing intermediate resistance
were Enterobacter aerogenes (T296) and two K. pneumoniae (T70 & T410) with
MIC of4, 8 and 2 mg/L, respectively.
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Table 11 Minimum inhibitory concentrations (MIC) against Cip of the Thai
clinical urinary-tract isolates.
COUNTRY NAME MIC ofCip (mg/L)
Thailand E. coli T 281 128
Thailand E. coli T 295 128
Thailand Acinetobacter baumanii T 76 128
Thailand Acinetobacter baumanii T 78 128
Thailand Acinetobacter baumanii T 537 128
Thailand Enterobacter aerogenes T 296 4
Thailand Enterobacter amnigenus T 75 32
Thailand Enterobacter cloacae T 400 32
Thailand Enterobacter cloacae T 401 32
Thailand Enterobacter sakazakii T 77 32
Thailand Citrobacterfreundii T1510 128
Thailand K. pneumoniae T 70 8
Thailand K. pneumoniae T 410 2
(reference strain) E. coli NCTC10418 0.016
(reference strain) P. aeruginosa NCTC10662 0.12
(reference strain) S. aureus NCTC 6571 0.12
(reference strain) Enterobacter sakazakii NCTC 5920 <0.06
Malaysia Acinetobacter baumanii KP 31, 32, 33 <0.03
Malaysia K. pneumoniae KP 3 & 5 0.06
Edinburgh Citrobacterfreundii KP CitS 0.012
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3.3.3 MORAXELLA ISOLATES
A Cip resistant clinical isolate Moraxella catarrhalis KP4/R (Edinburgh) revealed an
interesting MIC of 4 mg/L (Table 12), which is quite exceptional for this particular
bacteria while sensitive strain KP6/S had an MIC of <0.03 mg/L. It was then to be
investigated whether it had a gyrA or parC mutation as a mechanism of resistance.
As gyrA and parC of this bacterial strain had never been sequenced before, PCR and
sequencing primers were designed and based on Neisseria gonorrhoeae sequences.
Table 12 Minimum inhibitory concentrations (MIC) against Cip ofMoraxella




Edinburgh M. catarrhalis KP4/R 4.0
Edinburgh M. catarrhalis KP6/S <0.03
Edinburgh N. gonorrhoea KP14240 0.008
Edinburgh N. gonorrhoea KP13843 0.004
Edinburgh N. gonorrhoea KP31267 <0.001
3.4 DISCUSSION
In 1990, a group of researchers stated that high-level resistance to fluoroquinolones
(i.e. MIC of ciprofloxacin, >1 mg/L) is rarely found among clinical isolates of E. coli
(Barry et. al., 1990); however, >6% of clinical E. coli with Cip MIC of 1 mg/L was
found in Malaysia in 1994. Ciprofloxacin resistance among clinical isolates from
Malaysia and Thailand were high to seriously high, especially E. coli (MIC of 32 to
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128 mg/L). As so far reported, the highest level ofMIC against Cip for clinical E.
coli was 128 mg/L (Vila et. al., 1994), the same as found here. For Acinetobacter
baumannii, 64 mg/L (Bajaksouzian et. al., 1997) but 128 mg/L found here; and for
Enterobacter spp. and Citrobacter freundii, it seemed that there was no reports on
clinical high Cip resistance. This leads to concern of how they became so heavily
resistant.
Accordingly, some resistant isolates, along with sensitive bacteria of the same
species, were chosen for further study on mutation mechanism in gyrA and parC.
The chosen isolates were E. coli KP 88 and KP115 from Malaysia and T281 and
T295 from Thailand; together with two isolates whose gyrA and parC sequence had
never been sequenced: Citrobacter freundii T 410 (MIC of 128 mg/L) and
Enterobacter sakazakii T 77 (MIC of 32 mg/L). Also, isolate Moraxella catarrhalis
KP4/R was included for furthur study.
As several unusually high Cip resistant isolates were found, it supports the idea of
Turnidge (1995) that fluoroquinolone resistant rates are high in the developing
countries like Thailand and moderate in transitional countries like Malaysia.
Ofloxacin, norfloxacin and enoxacin were also tested for their activities against some
clinical isolates together with ciprofloxcin (Table 13).
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Table 13 Minimum inhibitory concentrations (MIC) against ciprofloxacin,
ofloxacin, norfloxacin and enoxacin of some Malaysian clinical





(reference strain) E. coli NCTC10418 0.016 0.5 ND ND
(reference strain) P. aeruginosa NCTC10662 0.12 2 1 1
(reference strain) S. aureus NCTC 6571 0.12 0.5 1 1
Edinburgh M. catarrhalis KP 4/R 4 ND ND ND
Edinburgh M. catarrhalis KP 6/S <0.032 8 16 16
Malaysia A. baumanii KP 7 64 16 >128 >128
Malaysia A. baumanii KP 23 128 16 >128 >128
Malaysia A. baumanii KP 24 64 16 >128 >128
Malaysia A. baumanii KP 29 64 16 >128 >128
Malaysia A. baumanii KP 47 8 4 ND ND
Malaysia Klebsiella sp. KP 50 4 4 ND ND
Malaysia A. baumanii KP 66 4 8 ND ND
Malaysia E. coli KP 88 128 128 >128 >128
Malaysia E. coli KP115 32 32 32 128
Note: ND indicates "not determined".
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4. GENETIC CHARACTERISATION OF MUTATION IN
THE QRDR OF GYRA AND PARC GENES OF
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4.1 INTRODUCTION
The occurrence of clinical isolates highly resistant to fluoroquinolones has been
reported recently. Bacterial resistance to fluoroquinolones drugs has been frequently
shown to occur concurrently with mutations in either or both gyrA (Chen et. al.,
1996; Gellert et. al., 1977; Hane & Wood, 1969; Heisig, 1996; Nakamura et. al.,
1989; Reece & Maxwell, 1991; Sugino et. al., 1977; Yoshida et. al., 1988, 1990a)
andparC (Chen et. al., 1996; Gootz et. al., 1996; Heisig, 1996).
By far the most commonly reported type of mechanism causing highly decreased
susceptibility to fluoroquinolone is a mutation in the specific sequence called
quinolone resistance-determining region (QRDR) (Yoshida et. al., 1990b) of gyrA
gene and, more recently, parC gene (Chen et. al., 1996; Heisig, 1996). Such
mutations are correlated to a change in MICs of a cell compared to a sensitive one.
The QRDR spans the area of the protein between alanine-67 and glutamine-106 ofE.
coli (Swanberg & Wang, 1987; Yoshida et. al., 1990a; Hallett & Maxwell, 1991).
As point mutations in QRDR were commonly found to be a main mechanism of
bacteria to resist fluoroquinolone activity, the following mutation analysis was
therefore designed to establish if unusually high resistance in the Malaysian and
Thailand isolates was associated with any mutations in QRDR ofgyrA and parC.
In order to obtain the QRDR sequences for mutation analysis, amplification of the
QRDR sequence of each isolate must be obtained and this was achieved mainly by
cell-directed polymerase chain reaction (PCR) technique. The PCR fragments were
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sequenced afterwards and finally analysed for mutations with the aim of identifying
any differences that were compatible with the unusually high resistance. The result
may provide useful information to best manage resistance in clinical bacteria.
Table 14 below shows all clinical bacterial isolates studied; 1 to 7 with unusually
high Cip resistance, 8 to 13 as sensitive controls.
Table 14 All Cip resistant bacteria of clinical isolates from Malaysia and




1 )E. coliKP 115 32 Malaysia
2) E. coli KP88 128 Malaysia
3)E. coli T281 128 Thailand
4) E. coli T295 128 Thailand
5) Enterobacter sakazakii Til 32 Thailand
6) Citrobacter freundii T1510 128 Thailand
7) Moraxella catarrhalis KP 4/R 4.0 Edinburgh
8) E. coli KP 42, 62, 90, 111, 126, & 147 <0.031 Malaysia
9) Ent. sakazakii NCTC5920 <0.06 (reference strain)
10) C. freundii KP CitS 0.012 Edinburgh
11) M. catarrhalis KP 6/S <0.03 Edinburgh
12) N. gonorrhoeae KP31267 <0.001 Edinburgh
13) N. gonorrhoeae KP13843 0.004 Edinburgh
14) N. gonorrhoeae KP 14240 0.008 Edinburgh
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4.2 METHODS
In order to get sequence information for mutation analysis, a number of experiments
were set up as followed:
4.2.1 Preparation of chromosomal DNA
4.3.1 DNA amplification by polymerase chain reaction (PCR)
4.4.1 Verification ofPCR product by agarose gel electrophoresis
4.5.1 DNA-strand separation
4.6.1 DNA sequencing
4.7.1 DNA sequencing gel electrophoresis
4.8.1 Mutation analysis
4.2.1 METHOD: PREPARATION OF CHROMOSOMAL DNA
This method was to separate chromosomal DNA from cells of interest so that the
preparations were suitable for amplification by PCR technique. This was done by
two methods: (1) 'enzyme lysis plus solvent extraction' and (2) boiling. The former
was designed by Zyskind and Bernsterin (1989), with a slight modification (full
details in 2.8.1.) The latter method was by simple lysing cells in a hypotonic solution
at high temperature (100°C) (full details in 2.8.2). Chromosomal preparation by
boiling is effective and simpler than the former method. However, the disadvantage
of the boiling method is that there is no appropriate way to verify the result, which
can be assumed after polymerase chain reaction result obtained.
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Chromosomal DNA preparations obtained by 'enzyme lysis plus solvent extraction'
were subsequently examined by agarose gel electrophoresis (full details in 2.8.3).
4.2.2 RESULT AND DISCUSSION
A uniform, single strong band of expected chromosomal DNA size on agarose gel
was produced from all 20 clinical bacteria. Figure 6 displays some representatives
chromosomal DNA bands. All bacteria gave bands of the same type and size.
Although each DNA concentration was not precisely the same as indicated by
intensity and thickness of bands, all DNA preparations were good enough to act as
DNA templates for PCR.
The modified method employed here for chromosomal DNA preparations proved to
be successful in producing fine chromosomal DNA for amplification by PCR
technique. Those DNA with high purity, correct size and appropriate quantity were
therefore to be amplified by PCR technique, as well as those chromosomal DNA
preparations prepared by boiling.
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Figure 6 UV illuminated chromosomal DNA bands prepared by 'enzyme lysis
plus solvent extraction' on agarose gel.
4.3.1 METHOD: DNA AMPLIFICATION BY POLYMERASE
CHAIN REACTION (PCR)
The objective was to amplify the QRDR segment of gyrA and parC genes of the 20
clinical bacteria in order to sequence the QRDR. Chromosomal DNA produced by
both 'enzyme lysis plus solvent extraction' and boiling (4.2.1) were used as template
to be hybridized by a set of primers for gyrA and for parC QRDR (full details in
2.8.4). The use of biotinylated primers (Table 1) provided the end labelling of PCR
product with biotin, which was needed in single-stranded DNA separation (4.4.1)
The PCR products were then verified on 1% agarose gel electrophoresis (full details
in 2.8.3).
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In case ofN. gonorrhoeae and M. catarrhalis, 10% glycerol were combined in PCR
reactions to improve the specificity and yield of PCR products; if this step was not
included multiple and non specific products were found.
4.3.2 RESULT AND DISCUSSION
PCR products were examined on 1% agarose gel (2.8.3) with standard DNA markers
"lOObp DNA ladder" (GibcoBRL, Montgomery County, Maryland). Bacteria in
Enterobacteriaceae was expected to produce 630 bp of gyrA QRDR and 475 bp of
parC QRDR, whereas those in Neisseriaceae were expected to produce 423 and 496
bp ofgyrA andparC QRDR, respectively.
Cell-directed PCR technique worked well and made the step of chromosomal DNA
preparation (4.2.1) unnecessary.
When producing parC QRDR, PCR products of expected sizes were achieved from
all the clinical bacteria, except from both M. catarrhalis KP4/R and KP6/S, which
produced multiple bands of non-expected sizes. However, three Neisseria
gonorrhoeae KP14240, KP13843 & KP31267 as Moraxella's positive control gave
good PCR bands of corrected size. Figure 7 displays representative bands of PCR
products of those clinical bacteria.
The cause of being unable to produce good PCR products ofparC QRDRs of both
M. catarrhalis could be that the sequences of the primers and the bacterium do not
perfectly match because the primers had been designed and based on N. gonorrhoeae
sequences. It might be possible that some nucleotides ofM. catarrhalis''s equivalent
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sequences were not complementary to that of the primers, which was likely to prime
to other sites with more or less complementary sequence.
With both M. catarrhalis, the same overall result was obtained even though different
conditions of PCR had been set up, i.e. different variables were devised: MgCk
concentration (2, 3, 4.5 and 5 mM), annealing temperature (50, 55, 60, 65 and 70°C),
addition of some additives (DMSO (5% final concentration) and glycerol (10% final
concentration). [The additives added were to promote polymerease stability and
processivity or increase hybridisation stringency, and strategies that reduce
nonspecific primer-template interactions.]
All the 38 PCR products obtained, of correct sizes, were next separated into two
single strand-DNA molecules for further sequencing.
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Figure 7 UV illuminated PCR products oiE. colVs gyrA QRDRs on
agarose gel.
4.4.1 METHOD: DNA-STRAND SEPARATION
This experiment was to separate PCR products, which are double-stranded DNA into
single-stranded DNA molecules so that they are ready to be sequenced. The
separation was accomplished by making use of Dynabeads®M-280 Streptavidin
(Dynal A.S., Norway), which is based on a magnetic biotin-streptavidin separating
technique (full details in 2.8.5). The use of Dynabeads, as a magnetizable solid phase,
for the capture and purification of PCR products, allows simple preparation of
immobilized single-stranded template, and therefore eliminates centrifugation steps
and simplifies liquid handling (no need for ethanol or phenol extraction).
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There were 40 double-stranded DNA samples from 20 clinical bacteria to be
separated- no PCR products ofparC from two ofM. catarrhalis were achieved.
4.4.2 RESULT AND DISCUSSION
All the PCR products were successfully separated into two single-stranded DNA
molecules (This was proved by the subsequently sequencing results). These both
complementary DNA strands were sequenced, as double checks, to assure correct
and reproducible sequencing results.
Note: These single-stranded DNA preparations can be stored in -20°C up to two
weeks. Precise concentrations of chemicals are critical, especially 0.1 M NaOH and
0.2 M HC1.
4.5.1 METHOD: DNA SEQUENCING
Good results can only be obtained when there is not a mistake through the course of
the sequencing experiment, especially in the time in termination reaction and in the
degree of temperature. Seventy-two single-stranded DNA molecules were manually
sequenced using radiolabel [35S] dATP (Amersham Life Sciences, UK) with a T7
Sequenase version 2.0 DNA Sequencing kit (US 70770) (full details with some
modifications in 2.8.6).
For DNA amplified with the biotinylated version of the reverse PCR primer and the
nonbiotinylated version of the forward PCR primer, the forward sequencing primer
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must be used for sequencing the immobilized DNA template. The reverse sequencing
primer must be used for sequencing the eluted DNA template.
All the samples were from 20 clinical bacteria and the regions to be sequenced were
of gyrA and parC QRDR. As recommended, each samples were sequenced at least
twice separately to ensure reproducible results.
4.5.2 RESULT AND DISCUSSION
At the end all the terminated sequencing mixtures were achieved and ready for next
step of this analysis. The mixtures were able to be kept at -20°C for up to 7 days.
It is recommended that, after completed extension in sequencing reaction, excess
sequencing primers and unincorporated nucleotides in the supernatant are removed
by another magnetic separation. However; when the magnetic separation was not
readily observed, fair sequencing results were still be obtained in this study.
4.6.1 DNA SEQUENCING-GEL ELECTROPHORESIS
After the extended sequencing-mixture samples were denatured by heating to 85°C
for 3 minutes, they were loaded onto 6% sequencing gels (17 inches x 14 inches x
0.2 mm) and run at gel temperature of 55°C, regardless of the wattage, for 5-8 hours.
Once electrophoresis was complete, the gel with the bottom glass plate was
submerged in a fixing solution (15% methanol and 5% acetic acid in water) for 20
minutes to wash off the urea. The gel was then dried and autoradiographed onto an
X-ray film, which was developed 10-20 hours later. The sequencing bands on the
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film were read, compared and analysed. The material and methods used are
described in full in 2.8.7.
4.6.2 RESULT AND DISCUSSION
All the gyrA and parC QRDR sequences were achieved and the results were shown
below, except parC QRDR sequences of both sensitive and resistant M. catarrhalis,
which were not accomplished owing to the lack of complementation between primers
and expected sites in parC region producing multiple DNA products of incorrect
size.
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4.6.2.1 RESULT: GYRA QRDR SEQUENCE OF
ENTEROBACTERIACEAE
A 630-base region of partial gyrA gene was sequenced and amino acid residues at
position 17 to 166 including QRDR (amino acid residues at 67-106) within brackets
are shown below. The codons 83 and 87 are underlined. From 2) to 8) red capitals in
resistant sequence indicate nucleotides and amino acids different from that of
ECGYRA or its control and sensitive sequence and only section where nucleotide
changes occurred is shown. (The numbers given along with all the sequences are
based on nucleotide numbers ofgyrA gene ofE. ECGYRA.)
1) Standard Cip sensitive-gyrT gene ofE. ECGYRA, as listed in GENBANK
(X06744), withMIC of<0.031 mg/L (Yoshida et. al. (1988).
231 g ctg aag age tcc tat ctg gat tat gcg atg teg gtc att gtt ggc
L
11
K S S Y L D Y A M S V I V G
277
± i
cgt gcg ctg cca gat gtc cga gat ggc ctg aag ccg gta cac cgt
R A L P D V R D G L K P V H R
333 cgc gta ctt tac gcc atg aac gta eta ggc aat gac tgg aac aaa
R V L Y A M N V L G N D w N K
367 gcc tat aaa aaa tct[gcc cgt gtc gtt ggt gac gta ate ggt aaa
A Y K K s A
£ l
R V V G D V I G K
412 tac cat ccc cat ggt
D /
gac teg gcg gtc tat gac acg ate gtc cgc
Y H p H G D S A V Y D T I V R
83 87
457 atg gcg cag cca ttc teg ctg cgt tat atg ctg gta gac ggt cag]
M A Q P F S L R Y M L V D G Q
106
502 ggt aac ttc ggt tct ate gac ggc gac tct gcg gcg gca atg cgt
G N F G S I D G D S A A A M R
547 tat acg gaa ate cgt ctg gcg aaa att gcc cat gaa ctg atg gcc
Y T E I R L A K I A H E L M A
592 gat etc gaa aaa gag acg gtc gat ttc gtt gat aac tat gac ggc
D L E K E T V D F V D N Y D G
637 acg gaa aaa att ccg gac gtc atg cca acc aaa att cct aac ctg 681
T £ K I P D V M P T K I P N L
166
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2) Six Cip sensitive-gyrT gene of E.coliKP42, 62, 90, 111, 126 and 147 (Malaysia)
with MIC of <0.031 mg/L.






























































































3) Cip resistant-gy/vl gene ofE. coliisolate KP115 (Malaysia) with an MIC
of 32 mg/L.
• Five nucleotides within QRDR were changed resulting in 2 amino-acid
mutations:
Ser-83-Leu and Asp-87-Asn.
• Two nucleotide outside QRDR were changed; no amino-acid mutation.
412 tac cat ccc cat ggt gac tTq gcg ct tat Aac acg ate gtc cgT
Y H p H G D L A V Y N T I V R
83 87
457 atg gcg cag cca ttc teg ctg cgt taC atg ctg gta gac ggt cag]
M A Q P F S L R Y M L V D G Q
106
502 ggt aac ttc ggt tcC ate gac ggc gac tct gcg gcg gca atg cgt
G N F G S I D G D S A A A M R
547 tat acg gaa ate cgt ctg gcg aaa att gcc cat gaa ctg atg gcc
Y T £ I R L A K X A H £ L M A
592 gat etc gaa aaa gag acg gtc gat ttc gtt gat aac tat gac ggc
D L £ K £ T V D F V D N Y D G
637 acg gaa aaa att ccC gac gtc atg cca acc aaa att cct aac ctg
T £ K I P D V M P T K I P N L
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4) Cip resistant-gyrT gene ofE. coli isolate KP88 (Malaysia), T281 & T295
(Thailand); all with MICs of 128 mg/L.
• Five nucleotides within QRDR were changed resulting in 2 amino-acid
mutations: Ser-83-Leu and Asp-87-Tyr.
• Three nucleotides outside QRDR were changed; no amino-acid mutation.
412 tac cat ccc cat ggt gac tTq gcg gtT tat Tac acg ate gtc cgT
Y H p H G D L A V Y Y T I V R
83 87
457 atg gcg cag cca ttc teg ctg cgt taC atg ctg gta gac ggt cag]
M A Q P F S L R Y M L V D G Q
106
502 ggt aac ttc ggt tcC ate gac ggc gac tct gcg gcg gca atg cgt
G N F G S I D G D S A A A M R
547 tat acg gaa ate cgt ctg gcg aaa att gcc cat gaa ctg atg gcc
Y T E I R L A K I A H E L M A
592 gat etc gaa aaa gag acg gtc gat ttc gtt gat aac tat gac ggc
D L E K E T V D F V D N Y D G
637 acg gaa aaa att ccT gac gtc atg ccG acc aaa att cct aac ctg
T £ K I P D V M P T K I P N L
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5) Cip sensitive-gyr^ gene ofC.freundii CitS (Edinburgh) with MIC of 0.012 mg/L.
In comparison to E. coli ECGYRA (1):
• 16 nucleotides within QRDR were changed resulting in 2 amino acids different:
Ser-83-Thr and Ile-112-Val.
• 29 nucleotides outside QRDR were changed; 3 amino acids different:
Leu-127-Met, Ala-128-Ser and Ile-155-Lys.
231 g ctg aag age tcA tat ctg gat tat gcg atg teg gtc fh ft rt gtt ggc
L
i n
K S S Y L D Y A M S V I V G
277
1 /
cgt gcg ctg cca gaC gtc cga gat ggc ctg aaA ccg gtT cac cgt
R A L P D V R D G L K P V H R
333 cgc gta ctt tac gcc atg aac gta TtG ggc aaC gac tgg aaT aaa
R V L Y A M N V L G N D W N K
367 gcc tat aaa aaa tct [gcc cgt gtc gtt ggt gac gta ate ggt aaa
A Y K K S A R V
f
V G D V I G K
412 tac caC ccT cat ggt gaT
O /
AcC gcC gtT taC gac acC atT gtT cgT
Y H P H G D T A V Y D T I V R
83 87
457 atg gcg cag cca ttc tcC Ttg cgt taC atg ctg gta gaT ggt cag]
M A Q P F S L R Y M L V D G Q
106
502 ggt aac ttT ggt tct Gtc gaT ggc gac tcC gcA gcg gcG atg cgt
G N F G S V D G D S A A A M R
112
547 tat acg gaa ate cgt Atg Teg aaa atC gcc cat gaG ctg atg gcT
Y T E I R M S K I A H E L M A
127 128
592 gaC ctG gaa aaa gaA acg gtT gat ttc gtC gat aac taC gac ggc
D L E K E T V D F V D N Y D G
637 acC gaa aaa aAA ccT gac gtc atg cca acc aaa att cct aac ctg
TEKKPDVMPTKI PNL
155 166
6) Cip resistant-gyr^ gene ofC.freundii isolate T1510 (Thailand) with MIC
of 128 mg/L. In comparison to the sensitive control (5):
• 2 nucleotides within QRDR were changed resulting in 2 amino-acid mutations:
Thr-83-Ile and Asp-87-Tyr.
• 2 nucleotides outside QRDR were changed; no amino-acid mutation.
412 tac cac cct cat ggt gat aTc gcc gtt tac Tac acc att gtt cgt
Y H P H G D I A V Y Y T I V R
83 87
457 atg gcg cag cca ttc tcc ttg cgt tac atg ctg gta gat ggt cag]
M A Q P F S L R Y M L V D G Q
106
502 ggt aac ttt ggt tct gtc gat ggc gac tcc gca gcg gcg atg cgt
G N F G S V D G D S A A A M R
547 tat acg gaa ate cgt atg teg aaa ate gcc cat gag ctg atg get
Y T E I R M S K I A H £ L M A
592 gac ctg gaa aaa gaa acg gtt gat ttc gtc gat aac taT gac ggc
D L £ K £ T V D F V D N Y D G
637 acG gaa aaa aaa cct gac gtc atg cca acc aaa att cct aac ctg
T £ K K P D V M P T K I P N L
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7) Cip sensitive-gyr^ gene ofEnterobacter sakazakii NCTC5920 withMIC
of<0.06 mg/L. In comparison to E. coli ECGYRA (1):
• 15 nucleotides within QRDR were changed resulting in no amino acid different.
• 30 nucleotides outside QRDR were changed; no amino acid different.
231 g ctg aaA age tcc tat ctg gaC tat gcg atg teg gtc att gtt ggc
LKSSYLDYAMSVIVG
277 cgt gcg ctT ccG gat gtc cga gat ggc etc aaA ccg gta cac cgt
RALPDVRDGLKPVHR




367 gcc taC aaa aaa tcC[gcc cgt gtc gtt ggt gac gta ate ggt aaa
AYKKSARVVGDVI GK
67
412 tac cat ccc caC ggt gaT tcC gcC gtc taC gaT acC atT gtA cgT
YHPHGD SAVYDTIVR
83 87
457 atg gcT cag ccG ttc teg ctg cgC tat atg ctg gtG gaT ggt cag]
MAQPFSLRYMLVDGQ
106
502 ggC aac ttc ggt tct ate gac ggc gac tcC gcC gcg gcG atg cgt
GNFGSIDGDSAAAMR
547 tat acg gaa ate cgt ctg gcg aaG atC gcc cat gaa ctg atg gcc
YTEIRLAKIAHELMA
592 gaC etc gaa aaa gaA acC gtT gat ttT gtC gat aac tat gac ggc
DLEKETVDFVDNYDG
637 acg gaa aaG atC ccg gac gtc atg ccG acc aaa atC ccG aaT ctg
TEKI PDVMPTKI PNL
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8) Cip resistant-gyr.^ gene ofEnterobacter sakazakii (Thailand) with MIC
of 32 mg/L. In comparison to the sensitive control (7):
• 13 nucleotides within QRDR were changed resulting in 2 amino-acid mutations:
Ser-83-Tyr, Asp-87-Asn.
• 29 nucleotides outside QRDR were changed; no amino-acid mutation.
231 g ctg aaa age tcc tat ctg gac tat gcg atg teg gtc att gtt ggc
LKSSYLDYAMSVIVG
277 cgt gcg ctG ccg gaC gtc cgC gat ggc ctG aaG ccg gta cac cgt
RALPDVRDGL KPVHR
333 cgc gta ctA tac gcc atg aac gtA ttg ggc aat gac tgg aat aaa
RVLYAMNVLGNDWNK
367 gcc tac aaa aaa tcT[gcc cgt gtc gtt ggt gac gta ate ggt aaa
AYKKSARVVGDVI GK
67
412 tac cat ccT caT ggt gat tAc gcG gtG tac AaC acc att gtC cgt
YHPHGDYAVYN TIVR
83 87
457 atg gcG cag ccA ttc teg ctg cgT taC atg ctg gtA gat ggt cag]
MAQPFSLRYMLVDGQ
106
502 ggT aac ttT ggt tct ate gac ggc gac tcc gcc gcg gcA atg cgt
GNFGS IDGDSAAAMR
547 tat acg gaa ate cgt ctg gcg aag atT gcc cat gaG ctg atg gcT
YTEIRLAKIAHELMA
592 gac ctG gaa aaa gaG acG gtt gat ttC gtT gat aac taC gac ggc
DLEKETVDFVDNYDG
637 acg gaa aaA atT ccT gac gtT atg ccA acG aaG ate ccA aaC ctg
TEKI PDVMPTK IPNL
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Results of the association of sequence changes with Cip MIC are shown in Table 15
below.
Tahle 15 A summary of the association of QRDR alterations in gyrA of E. ,
C. freundii and Ent. sakazakiiwith Cip MICs are shown below.
NAME and COUNTRY Amino Acid Number (mg/L)
1) Sensitive E. coli ECGYRA, GENBANK Ser (S) Asp (D) <0.031
2) Sensitive E. coli (6 isolates), Malaysia Ser (S) Asp (D) <0.031
3) Resistant E. coli KP115, Malaysia Leu (L) Asn (N) 32




Leu (L) Tyr (Y) 128
5) Sensitive C. freundii CitS Edinburgh Thr(T) Asp (D) 0.012
6) Resistant C. freundii T1510, Thailand lie (I) Tyr (Y) 128
7) Sensitive Ent. sakazakii NCTC5920, NCTC Ser (S) Asp (D) <0.06
8) Resistant Ent. sakazakii Thailand Tyr (Y) Asn (N) 32
There were 6 Cip resistant isolates altogether with their sensitive controls. Table 15
summarizes QRDR alterations of amino acids in gyrA of those Enterobactereaceae
tested Three E. coliisolates (4) with MIC of 128 mg/L, one from Malaysia and two
from Thailand, showed a point mutation at Ser-83 causing a substitution by Leu (Ser-
83-Leu) and a mutation at Asp-87 causing a substitution by Tyr (Asp-87-Tyr). The
fourth E. coli isolate (3) from Malaysia also had a Leu substitution at 83 (Ser-83-
Leu) but an Asn substitution at 87 (Asp-87-Asn), this caused the lower MIC of 32
106
mg/L. The fifth isolate was C. freundii (6) with MIC of 128 mg/L, from Thailand.
This isolate had an lie substitution at position 83 for Thr (Thr-83-Iso); we have
determined that Thr is normal at this position in sensitive isolates of this species (5).
This isolate had a mutation Asp-87-Tyr, similar to those mutations found in the
highly-resistant E. coli (MIC of 128 mg/L). Another resistant isolate was an Ent.
sakazakii Til (8) with MIC of 32 mg/L, also from Thailand. This isolate had Tyr at
position 83 and Asn at 87 while its sensitive control isolate (7), like in E. coli, had
Ser at 83 and Asp at 87. Interestingly, a mutation to 87-Asn gave lower resistance
than mutation to Tyr in both E. coli and Ent. sakazakii. None of the above mutations
was found in 6 quinolone sensitive clinical E. coli isolates from Malaysia. Some
nucleotide mutations were found outside QRDR in some resistant isolates but
producing no amino-acid mutation.
There were 45 nucleotides of sensitive C. freundii CitS (5) which were found to be
different from that of ECGYRA, resulting in 5 different amino acids at position 83,
112, 127, 128 and 155 (2 changes within QRDR: Ser-83-Thr and Ile-112-Val; 3
changes outside QRDR: Leu-127-Met, Ala-128-Ser and Ile-155-Lys).
There were 45 nucleotides of sensitive Ent. sakazakii isolate NCTC5920 (7) which
were different to that of sensitive E. coli ECGYRA, giving no amino acid change.
These were no other gyrA amino acid residues found to be associated with Cip
resistance other than those at 83 and 87 in all these Malaysia and Thailand's clinical
isolates.
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There were some silent alterations in nucleotide sequence at position 438, 456, 483
and 516, which differed from all E. coli published sequences in GENBANK, and
these were common to both sensitive and resistant bacteria isolated from Thailand
and Malaysia (Table 16).
Table 16 Unique nucleotides among ciprofloxacin sensitive and resistant E. coli
isolates from Malaysia and Thailand compared to published sequences
of the same species in GENBANK.
Escherichia coli
BASE POSITION
438 456 483 516
The GENBANK sequences (ECGYRA,
ECGYRAD, ECGYRA1 & ECGYRAAM) C C T T
I Six Cip-sensitive E. coli
(KP42,62, 90, 111, 126 & 147)
T T C C
I Six Cip-sensitive E. coli
(KP88, KP115, T281 & T295)
T T C C
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4.6.2.2 RESULT: GYRA QRDR SEQUENCE OF
NEISSERIACEAE
A 423-base region of partial gyrA gene was sequenced and amino acid residues at
position 54 to 164 including E. colVsequivalent QRDR (amino acid residues at 67-
106) within brackets are shown below. The E. coli equivalent codons 83 and 87 are
underlined. From 10) onwards red capitals in resistant sequences indicate nucleotides
and amino acids different from that ofN. gonorrhoeae NGU08817 or its control and
sensitive sequence and only section where nucleotide changes occurred is shown.
9) Standard Cip sensitive-gyr.T gene ofNeisseria gonorrhoeae NGU08817, as listed
in GENBANK (U08817), withMIC of<0.001 mg/L (Belland et. 1994).
184 gag ctg aaa aat aac tgg aat gcc gcc tac aaa aaa teg[gcg cgc
£ L K N N w N A A Y K K s A R
54 67
229 ate gtc ggc gac gtc ate ggt aaa tac cac ccc cac ggc gat tcc
I V G D V I G K Y H p H G D S
83
274 gca gtt tac gac acc ate gtc cgt atg gcg caa aat ttc get atg
A V Y D T I V R M A Q N F A M
87 95 97 98
319 cgt tat gtg ctg ata gac gga cag]ggc aac ttc gga teg gtg gac
R Y V L I D G Q G N F G S V D
101 103 106
364 ggg ctt gee gcc gca gcc atg cgc tat acc gaa ate cgc atg gcg
G L A A A A M R Y T E I R M A
409 aaa ate tea cat gaa atg ctg gca gac att gag gaa gaa acc gtt
K I S H E M L A D I E E E T V
454 aat ttc ggc ccg aac tac gac ggt age gaa cac gag ccg ctt gta
N F G P N Y D G S E H E P L V
499 ctg ccg ace cgt ttc ccc 516
L P T R F p
164
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10) Cip sensitive-gy/vl gene ofA. gonorrhoeae KP31267 (Edinburgh) with MIC
of<0.001 mg/L.
• There was no any nucleotide changed to that ofNGU08817 (9)
11) Cip resistant-gyrT gene of A. gonorrhoeae KP13843 (Edinburgh) with MIC of
0.004 mg/L.
• Altogether 2 nucleotides were changed resulting in 2 amino-acid mutations in
QRDR: Ser-83-Phe and Asp-87-Gly.
229 ate gtc ggc gac gtc ate ggt aaa tac cac ccc cac ggc gat tTc
IVGDVI GKYHPHGDF
83
274 gca gtt tac gGc ace ate gtc cgt atg gcg caa aat ttc get atg
AVYGTIVRMAQNFAM
87
12) Cip resistant-gyrvl gene ofA gonorrhoeae KP14240 (Edinburgh) with MIC of
0.008 mg/L.
• Altogether 2 nucleotides were changed resulting in 2 amino acid mutations in
QRDR: Ser-83-Phe and Asp-87-Asn.
229 ate gtc ggc gac gtc ate ggt aaa tac cac ccc cac ggc gat tTc
IVGDVIGKYHPHGDF
83




13) Cip sensitive-gyr-4 gene of M.catarrhalis KP 6/S (Edinburgh) with MIC
of<0.03 mg/L.
• Twenty six nucleotides within QRDR were changed resulting in 6 amino acids
different: Ile-69-Val, Ser-83-Ile, Asn-95-Pro, Ala-97-Ser, Met-98-Leu,
Val-101-Met and Ile-103-Val.
• Fifty eight nucleotides outside QRDR were changed; 22 amino-acid different.
197 aac tgg aaC AAG Ccc tac aaG aaa tcC[gcC cgT
N W N K P Y K K S A R
58 67
229 GtG gtc ggc gac gtG ate ggt aaG tac cac ccG cac ggc gaC ATc
V V G D V I G K Y H P H G D I
69 83
274 gcG gtC tac gac acc ate gtG cgC atg gcg caG CCG ttc TcG Ctg
A V Y D T I V R M A Q P F S L
87 95 97 98
319 cgC taC Atg ctg Gta gac ggC cag]ggc aac ttc ggT teg gtg gac
R Y M L V D G Q G N F G S V D
101 103 106
364 ggC GAC AAc gcc gca gcc atg cgA taC acc gaa GtG cgc atg gcC
G D N A A A M R Y T £ V R M A
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409 aaG CtG GcC cat gaa Ctg ctg gcG gac CtG gaA AaG gaa acc gGt
K L A H £ L L A D L E K £ T G
454 CGA CtG ggT GcC aac tac gaT ggC aCc gaG caG ATC ccg GCG gtC
R L G A N Y D G T £ Q I P A V
499 Atg ccg acc AAG AtT ccc 516
M P T K I p
164
14) Cip resistant-gyr/l gene M. catarrhalis KP 4/R (Edinburgh) with MIC
of4.0 mg/L.
• The nucleotide sequence was exactly the same as that of the sensitive
catarrhalis KP6/S (13).
Ill
Table 17 Conclusion of the association ofQRDR alterations in of
gonorrhoeae and M.catarrhaliswith Cip MICs are shown below.
The amino acid number is that ofgyrA equivalence of coli.
Amino Acid MIC
Name and Country Number ofCip
===_^======= 83 87 (mg/L)
9) Sensitive N. gonorrhoeae NGU08817, GENBANK Ser(S) Asp (D) <0.001
10) Sensitive N. gonorrhoeaeKP31267, Edinburgh Ser(S) Asp (D) <0.001
11) Resistant N. gonorrhoeaeKP13843, Edinburgh Phe (F) Gly(G) 0.004
12) Resistant N. gonorrhoeae KP14240, Edinburgh Phe(F) Asn(N) 0.008
13) Sensitive M. catarrhalis KP 6/S, Edinburgh lie (I) Asp (D) <0.03
14) Resistant M. catarrhalis KP 4/R, Edinburgh lie (I) Asp (D) 4.0
There were three Cip resistant isolates altogether with their sensitive controls.
Fortunately the primer T1446 & T1447 (Table 1) designed on N. gonorrhoeae
NGU08817, did work for Moraxella catarrhalis. This experiment focused on
resistant M. catarrhalis KP4/R (14) on its unusual high Cip MIC of 4.0 mg/L.
Interestingly, the evidence showed that its nucleotide sequence was not different at
all from that of its sensitive control strain with MIC of 0.03 mg/L. Table 17
concludes QRDR alterations, only position 83 and 87 were altered, in gyrA of those
Neisseriaceae tested. Both sensitive (13) and resistant (14) catarrhalis had Ile-83
and Asp-87. Thus it can conclude that these two amino acids are normal for
catarrhalis and the difference in sequence might be found in parC sequence.
Additionally, this is probably be the first time that QRDR of the gyrA sequence of
Moraxella has been elucidated. There were 84 nucleotides of the sensitive
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catarrhalis (13), which were different from that of sensitive control N. gonorrhoeae
(9 or 10), resulting in 28 different amino acids (6 within QRDR).
As expected, the sensitive control N. gonorrhoeae KP31267 (10) had no alterations
to that of N. gonorrhoeae NGU08817 (9). Two resistant N. gonorrhoeae KP13843
(11) and KP14240 (12) had 2 amino acid mutations. One mutation that was shared in
common was Ser-83-Phe. The other was Asp-87-Gly for KP13843 (11) and Asp-87-
Asn for KP14240 (12). The difference at 87 is more likely to be responsible for their
difference in MICs.
There were no gyrA amino acid residues found to be associated with Cip resistance
other than those at 83 and 87 in all these clinical N. gonorrhoeae and M. catarrhalis.
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4.6.2.3 RESULT: PARCQRDR SEQUENCE OF
ENTEROBACTERIACEAE
A 475-base region ofparC gene was sequenced and amino acid residues at position
26 to 135 including E. coifs equivalent QRDR (amino acid residues at 67-106)
within brackets are shown below. The E. coli gyrA equivalent codons at 83 and 87
are underlined. From 16) red capitals in resistant sequence indicate nucleotides and
amino acids different from that of ECOPARC or its control and sensitive sequence
and only section where nucleotide changes occurred is shown.
15) Standard Cip sensitive-parC gene ofE. coli ECOPARC, as listed in GENBANK
(g147105), withMIC of<0.031 mg/L (Kato et. al. 1990).
92 atg tac gtg ate atg gac cgt gcg ttg ccg ttt att ggt gat ggt
M Y V I M D R A L P F I G D G
26
137 ctg aaa cct gtt cag cgc cgc att gtg tat gcg atg tct gaa ctg
L K P V Q R R I V Y A M S E L
182 ggc ctg aat gcc age gcc aaa ttt aaa aaa teg[gcc cgt acc gtc
G L N A S A K F K K S A R T V
67
227 ggt gac gta ctg ggt aaa tac cat ccg cac ggc gat age gcc tgt
G D V L G K Y H P H G D S A C
83
272 tat gaa gcg atg gtc ctg atg gcg caa ccg ttc tct tac cgt tat
Y E A M V L M A Q P F S Y R Y
87
317 ccg ctg gtt gat ggt cagjggg aac tgg ggc gcg ccg gac gat ccg
P L V D G Q G N W G A P D D P
106
362 aaa teg ttc gcg gca atg cgt tac acc gaa tcc egg ttg teg aaa
K S F A A M R Y T E S R L S K
407 tat tcc gag ctg eta 421
Y S E L L
135
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16) Six Cip sensitive-parC gene of E. KP 42, 62, 90, 111, 126 and 147
(Malaysia) with MIC of <0.031 mg/L.
• The nucleotide sequence was exactly the same as that of the control
E.coliECOPARC (16).
17) Cip resistant-parC gene ofE. coli isolate KP115 (Malaysia) with anMIC
of 32 mg/L.
• One nucleotide within QRDR were changed resulting in 1 amino-acid mutation:
Ser-83-Ile.
• One nucleotide outside QRDR were changed; no amino-acid mutation.
227 ggt gac gta
G D V




L G K Y
75
atg gtc ctg atg
M V L M
cat ccg cac ggc
H P H G
gcg caG ccg ttc
A Q P F
gat aTc gcc tgt
D I A C
83
tct tac cgt tat
S Y R Y
18) Cip resistant-parC gene ofE. coli isolate KP88 (Malaysia), T281 & T295
(Thailand); all with MICs of 128 mg/L.
• The nucleotide sequence was exactly the same as that ofKP115 (17).
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19) Cip sensitive-/?arC gene of C.freundii CitS (Edinburgh) with MIC of 0.012
mg/L.
In comparison to E. coli ECOPARC (15):
• 6 nucleotides within QRDR were changed resulting in no amino acids different;
• 20 nucleotides outside QRDR were changed; no amino acids different.
92 atg tac gtC ate atg gac AgG gcg ttg ccA ttt att ggc gat ggt
M Y V I M D R A L P F I G D G
26
137 Ttg aaa ccC gtt cag cgT cgc att gtg tat gcA atg tcC gaa ctg
L K P V Q R R I V Y A M S E L
182 ggG ctg aat gcc age gcc aaa ttt aaa aaa tcC[gcc cgt acc gtc
G L N A S A K F K K s A R T V
67
227 ggt gac gtG ctg ggt aaa tac caC ccg cac ggc gaC age gcc tgC
G D V L G K Y H P H G D S A C
83
272 tat gaa gcg atg gtG ctg atg gcg caG ccg ttc tct tac cgt tat
Y E A M V L M A Q P F S Y R Y
87
317 ccg ctg gtt gat ggt cag]ggA aac tgg ggG gcg ccg gac gat ccC
P L V D G Q G N W G A P D D P
106
362 aaa tcC ttc gcg gcG atg cgt taT acc gaa tcc cgC ttg tcT aaa
K S F A A M R Y T E S R L S K
407 tat tcc gag ctg eta 421
Y S E L L
135
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20) Cip resistant-parC gene ofC. freundii isolate T1510 (Thailand) with MIC
of 128 mg/L. In comparison to the sensitive control (19):
• 1 nucleotides within QRDR were changed resulting in no amino-acid
mutation;
• 7 nucleotides outside QRDR were changed; 2 amino-acid mutations:
Ser-132-Ala and Leu-134-Val.
272 tat gaa gcg atg gtg ctg atg gcg caA ccg ttc tct tac cgt tat
YEAMVLMAQPFSYRY
87
317 ccg ctg gtt
P L V
362 aaa tcc ttc
K S F
gat ggt cag]ggG
D G Q G
106
gcg gcg atg cgt
A A M R
aac tgg ggg gcg
N W G A
tat acc gaa tcc
Y T E S
ccg gac gat ccc
P D D P
cgc ttg tct aaa
R L S K
407 tat GcG gaA GtC ctG 421
Y A E V L
132 134
21) Cip sensitive-parC gene ofEnterobacter sakazakii NCTC5920 withMIC
of<0.06 mg/L. In comparison to E. coli ECOPARC (15):
• 11 nucleotides within QRDR were changed resulting in no amino acid different.
• 18 nucleotides outside QRDR were changed; no amino acid different.
92 atg tac gtg ate atg gac cgt
M Y V I M D R
26
137 ctg aaG ccC gtt cag cgc cgc
L K P V Q R R
182 ggG ctg aat gcT age gee aaG
G L N A S A K
227 ggC gac gtG ctg ggt aaa tac
G D V L G K Y
272 tat gaa gcg atg gtG ctg atg
Y E A M V L M
87
317 ccg ctg gtG gat ggC cag]ggg
P L V D G Q G
106
362 aaa tcC ttc gcg gca atg cgt
K S F A A M R
407 tat tcc gag ctg eta 421
Y S E L L
gcg ttg ccg ttt atC ggG gat ggt
ALPFIGDG
atC gtC tat gcg atg tcC gaa ctg
IVYAMSEL
ttt aaG aaa tcC[gcc cgt acc gtc
FKKSARTV
67
cat ccg cac ggc gaC age gcc tgC
HPHGD SAC
83
gcC caG ccg ttc tct taT cgC tat
AQPFSYRY
aac tgg ggG gcg ccg gac gat ccg
NWGAPDDP
taT acc gaa tcc cgC Ctg tcT aaa
YTESRLSK
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22) Cip resistant-parC gene ofEnterobacter sakazakii Til (Thailand) withMIC
of 32 mg/L. In comparison to the sensitive control (21):
• one nucleotide within QRDR was changed resulting in one amino-acid
mutations: Ser-83-Ile;
• two nucleotides outside QRDR were changed; one amino-acid mutation:
Ser-60-Thr.
92 atg tac gtg ate atg gac cgt
M Y V I M D R
137 ctg aag ccc gtt cag cgc cgc
L K P V Q R R
182 ggg ctg aat get aCc gee aag
G L N A T A K
60
227 ggc gac gtg ctg ggt aaa tac
G D V L G K Y
gcg ttg ccg ttt ate ggg gat ggC
ALPFIGDG
ate gtc tat gcg atg tcc gaa ctg
IVYAMSEL
ttt aag aaa tcc[gcc cgt acc gtc
FKKSARTV
67
cat ccg cac ggc gac aTc gcc tgc
HPHGDIAC
83
Table 18 Conclusion of the association ofQRDR alterations in parC of coli,
C. freundii and Ent. sakazakiiwith Cip MICs are shown below.
The amino acid number is that ofgyrA equivalence of coli.
Name and Country
Amino Acid
Number MIC (mg/L)of Cip83 87
15) Sensitive E. coli ECOPARC, GENBANK Ser (S) Gin (E) <0.031
16) Sensitive E. coli (6 isolates), Malaysia Ser (S) Gin (E) <0.031
17) Resistant E. coli KP115, Malaysia He (I) Gin (E) 32
18) Resistant E. coli KP88,
T281 & T295. Malaysia
lie (I) Gln(E) 128
19) Sensitive C. freundiiCitS Edinburgh Ser(S) Gin (E) 0.012
20) Resistant C. freundii T1510, Thailand Ser (S) Gln(E) 128
21) Sensitive Ent. sakazakii NCTC5920, NCTC Ser (S) Gin (E) <0.06
22) Resistant Ent. sakazakii Thailand lie (I) Gln(E) 32
Fortunately, the primers V4640 and V4641 (Table 1) designed on E. colVs gyrA
sequence amplified C. freundii and Ent. sakazakii. Table 18 summarizes QRDR
alterations in parC of these bacteria. ParC sequences revealed here in all nine
Malaysia and Thailand E. coli isolates displayed that there were no unique nucleotide
alterations as had been found in the E. coli's gyrA sequence (2, 3 & 4). In fact, there
were only two nucleotide changes and only detected in 3 resistant E. coli isolates (16,
17 & 18): one was a-298-g and silent, the other was g-264-t causing Ser-83-Ile. This
amino acid mutation was common among the three resistant isolates regardless of
whether the MIC was 32 or 128 mg/L. It is likely, therefore, that the gyrA gene is
more responsible for Cip resistance than parC gene in E. coli.
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A 330-bp sequence of C.freundifs and Ent. sakazakifs parC, including their
QRDR, were revealed for the first time. No difference in amino acids was discovered
between the GENBANK E. colisequence and that of freundii (19); but there were
26 nucleotides different and 6 were within QRDR. Between the sensitive and
resistant C. freundii isolates (20), there were no amino acid changes within QRDR
but two mutations outside QRDR. Neither mutations is likely to have an effect on the
MICs, nor is the Ser-60-Thr of the resistant Ent. sakazakii isolate (22) which is
outside the QRDR. The resistant isolate, however, had a mutation within QRDR:
Ser-83-Ile. Again, there was no difference in amino acid between parC genes of
Ent. sakazakii and the GENBANK E. coli; nevertheless, there were 29 different
nucleotides (11 within QRDR) were found between sensitive Ent. sakazakii
NCTC5920 (21) and the GENBANK E.coliECOPARC (15).
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4.6.2.4 RESULT: PARCQRDR SEQUENCE OF NEISSERIACEAE
A 496-base region of partial parC gene was sequenced and amino acid residues at
position 22 to 147 including E. coli's equivalent QRDR (amino acid residues at 75-
115) within brackets are shown below. The E. coli equivalent codons 83 and 87
are underlined. From 16) the red capitals in the resistant sequence indicate
nucleotides and amino acids different from that ofN. gonorrhoeae NGU08817 or its
control. Only the section where nucleotide changes occurred is shown.
23) Standard Cip sensitive-parC gene of N.gonorrhoeaeNGU08907, as listed in
GENBANK (g529409), withMIC of<0.001 mg/L (Belland et. 1994).
76 etc gaa tac gcc atg age gtg gtc aaa ggc cgc gcg ctg cct gaa
L £ Y A M S V V K G R A L P £
22
121 gtt tea gac ggc caa aag CCC gtg cag egg cgc att ttg ttt gcc
V S D G Q K p V Q R R I L F A
166 atg cgc gat atg ggt ttg acg gcg ggg gcg aag ccg gtg aaa teg
M R D M G L T A G A K P V K S
211[gcg cgc gtg gtc ggc gag att ttg ggt aaa tac cat ccg cac ggc
A R V V G £ I L G K Y H P H G
67
256 gac agt tcc gcc tat gag gcg atg gtg cgc atg get cag gat ttt
D S S A Y £ A M V R M A Q D F
83 87
301 acc ttg cgc tat ccc tta ate gac ggc ate]ggc aac ttc ggt teg
T L R Y p L I D G I G N F G S
106
346 cgc gac ggc gac ggg gcg gcg gcg atg cgt tac acc gaa gcg egg
R D G D G A A A M R Y T £ A R
391 etc acg ccg att gcg gaa ttg ctg ttg tcc gaa ate aat cag ggg
L T P I A £ L L L S £ I N Q G
436 acg gtg gat ttt atg ccg
T V D F M P
147
122
24) Cip sensitive-gyr/4 gene of N.gonorrhoeae KP31267 (Edinburgh) with MIC
of<0.001 mg/L.
• One nucleotide outside QRDR was changed resulting in no amino-acid
mutation.
391 ctG acg ccg att gcg gaa ttg ctg ttg tcc gaa ate aat cag ggg
LTPIAELLLSEINQG
25) Cip resistant-parC gene of N.gonorrhoeaeKP13843 (Edinburgh) withMIC
of 0.004 mg/L.
• Two nucleotides within QRDR were changed resulting in one amino-acid
mutations: Glu-87-Gly.
• One nucleotide outside QRDR were changed; no amino-acid mutation.
256 gac agt tcc gcc tat gGg gcg atg gtg cgc atg get cag gat ttt
D S S A y G A M V R M A Q D F
83 87
301 acc ttg cgc taC ccc tta ate gac ggc ate]ggc aac ttc ggt teg
T L R y p L I D G I G N F G S
106
346 cgc gac ggc gac ggg gcg gcg gcg atg cgt tac acc gaa gcg egg
R D G D G A A A M R Y T E A R
391 ctG acg ccg att gcg gaa ttg ctg ttg tcc gaa ate aat cag ggg
L T P I A E L L L S E I N Q G
26) Cip resistant -parCgene of NgonorrhoeaeKP14240 (Edinburgh) withMIC
of 0.008 mg/L.
• The sequence was exactly the same as that ofN. gonorrhoeae KP14240 (24).
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Table 19 Conclusion of the association ofQRDR alterations in of TV.
gonorrhoeae and M. catarrhalis with Cip MICs are shown below.







23) Sensitive TV. gonorrhoeae NGU08817, Ser (S) Gin (E) <0.001
24) Sensitive TV. gonorrhoeae KP31267, Ser (S) Gin (E) <0.001
25) Resistant TV. gonorrhoeae KP13843, Ser (S) Gly (G) 0.004
26) Resistant TV. gonorrhoeae KP14240, Ser (S) Gly (G) 0.008
Unfortunately, the primers V4642 and V4643 (Table 1) designed on TV.
gonorrhoeae's parC sequence did not work for catarrhalis as stated before in
4.3.2. It is therefore not possible to conclude why catarrhalis (28) had a high Cip
MIC. Table 19 summarizes the QRDR alterations in parC of those in neisseriaceae.
The resistant TV. gonorrhoeae KP13843 (25) had an MIC of 0.004 mg/L and
KP14240 (26) had an MIC of 0.008 mg/L. The latter had exactly the same parC
sequence and only one mutation in QRDR, Glu-87-Gly.
Figure 8 compares all gyrA and parC QRDR amino acids of resistant clinical isolates

















RVVGDVI G K Y H P H GDSAVYDT I VRMA'Q P F S LRYMLVDGO
TIVRMAQ PFSLRYMLVDGQ




TIVRMAQ P F SLRYMLVD GQ
T i vRMAQ^Fgg] YSBLBDGQ
T I VRMAQ| FMRYBLBDGQ
T I VRMAQ|FS0P Y g|L 3D G Q
T I V RMAQ P F S L RYM L V D G Q
TIVRMAQPFSLRYMLVDGQ
RT V G D V LGKYHPHGDSAC YEAMVLMAQ PFSYRYPLVDG
RTVGDVLGKYHPHGDBA C Y EAMVLMAQPFSYRYPLVDG
RTVGDVLGKYHPHGE>(A C Y EAMVLMAQ PFS YRYPLVDG
?TVGDVLGKYHPHGDSACYEAMVLMAQ PFS Y RY P LVP G
RTVGDVLG KY H PH G DS A C Y EAMV LMAQPFS Y R Y P LVD G
RTVGDVLGKYHPHGD SAC Y EAMVLMAQP F S Y RY P LVD G
RTVGDVLGKYHPHGD |ACY EAMV L MAQ PFS Y RYPLVDG
32 ooli 67 ARVVGDVIGKYHPHGD3AVY H
128ooli 67 ARVVGDVIGKYHPHGD LAVY Y
C.freu. ARVVGDVIGKYHPHGDaAVY a
T1510 RVVGDVIGKYHPHGD i AVY a
E. saka. ARVVGDVIGKYHPHGD s AVY D
177 ]\RVVGDVIGKYHPHGD Y AVY 3
N. gono. 75 A R VGDVIGKYHPHGD S AVY D
KP13843 75 A R VGDVIGKYHPHGDFAVY
KP14240 75 A R VGDVIGKYHPHGD FAVY
KP 6/S ARVVGDVIGKYHPHGD 3AVY
KP 4/R ARVVGDVIGKYHPHGD i AVY
71 ARak/G LGKYHPHGDSg YEAMVgjMAQjaftl RY P L DG i
71 ARlVVGei LGKYHPHGDS| YHAMVHmaqHIftl RYPL DG i

























Figure 8 Alignment of amino acid sequences of QRDRs of the gyrA and parC
from clinical bacteria. The numbers at the beginning of the sequences
indicate the first amino acid of the QRDR. Letters in black indicate
sequence identity, otherwise in blue or red. Letters in red indicate
mutation to its sensitive control. Residues at 83 and 87 are marked by
an asterisk.
E. coli = Sensitive Escherichia coli KP42, 62, 90, 111, 126 and 147
32 coli = Resistant Escherichia coli KP115
128coli = Resistant Escherichia coli KP88, T281 & T295
C. freu. = Sensitive Citrobacter freundii CitS
T1510 = Resistant Citrobacter freundii T1510
E. saka. = Sensitive Enterobacter sakazakii NCTC5920
T77 = Resistant Enterobacter sakazakii T77
N. gono. = Sensitive Neisseria gonorrhoeae KP31267
KP13843 = Resistant Neisseria gonorrhoeae KP 13843
KP 14 2 4 0 = Resistant Neisseria gonorrhoeae KP 14240
KP 6/S = Resistant Moraxella catarrhalis KP 6/S
KP 4/R = Sensitive Moraxella catarrhalis KP 4/R
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4.3 CONCLUSION AND DISCUSSION
Partial sequences of the gyrA and parC genes of seven resistant clinical isolates and
their sensitive controls, were determined at least twice separately to assure
reproducible data. All amino acid mutations (shown in red in Figure 8) found in
QRDR of either gyrA or parC genes in all the isolates were at position 83 and 87
only (E. coifs gyrA homologous position). One of the Edinburgh isolates was M.
catarrhalis with an MIC of 4.0 mg/L. No difference was found in the gyrA sequence
between the sensitive (KP6/S) and resistant (KP4/R) strain of M. catarrhalis.
However, no parC sequences of both isolates could be achieved. Consequently, the
resistant mechanism of the M. catarrhalis remains unresolved.
As for the six remaining isolates, they were extremely highly resistant to Cip and
were from Malaysia and Thailand. Four of the six were E. coli and the rest were C.
freundii and Ent. sakazakii. Five had three point mutations: two in gyrA (at 83 and
87) and one in parC (at 83) genes. However, there was no parC mutation in C.
freundii. It is reasonable to conclude that the high resistance in these three bacterial
species was largely a result of the two mutations at gyrA 83 and 87. Further
mutations at parC 83 would produce even higher resistance. Four point mutations at
gyrA 83, 87, parC 83 and 87 could bring the highest level of fluoroquinolone
resistance as found by Vila et. al. (1996), who reported four mutations at 83 and 87
of gyrA and parC in a clinical E. coli found in Spain with the highest ever reported
Cip MIC of 128 mg/L.
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As only mutations at gyrA 83 and 87 were sufficient to generate extremely high
resistance in C. freundii T1510 and no other mutations found in QRDR ofparC, it
reasonably leads to the suggestion that DNA gyrase is the primary target of Cip or
other fluoroquinolones in C. freundii.
The gyrA Ser-83-Leu mutation is of all concern because it was found in common in
all four resistant E. coli isolates examined here and several others with two point
mutations (83 and 87 of gyrA or also parC) and very high to extremely high
resistance (Cip MIC of 8-128 mg/L) (Heisig et. al., 1993; Vila et. al., 1996).
The mutation gyrA Asp-87-Tyr seems to enhance resistance more than any other
mutations at this position 87 as it was found in all three resistant E. coli and one C.
freundii isolates-all with Cip MICs of 128 mg/L. At the same position the less
commonly-found and less resistant mutation was Asp-87-Asn encountered in two
resistant isolate E. coli KP115 and Ent. sakazakii T77 both with a Cip MIC of 32
mg/L. However, KP115 and T77 had a different amino acids substitution at gyrA-%l\
Leu for KP115 and Tyr for T77. This finding is in accordance with the data by Vila
et. al. (1996) that Asp-87-Asn was also detected in several E. coli isolates with Cip
MIC of <_64 mg/L and the E. coli with Asp-87-Tyr had the highest MIC of 128
mg/L.
Instead of "Ser" at gyrA 83, C. freundii have "Thr" and M. catarrhalis have "lie".
These Thr-83 and Ile-83 may provide both bacteria with some intrinsic resistance
against fluoroquinolones according to Huang (1992), who reported Thr at position
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83, instead of Ser, might be sufficient to raise the drug sensitivity by an order of
magnitude as in the cases of Klebsiella pneumoniae and Campylobacter jejuni.
Additionally, Huang (1994) stated that the presence of amino acids other than Ser or
Thr at the 83 position appeared to render bacteria resistance to fluoroquinolone drugs
at even higher levels.
It becomes clear that both amino acid positions 83 and 87, located in QRDR, ofgyrA
play significant role in extremely high resistance in bacteria studies here. The
analogous parC 83 and 87 could also be involved in the resistant phenotype, but less
significant, and parC 83 is likely to be more meaningful than parC 87. Although
point mutations in all these four positions were not discovered in any one clinical
isolate studied here; nevertheless, it is plausible that the homologous mutations at 83
and 87 of gyrA and parC could be a future mechanism that will produce the highest
ever level of fluoroquinolone resistance in bacteria.
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5. MUTUAL ANTAGONISM BY CIP AND RIF
It has been suggested that fluoroquinolones should be used in conjunction with a
second antibacterial in order to prevent the emergence of fluoroquinolonre-resistant
organisms during therapy (Scully et. al. 1986; Farrag et. al., 1986). Clinical trials
have shown that the combinations of Cip with benzylpenicillin, vancomycin (Cell
wall antagonists) (Smith et. al., 1988) or netilmicin (aminoglycoside) are successful
in treating febrile episodes in neutropenic patients (Lewin and Smith, 1990). They
could be used in combination with aminoglycosides or cell wall antagonists (Smith
& Lewin, 1988.)
The use of any other drug together with fluoroquinolones does not necessarily mean
that an improvement will be found in curing bacterial infections. In fact, mutual
antagonism exists. Some drugs antagonise the action of quinolones and so must not
be used clinically with them. For example, sub-inhibitory concentrations of
chloramphenicol, rifampicin, tetracycline, clindamycin and erythromycin all
antagonised the killing activity of nalidixic acid, ciprofloxacin and ofloxacin against
E. coli KL16 (Lewin & Smith 1989). At concentration exceeding their MICs,
novobiocin and coumermycin antagonised their bactericidal activities of nalidixic
acid, ciprofloxacin, ofloxacin and norfloxacin against E. coli KL16 (Lewin & Smith
1989). In general it has been suggested that fluoroquinolones should not be combined
with protein or RNA synthesis inhibitors.
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In an attempt to examine mutual antagonism by chloramphenicol (Cm) and
rifampicin (Rif) against Cip in E. coli NCTC10418, experiments were primarily set
up to investigate the effects of interval exposure and removal of Cm and Rif. This
should reveal the true nature ofmutual antagonism.
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5.1 BACTERIAL RESPONSE AGAINST CIP
5.1.1 Escherichia coli
As mentioned earlier in ANTIBACTERIAL ACTIVITY (page 56) all
fluoroquinolones gave a biphasic bacterial survival curve when a given bacterium is
treated over a range of concentrations during a single time interval. This experiment
aimed to investigate whether some E. coli other than E. coli NCTC10418, had a dose
response curve in the usual biphasic format. It was also to confirm the existence of
the curve for an E. coli so that the bacteria could be used for next experiments.
METHOD
To investigate the response of bacteria to ciprofloxacin (Cip) at various
concentrations, E. coli KL16, E. coli NCTC10418 and clinical E. coli were grown by
adding one loopful of an overnight culture of each strain into a standard vial
containing 10 ml of Iso-Sensitest broth which was incubated by shaking overnight at
37°C. Subsequently, 0.5 ml of these cultures were inoculated into 9.9 ml of
prewarmed Iso-Sensitest broth and shaked at 37°C for 90 minutes. Then 0.1 ml of
these cell suspensions were used as inoculum. After adding inoculum into 9.9 ml of
Iso-Sensitest broth in vials containing various final concentrations ofCip (0.01, 0.02,
0.04, 0.08, 0.16, 0.32, 0.64, 1.28, 2.56, 5.12 and 10.24 mg/L) and no Cip as control,
the cultures were incubated for 180 min at 37°C. Subsequently, spread plating viable
count were performed on Columbia base agar to monitor the response.
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RESULT
It is apparent that both E. coli NCTC10418 and the clinical E. coli showed biphasic
survival curves with MIC at 0.64 mg/L as the single most bactericidal concentration.
However, as seen in Figure 9. E. coli KL16 responded in different way showing a
convex curve, not the usual biphasic, with maximum kill at 10.24 mg/L which was
the highest concentration used here. This ensured that not all E. coli responded to Cip
in the same pattern and E. coli KL16 was more resistant to Cip than those of other E.
coli tested. This is in contrast to the results for KL16 of some other workers and so it
was decided to continue with E. coli NCTC10418.
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This experiment aimed to investigate whether a S. aureus exhibits the same survival
curve as that ofE. coli.
METHOD
The same procedure applied here was the same as that used in 5.1.1 (except that the
highest concentration of Cip was 2.56 mg/L) and the culture was S. aureus
NCTC6571.
RESULT
As seen in Figure 10 S. aureus did not show a biphasic survival curve and was
slightly more resistant to Cip than E. coli NCTC10418 and the clinical E. coli, but
much less resistant compared to E. coli KL16.
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Figure 10 Bacterial survival curves ofStaphylococcus aureus treated with Cip
at concentrations 0-10.24 mg/L.
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5.2 BACTERIAL RESPONSE AGAINST Cip UNDER
PROTEIN INHIBITORS
As it is commonly accepted that antibacterials such as Cm and Rif, antagonise killing
activity of fluoroquinolones but there is no information available on bacterial
response to the drugs when those protein inhibitors are exposed to bacteria before
and after being treated with fluoroquinolones, and when Cip and Rif are removed.
5.2.1 INHIBITOR ADDITION AT 60 MIN AFTER Cip
EXPOSURE
The purpose of this experiment was to examine the response of E. coli NCTC10418
towards Cip when both or each Cm and Rifwere added after Cip.
METHOD
With E. coli NCTC10418 a similar procedure as in 5.1.1 was carried out employing
Iso-Sensitest broth containing Cip at a concentration of 0.64 mg/L. Rif and/or Cm
were added to the medium to the final concentration of 20 mg/L each after 60 minute
of incubation (Table 20)
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Figure 11 Bacterial survival curves ofEscherichia coli NCTC10418 treated
with Cip with Cm and Rif addition at 60 min after Cip exposure.
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RESULT
Figurre 11 showed that when Rif (line 2) or Cm (line 4) or the combination of both
(line 3) were in the medium, E. coli NCTC10418 had slightly less antagonism than
with no addition (line 1). It can be concluded that the bacterial protein inhibitors
antagonised the bactericidal activity of Cip. However, these differences were
considerably less than they were when the drug was added at 30 mins. Perhaps the
longer the bacterium was challenged, the less the antagonist effect. In any case as the
difference of the effect of these three additions at 60 min on the bacteria was so
small, it was considered advisable in the next experiment (5.2.2) to add the protein
synthesis inhibitors earlier.
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5.2.2 Cm ADDITION AT 0, 30 AND 60 MIN AFTER Cip
EXPOSURE AND Cip ADDITION AT 0 AND 30 MIN
AFTER Cm EXPOSURE
This experiment was designed to examine the antagonism of Cip with Cm by
exposing E. coli NCTC10418 to Cm before, after and the same time as Cip
treatment.
METHOD
The procedure carried out here was the same as that in 5.2.1 except that the addition
ofantibacterials to the medium were changed as shown Table 21.
RESULT
In Figure 12 there were more survivors of E. coli NCTC10418 when Cm and Cip
were added at the beginning of the incubation - Cm addition at 0 min (line 6)
compared to that with only Cip (line 3). It was, therefore, apparent that Cm
antagonised Cip bactericidal activity. This antagonism seemed to be less when Cm
was added at either 30 (line 4) or 60 min (line 5) after the bacteria were exposed to
Cip.
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Figure 12 Bacterial survival curves of coli NCTC10418 treated with Cm
before, after and at the same time as Cip.
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The antagonism appeared to be strengthened when the cells exposed to Cm 30 min
prior to the addition of Cip as seen in line number 2 (Cip addition at 30 min). It was
quite clear that the Cip bactericidal activity was much reduced when the organism
was exposed to Cm at the same time as Cip (line 6) or when Cm was added 30 min
prior to Cip (line 2) compared to the survival curve with Cip alone (line 3). In order
to be certain on the antagonism caused by Cm added 30 min before (line 2), the next
experiment 5.2.3 was to investigate the effect ofCm added up to 120 min before Cip.
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5.2.3 Cip ADDITION AT 0, 30, 60, 90 AND 120 MIN AFTER Cm
EXPOSURE
The aim of this experiment was to examine further the antagonism against Cip by
Cm exposing E. coli NCTC10418 up to 120 minutes before Cip treatment.
METHOD
The procedure carried out here was the same as that in 5.2.1 except that the presence
and/or addition ofCip and Cm in the medium was as shown Table 22.
RESULT
The result (Figure 13) showed that the earlier the Cip was added, the more cells were
killed, but the killing rates seemed to be the same for each Cip addition regardless of
time. This revealed that the time difference, at which the bacteria were exposed to
Cm, did not affect the overall bactericidal activity of Cip. In addition Cip activity
against E. coli NCTC10418 was decreased by Cm regardless of the time (0 to 120
min) the bacteria were previously subjected to Cm.
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Tahle 22 Pattern of antibacterial additions of Cm and Cip in experiment 5.2.3
Line
Incubation Time (min)
0 30 60 90 120 150 180 240
l Cm |y«l m is is IS IS
2 Cm Cip is is is IS IS Is
3 ! Cm (S Cip s (Ml IS IS IS
4 Cm is (S Cip IS IS IS (S
5 Cm
| -
|y=l CS is Cip IS (S IS
6 !Cip+Cm OS IS (=1 IS IS IS s
Time (mini
Figure 13 Bacterial survival curves of E. coli NCTC10418 treated with Cm
at the same time and up to 120 before Cip.
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5.2.4 Cip ADDITION AT 0, 30, 60, 90 AND 120 MIN AFTER RIF
EXPOSURE
This experiment was to investigate the effect of Rif added 0 to 120 min before Cip
on bacterial response ofE. coli NCTC10418.
METHOD
The procedure carried out here was the same as that in 5.2.1 except that the presence
and addition ofRif and Cip in the medium were as shown in the Table 23.
RESULT
The result in Figure 14 showed apparently the same pattern as that in Figure 13
emphasizing that both bacterial protein (Cm) and RNA synthesis (Rif) inhibitors
were able to slow down the activity of Cip when added to the organism at least 120
min before the fluoroquinolone. Again the Cip killing rates were nearly the same.
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Table 23 Pattern of antibacterial additions ofRif and Cip in experiment 5.2.4
Line
Incubation Time (min)
0 30 60 90 120 150 180 240
1 Rif b g~) b b b b b
2 Rif Cip b b b b b b
3 Rif b Cip b b b b b
4 Rif b b Cip b b b b
5 Rif b b b Cip b b b
6 Cip+Rif b b b b b b b
Time (mini
Figure 14 Bacterial survival curves ofE. coli NCTC10418 treated with Rif
at the same time and up to 120 before Cip.
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5.2.5 BACTERIAL PROTEIN INHIBITOR REMOVAL AFTER
THE FIRST 30MIN OF INCUBATION.
No study has reported whether or not the antagonism caused by Cm and Rif is
reversible and it is, therefore, important to investigate this. This can be done by
removal Cm and Rif after a fixed period of exposure. Experiments 5.2.5.1 and
5.2.5.2 were set up using the similar procedure as in 5.2.1 except for some
modifications in the addition and removal of Cm, Rif and Cip; the patterns of
addition and removal ofCm are shown in Table 24 and Rif in Table 25.
5.2.5.1 Cm removal
Method
After incubating E. coli NCTC10418 with Cm (20 mg/L) for 30 min, cells were
washed to remove Cm by centrifuged at 3000g for 10 min and put into four vials
containing Iso-Sensitest broth with diferent drugs. Vials contained Cm (20 mg/L),
Cm (20 mg/L)+Cip (0.64 mg/L), none, or Cm (20 mg/L), respectively (Table 24).
The net quantities of the medium were the same as before. The four vials were then
incubated and samples withdrawn for viable counting.
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Result
Bacterial response in Figure 15 showed that Cip perform its bactericidal effect on the
cells previously exposed to Cm (line 4). Nevertheless, bactericidal effect ofCip was
reduced by Cm when they were put together (line 2). As expected E. coli
NCTC10418 grew well (line 3), and remained somewhat stable when Cm had been
taken out (line 1).
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Figure 15 Bacterial survival curves of EcoliNCTC10418 when studied the
effect of Cm removal on antagonism against Cip. (The pattern of




The procedure carried out here was the same as that in 5.2.5.1 except that Rif was
used instead of Cm and the format of addition and removal of the drugs were as
shown in Table 25.
Result
In Figure 16, it was surprising that Cip added at 30 min-incubation time together
with Rif (line 2), was so active against the E. coli previously exposed to Rif for 30
min. The Cip killing activity against the cells (line 2) was the same as that in line 4
with Cip alone (no Rif readded). Therefore, it was concluded that Rif did not
antagonise Cip activity under these conditions. As for the control treatment with no
drugs (line 3) E. coli NCTC10418 started to grow as predicted after Rif was
removed. Another control (line 1) showed that readded Rif still had a killing effect
on the cells previous exposed to Rif.
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Figure 16 Bacterial survival curves of E. coli NCTC10418 when studied the
effect of Rif removal on antagonism against Cip. (The pattern of
addition and removal were as shown in Table 25.)
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DISCUSSION
According to the results from experiment 5.2.3 and 5.2.4, the overall bactericidal rate
of Cip was not changed by period of time (0-120 min) Cm or Rif challenged the
cells. It was confirmed that Cip killing activity was antagonised by both Cm and Rif
on E. coli NCTC10418. These results are in substantial agreement with many
researchers.
It is clear that Cip regained its bactericidal effect throughout the rest of 150 mins of
the experiments (5.2.5.1 & 5.2.5.2) on Cm or Rif 30 min-exposed E. coli when either
Cm or Rif had been removed. When Cm was combined with Cip, the antagonism
against Cip existed on the 30 min Cm-exposed E. coli as there were more survivors
(line 2 in Figure 15) than that with Cip alone (line 4 in Figure 15). In marked
contrast, the antagonism against by Rif vanished on the 30 min Rif-exposed E. coli
as bactericidal activity of Cip stayed unchanged between Cip alone (line 4 in Figure
16) and Cip with Rif (line 2 in Figure 16); the same number of survivors throughout
the rest of 150 mins of experiment. A possible explanation to explain why no such
antagonism by Rif when E. coli NCTC10418 had been exposed to Rif for 30 mins,
requires more information. It might be that the antagonism caused by Cm is
reversible, but it is not by Rif. Nevertheless, we can no longer assume that Rif
antagonises bactericidal activity ofCip on E. coli in all situations.
E. coli NCTC10418 and clinical E. coli did show biphasic survival curve when
treated with Cip. Nevertheless, it can be concluded that not all E. coli responses to
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Cip bactericidal activity by producing the biphasic curve; E. coli KL16 did show a
convex curve, not the usual biphasic one. S. aureus NCTC6571 also did not display
the biphasic but a very common curve caused by any other bactericidal drug.
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6. DISCUSSION
INVESTIGATION OF CIPROFLOXACIN RESISTANCE IN CLINICAL
BACTERIAL ISOLATES
My findings are consistent with the premise that bacterial clinical isolates in Malaysia
and Thailand were highly Cip resistant. In addition, the resistance in these urinary
tract bacterial isolates was among the highest ever reported. The six A. baumannii
found in Malaysia had very high resistance with an MIC of 64 mg/L, and one A.
baumannii had an even higher MIC of 128 mg/L. Although clinical E. coli with high
level resistance to Cip (MIC >1 mg/L) were rare in 1990 (Barry et. al., 1990), we can
no longer assume that this incidence remains low because in 1994, at least, more than
6% of such isolates in Malaysia were resistant, and this figure could be worse in
Thailand. More interestingly, the level of Cip resistance of clinical E. coli from both
Malaysia and Thailand was the highest ever reported. From Malaysia, two E. coli had
unusually high resistance with MICs of 32 and 128 mg/L and two E. coli from
Thailand had MICs of 128 mg/L. Vila et. al. (1994) previously reported the highest
level of MIC against Cip for clinical E. coli was 128 mg/L. Some of the other
screened urinary-tract isolates from Thailand which had remarkably high resistance to
Cip were one C. freundii (128 mg/L), three A. baumannii (128 mg/L) and three E.
spp. (32 mg/L). Bajaksouzian et. al. (1997) had previously reported that the highest
level of resistance for clinical A. baumannii was 64 mg/L. One possible conclusion
for high resistance found in Malaysia and Thailand is likely to be that the drugs have
been used extensively as no strict regulation have been applied, particularly because of
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the high rate of bacterial infection diseases resulting from lower standards of living,
urban overcrowding, poorer sanitation and lower vaccination rates. Ill-informed
attitudes towards the use of drugs, such as minor bacterial infections requiring
antibiotic treatments and faliure to complete the frill dose, could promote the
development of drug resistance. Furthermore, if fluoroquinolones use in farming
practice is proved to have some connection with human bacterial resistance, a large
and prominent agriculture industry in both Thailand and Malaysia might have played a
significant role in the very high prevalence of resistance found in this study. However,
development of resistance to the fluoroquinolones and transfer of that resistance
among animal and human pathogens has been viewed as controversial. The evidence
that antibiotic use in animals was the cause of human bacterial resistance was lacking
or circumstantial and has never been proved (Corpet, 1996; Tollefson, Altekruse &
Potter, 1997).
Some reports suggest there is a possible connection between animal and human
antibiotic resistant bacteria, for example zoonotic microorganisms can be transmitted
to humans through contact with animal populations, either directly or through the
consumption of contaminated food (Tollefson, Altekruse & Potter, 1997). Also, eight
veterinary isolates of E. coli received from the Ministry of Agriculture Fisheries and
Foods in the United Kingdom had fluoroquinolone resistance due to a mutation at
gyrA Ser-83-Leu with a Cip MIC of 2 mg/L (Everett et. al., 1996). Furthermore,
veterinary salmonella isolates of Salmonella spp. had gyrA Ser-83-Phe and Asp-87-
Gly mutations. There is also a possible link between the use of avoparcin (a
glycopeptide showing cross-resistance to medically important glycopeptides), the
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selection of Vancomycin-resistant enterococci (VRE) found in sewage, from stools of
healthy farm animals and animal products, and and humans becoming colonized via
the food chain (Bates, 1997).
With the highest MIC of Cip ever found, this study supports the report of Turnidge
(1995) that developing countries showed higher antibiotic resistance as these
countries often allow quinolones to be freely available over the counter for urinary
tract and other simple infections. The findings of this thesis, including the Cip-
resistant Moraxella catarrhalis (MIC of 4 mg/L) found in Edinburgh, points to the
concern as to what these bacteria have in common that allows them became so highly
resistant.
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GENETIC CHARACTERISATION OF MUTATION IN THE QRDR OF
GYRA AND PARC GENES OF CIP RESISTANT BACTERIA OF CLINICAL
ISOLATES
Mutation at 83 and 87 and number ofmutations
Resistance to fluoroquinolones is mediated via mutations giving altered amino acids in
the quinolone resistance determining region of DNA gyrase and topoisomerase IV.
Specific amino acids within gyrA or parC QRDR correlate with sensitivity against
fluoroquinolones because the two sequences code for a specific part ofDNA gyrase
and topoisomerase IV, respectively, which are the molecular targets of
fluoroquinolone antibiotics. In addition, according to previous studies (Hallett and
Maxwell, 1991; Oram & Fisher, 1991; Ruiz et al., 1995; Yoshida et al., 1990a) and
confirmed by this study, the important positions for mutations are at 83 and 87 in both
gyrA and parC genes; mutations here are associated with a significant increase in the
resistance towards all quinolones. In fact, this study found no changes in positions in
QRDR other than 83 and 87 in all the nine resistant isolates. Therefore, the significant
difference in sensitivity towards fluoroquinolones must involve these crucial 83 and 87
positions. The factors surrounding these four gyrA and parC 83 and 87 positions that
determine their effect on resistance are (1) that either DNA gyrase or topoisomerase
IV is the primary target, (2) in which position is the mutation, (3) the number of
mutations and (4) the types of amino acids before and after mutation at these
positions.
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(1) DNA gyrase or topoisomerase IV as the primary target
When both gyrA and parC QRDR of a given bacterium are known, it is clear that
mutations at positions 83 and 87 in either gyrA or parC genes are more significant
than the others in the manifestation of resistance against fluoroquinolone antibiotics.
The explanation is that either DNA gyrase or topoisomerase IV is a primary molecular
target of fluoroquinolones. It is clear that DNA gyrase mutations at gyrA 83 and 87
are more influential than the mutations at parC 83 and 87 in conferring resistance for
bacterial species whose DNA gyrase is the primary target of fluoroquinolone drugs,
such as E. coli (Reece & Maxwell, 1991), E. cloacae (Deguchi et. el., 1997b), K.
pneumoniae (Deguchi et. el., 1997c). Similarly, mutations at parC 83 and 87 are
more influential for those species whose topoisomerase IV is the main target, such as
S. pneumoniae (Pan et. al., 1996; Munoz & Delacampa, 1996), S. aureus (Campa et.
al., 1997; EY, Trucksis & Hooper. 1996; Ferrero et. al., 1994; Hooper, 1995).
Topoisomerase IV might also be the primary target in the case of E. faecalis
(Kanematsu et. al., 1998).
(2) The mutation position
It seems that amino acid substituting for Ser at mutation gyrA 83 can either be Leu,
Iso, Tyr, or Phe as found in this study. Which amino acid is substituted does not have
an important role in the level of resistance; it is the loss of serine at position 83 that is
more significant than the substituting amino acid. However, mutation at this position
is a basic requirement for the bacterium to become resistant.
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GyrA and parC 83 code for Ser which is considered a direct quinolone-binding site of
the enzymes (Maxwell, 1992). Mutations at these positions are therefore a basic
requirement for high resistance. Yonezawa et. al., (1995b) suggested that the Asp-87
ofgyrA gene interacts with quinolone drugs. That suggestion must also apply to Glu-
87 ofparC gene which is homologous to gyrA gene. In fact Glu and Asp are both
acidic amino acids and act in a very similar manner. It is probable that the position 87
might be another binding site of the quinolone as mutations at this position alone have
an effect on fluoroquinolone sensitivity more or less than that of the same bacterium
with a mutation at 83 alone. When mutations occurred at both position 83 and 87,
fluoroquinolone resistance is much higher than that when only one mutation is present
either at position 83 or 87. In addition, it is certain that mutations at both 83 and 87
ofeither gyrA orparC genes (,gyrA 83 and 87 or parC 83 and 87) are more significant
than two mutations at both 83, or both 87 of gyrA or parC. So for maximum effect
the two mutations must occur in the same gene. Based on published data, very high
fluoroquinolone resistance (Cip MIC of >16 mg/L) seems to require at least two
mutations which are usually at gyrA 83 and 87 in the case of E. coli whose primary
target for fluoroquinolones is gyrA. Additionally, two mutations at parC 83 and 87
occurred in E. coli would produce a lower level of resistance (Cip MIC of <16 mg/L).
An E. cloacae which had a very high Cip MIC of 25 mg/L had two mutations in gyrA
at Ser-83 and Asp-87 and no mutation parC (Deguchi et. al., 1997b). Similarly, for
those whose primary target is topoisomerase IV such as the Gram-positive bacteria,
the two mutations needed for high fluoroquinolone resistance must be at parC 83 and
87, rather than gyrA 83 and 87 (Ferrero et. al., 1994; Hooper, 1995; Campa et. al.,
1997).
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Other point mutations in gyrA or parC QRDR are of less influence as their effects are
insignificant on sensitivity. Generally, as far as the type of substituting amino acid is
concerned, mutations in QRDR other than at the position 83 and 87 do not play an
important role on the level of resistance. However, there may be some particular
substitutions in particular species of substituting amino acid at the positions other than
at 83 and 87 that raise the level of resistance significantly. An example of this was
found by Cambau et. al. (1992) who showed that an E. coll with one mutation at
gyrA Gly-81-Asp had a Cip MIC of 16 mg/L. This mutation did appear to increase the
MIC and has been found on just one occasion. However, it is possible that the high
resistance reported by Cambau et. al. (1992) is largely due to mutations inparC genes
because the researchers did not look at topoisomerase IV which was unknown at that
time. This comment is probably true for some other previous studies and we would
need more information on the parC sequence to gain more understanding of the
resistance mechanism of bacteria through a combination of mutations in gyrA and
parC genes. Consequently, only those published results with information on both
gyrA and parC QRDR will be directly compared with the data reported in this thesis.
They are probably the only sets that are fully valid.
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(3) Numbers ofmutations
The one simple conclusion about the number of mutations at positions 83 and 87 is
that the more mutations, the higher the resistance against fluoroquinolones. It appears
that two mutations at 83 and 87 positions in both gyrA and parC is the most efficient
way for a bacterium to become highly resistant to fluoroquinolones. In this state we
can probably assume that the drugs would not bind properly to the two target
enzymes. In general, the more mutations, the higher level of resistance in all bacterial
species, both Gram-positive and Gram-negative.
(4) Types of amino acids before and after mutations
Sensitive strains of C. freundii have a Thr at gyrA 83 instead of the Ser. M.
catarrhalis has lie at this position. These substitutions, Thr-83 and Ile-83, may
provide both bacteria with some intrinsic resistance against fluoroquinolones. Huang
(1992) reported Thr at position 83 instead of Ser might be sufficient to raise the drug
sensitivity by an order of magnitude as in the cases of Klebsiella pneumoniae and
Campylobacter jejuni. Additionally, Huang (1994) stated that the presence of amino
acids other than Thr at the 83 position appeared to render even higher intrinsic
resistance to fluoroquinolones.
The type of substituting amino acids may also play an important role in resistance.
Tyrosine (Tyr) at gyrA Asp-87 mutation probably increases fluoroquinolone
resistance more than by Asparagine (Asn) at the same position. In this study it seems
that mutation gyrA Asp-87-Tyr was the only difference that caused three resistant
isolates of E. coli {gyrA Ser-83-Leu, Asp-87-Tyr & parC Ser-83- lie) to have a
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higher MIC of 128 mg/L than another E. coli isolate (gyrA Ser-83-Leu, Asp-87-Asn
& parC Ser-83- lie) with Asn at the same position as Tyr and a lower MIC of 32
mg/L. The substitution of Tyr at position gyrA Asp-87 was associated with the
highest MIC level in a C. freundii isolate (MIC of 128 mg/L) together with another
one more mutation gyrA Thr-83-Iso. Furthermore, this study showed that the
substitution of Asn at position gyrA Asp-87 was associated with an MIC of 32 mg/L
in a resistant isolate ofEnt. sakazakii (gyrA Ser-83-Tyr, Asp-87-Asn, & parC Ser-83-
Ile). The higher resistance associated with Tyr substitution rather than Asn is in
accordance with the report on E. coli by Vila et. al. (1996) who showed that the gyrA
Asp-87-Tyr substitution occurred in several isolates, for example the substitutions
(gyrA: Ser-83-Leu, Asp-87-Tyr & parC: Glu-87-Lys) produced a Cip MIC of < 64
mg/L while gyrA Asp-87-Asn caused a lower Cip MIC of 8 mg/L in some other
isolates (gyrA: Ser-83-Leu, Asp-87-Asn & parC: Glu-87-Lys). There are further
individual examples of Tyr and Asn substituting at gyrA Asp-87, as well as some
alternative substituting amino acids causing increased resistance at position 83 and 87.
There are also examples of other different substituting amino acids at other mutation
sites occurring in the same organism.
The role of the substituting amino acid in certain positions on fluoroquinolone
resistance needs more investigation to correlate its effect on resistance level,
especially when there are three or more different mutations and different substituting
amino acids.
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Relations ofORDR mutations and their sensitivity in the nine Cio resistant isolates
Among all the nine Cip-resistant isolates in this study, all amino acid mutations
(shown in red in Figure 8) found in QRDR were only at position 83 and 87 of gyrA
and parC genes. The number of mutations and whether they were in gyrA or parC
genes can be used to categorise these resistant 9 isolates:
(1) four isolates with three mutations at positions gyrA 83 and 87 and parC 83:
- E. coli KP88, T281 and T295 with anMIC of 128 mg/L
(gyrA Ser-83-Leu, Asp-87-Tyr & parC Ser-83- He),
- E. coli KP115 with an MIC of 32 mg/L
(gyrA Ser-83-Leu, Asp-87-Asn & parC Ser-83- lie) and
- Ent. sakazakii (T77) with anMIC of 32 mg/L
(gyrA Ser-83-Tyr, Asp-87-Asn, & parC Ser-83-Ile)
(2) one isolate with two mutations at positions gyrA 83 and 87:
C. freundii T1510 with an MIC of 128 mg/L
(gyrA Thr-83-Iso & Asp-87-Tyr)
(3) one isolates with two mutations at gyrA 83 and parC 87:
- N. gonorrhoeae KP14240 with anMIC of 0.008 mg/L
(gyrA Ser-83-Phe & parC Gln-87-Gly)
(4) one isolate with one mutations at gyrA 83
- N. gonorrhoeae KP13843 with anMIC of 0.004 mg/L
(gyrA Ser-83-Phe)
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(5) one isolate with not-fully-known numbers ofmutations due to unsolvedparC
sequence
- M. catarrhalis KP4/R with an MIC of 4 mg/L
(no mutations at gyrA QRDR)
The relations between those mutations and level of resistance can be explained based
on the factors. Three mutations (category 1) were found in four Enterobacteriaceae
isolates: the first two were identical in E. coli (gyrA Ser-83-Leu, Asp-87-Tyr & parC
Ser-83-Ile) which had the highest ever reported MICs of 128 mg/L, the third was a
single E. coli isolate (gyrA Ser-83-Leu, Asp-87-Asn & parC Ser-83-Ile) with an MIC
of 32 mg/L, and the last was one Ent. sakazakii isolates (gyrA Ser-83-Tyr, Asp-87-
Asn & parC Ser-83-Ile) with an MIC of 32 mg/L. This is a result of the high numbers
ofmutations at the position 83 and 87 and two mutations occurred at gyrA 83 and 87
coding for both binding-site amino acids of their primary target DNA gyrase. In the
case of E. coli, the reason that one isolate was less resistant (32 mg/L) could be due
to the only identifiable difference which was an Asn at position gyrA Asp-87, and the
other E. coli isolates in this category had Tyr, (which is less polar then Asn).
Mutation Asp-87-Asn was also found in the Ent. sakazakii isolate which had the same
lower MIC level as found in the E. coli isolate with the same Asp-87-Asn. Both E.
coli and Ent. sakazakii would be less resistant if there were fewer mutations and
mutation at parC 83 would be less significant than that at gyrA 83 and 87. This can be
seen in the case of E. coli in Table 4. Moreover the resistance of these four isolates
could be stronger if there is one more mutation at parC 87 as this would change all
binding sites of both homologous enzymes.
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Two mutations (category 2) caused a resistant C. freundii isolate (gyrA Thr-83-Iso &
Asp-87-Tyr) which also had very high MICs of 128 mg/L. Once again, for the same
reason as above, the two mutations are contributory to resistance as they code for
both of the binding-site amino acids of fluoroquinolone molecular target. This isolate
would become more resistant if there are more mutations at positionparC 83 and 87.
Two mutations (category 3) caused a small degree of resistance in the isolate N.
gonorrhoeae KP14240 (MIC of 0.004 mg/L). This is also true in some other studies.
In the case ofE. coli with mutation category 3 is likely to have a Cip MIC less than
32 mg/L; for example, an E. coli with mutation gyrA Ser-83-Leu & ParC Glu-87-Lys
had a Cip MIC of 4 mg/L Vila et. al., 1996). Despite the same number of mutations,
mutation category 3 is less significant than those in category 2 which generates the
assumption that substitution ofnot one but both binding sites of either DNA gyrase or
topoisomerase IV is required for fluoroquinolones to block the two essential enzyme
acitivities. In other words, both mutations at either gyrA or parC 83 and 87 are more
critical than that at gyrA Ser-83 and parC Glu-87 found in the isolate KP14240, and
than any other relevant combinations of the two mutations.
Nevertheless, there is a special case ofmutation category 3 found in an E. coli with an
MIC as high as that ofmutation category 1. (See the section "4 Types of amino acids
before and after mutations" for an explanation.
One mutation (category 4) produced lower resistance levels than that caused by
mutation category 3. In this study N. gonorrhoeae KP13843 had a single mutation at
gyrA Ser-83-Phe and a MIC of 0.004 mg/L which was less than that of the same
164
species N. gonorrhoeae KP14240 (MIC of 0.008 mg/L). The reason that mutation
category 4 was less resistant than that in mutation category 3 is due to fewer numbers
mutations at the position 83 and 87. However, the difference between these two
categories is not much. Based on published data, it is likely that some other type of
substituting amino acid in all 3 potential mutation sites in these category 3 and 4
isolates could make a considerable difference in the level of resistance between these
two N. gonorrhoeae, making them much closer or further away or even make the
resistance level caused by category 4 higher than that caused by category 3.
The sensitive (KP6/S) and resistant (KP4/R) isolates of M. catarrhalis had no
mutations in gyrA QRDR as well as no difference in the whole region of gyrA
sequence studied here and their parC sequence was not achieved. Consequently, the
definite resistance mechanism of the M. catarrhalis cannot be concluded. It is,
however, assumed that mutations at parC gene would be responsible for the 4 mg/L
resistance ofM. catarrhalis KP 4/R, and, as such, topoisomerase IV is believed to be
its primary target of fluoroquinolones.
As stated earlier, the type ofmutations at 83 and 87 also plays an important role and
could increase, by two or three magnitudes of the Cip resistance level. While only
mutations at gyrA 83 and 87 were sufficient to produce extremely high resistance in
C. freundii T1510 and no other mutations found in the QRDR ofparC, it leads to the
reasonable suggestion that DNA gyrase is the primary target of Cip or other
fluoroquinolones in C. freundii. It is probable that Ent. sakazakifs DNA gyrase is the
primary target of fluoroquinolones as the pattern of point mutations was the same as
in E. coli. In the case of M. catarrhalis, although no parC gene sequence was
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revealed, it is believed that its topoisomerase IV is the primary target of
fluoroquinolones like S. aureus (Campa et. al., 1997, Ferrero et. al., 1994; Ferrero,
Cameron & Crouzet, 1995; Hooper, 1995) as there were no mutations discovered in
the gyrA gene.
One plausible conclusion could be that mutations in gyrA and/or parC at position 83
and 87 are the most important for all fluoroquinolone resistance. Although point
mutations in all these four positions were not discovered in any one clinical isolate in
this research; nevertheless, it is convincing to suppose that the homologous mutations
at 83 and 87 of gyrA and parC could produce the highest ever level of
fluoroquinolone resistance. Specifically, the four point mutations could be
gyrA Ser-83-Leu/Iso/Phe/Ile/Tyr/Trp,
gyrA Asp-87-Tyr/Asn/Lys/Val/Glu/Ala/Phe/Ser,




The silent mutations in gyrA of ten clinical isolates of both Cip-sensitive and -resistant
E. coli were also unique in the type of substituting base: c-438-t, c-456-t, t-483-c and
t-516-c. These surprising four unique mutations could be used as a reference to
demonstrate if an E. coli isolate is close to those of E. coli from Malaysia and
Thailand.
Malaysia and Thailand perhaps share the same clinical bacterial reservoir
It is quite likely that clinical E. coli in Malaysia and Thailand were very close or they
were the same isolate. This was inferred from the fact that resistant E. coli isolates
with the same MIC of 128 mg/L: one from Malaysia and two from Thailand, shared
the same complete both gyrA and parC nucleotide sequence of 1032 bp and, in
addition, these three E. coli shared the same four one point-nucleotide silent
mutations with five sensitive and one resistant E. coli from Malaysia; these silent
mutations were not found in any GENBANK sequences and so they are unique. These
findings implied that these ten clinical E. coli isolates were from the same source or
the spread of the bacteria between these two neighbouring countries was very
common. It is therefore plausible to assume that Malaysia and Thailand share the
same clinical bacterial reservoir and that these are a quite distinct class of E. coli,
different from those in western industrialised countries.
Primer Design
Although the approach of revealing unknown gyrA and parC sequences of some
bacteria in this research here, by designing primer sequence on conserved regions of
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E. coifs and N. gonorrhoeae's sequences, is not always ideal; it does work. As a
result, part of both gyrA and parC of C. freundii and Ent. sakazakii and gyrA ofM
catarrhalis have been revealed for the first time. These known sequences are, of
course, vital points of information for accomplishment of those whole sequences of
the bacteria and perhaps of other close related bacteria. Unfortunately, the approach
did not work in case ofM. catarrhalis's parC gene and the reason must be that the
primer sequence just simply did not match parC sequence of the bacteria as hoped. It
is likely that conserved regions, from where the primers were designed, between M.
catarrhalis and N. gonorrhoeae are different. At least this slim chance had been well
aware as to the fact that percentage of nucleotides different betweeen the gyrA
sequences (321 bp) of sensitive M. catarrhalis (13) and N. gonorrhoeae NGU08817
(9) were as much as 25%: 84 nucleotides different resulting in 28 amino acids
different (6 within QRDR). The only time-saving method to determine the M.
catarrhalis''s parC sequence is again to follow the same approach but improve the
design of the primer sequence based on parC sequence of P. aeruginosa (PSEGAS),
not on N. gonorrhoeae, since these bacteria share a higher degree of similarity (96%)
in gyrA sequence than that ofN. gonorrhoeae (74%). It might as well be a good idea
to choose other conserved regions further away from QRDR.
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First published sequence
This is the first report on the sequences of the gyrA and parC QRDR of C. freundii
and E. sakazakii, and gyrA QRDR ofM. catarrhalis. When compared the nucleotide
sequences to the database ofNCBI, BLAST (http://www3.ncbi.nlm.nih.gov/BLAST/)
for similarity, the result are shown below:
• gyrA sequence (page 104?) of C. freundii CitS (5) was closest to Klebsiella
pneumoniae (KPGYRA) with 91% (413/451) identity, and with 88% (400-451)
identity with E. coli (ECGYRA).
• parC sequence (page 118?) of C. freundii CitS (19) was closest to E. coli
(ECU28377, ECAE000384 and ECOPARC) with 92% (304/330) identity, and
with 88% (290/329) identity with Salmonella typhimurium (STYPARCF).
• gyrA sequence (page 106?) of Ent. sakazakii NCTC5920 (7) was closest to
Klebsiella pneumoniae (KPGYRA) with 91% (411/451) identity, and with 90%
(406/451) identity with E. coli (ECGYRA).
• parC sequence (page 120?) of Ent. sakazakii NCTC5920 (21) was closest to E.
coli (ECOPARC) with 91% (301/330) identity, and with 89% (293/329) identity
with Salmonella typhimurium (STYPARCF).
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• gyrA sequence (page 113?) of M. catarrhalis KP 6/S (13) was closest to P.
aeruginosa (PSEGAS) with 96% (308/320) identity, and with 77% (246/319)
identity with E. coli (ECGYRA). However, it shared only 74% (233/312) identity
with N. gonorrhoeae (NGU08817) whose sequence had been used for the M.
catarrhalis primer design.
As expected, parC sequence of C. freundii is closest to that of E. coli than any
others [with only 65% (174/265) identity with K. pneumoniae (KPGYRA)].
Surprisingly, the gyrA sequence of C. freundii is closer to that of K. pneumoniae
(KPGYRA) than that ofE. coli (either those in Europe, the U.S.A. or th Asian strains
described here) whose sequence had been the basis for the primer design. Similarly,
the parC sequence ofEnt. sakazakii, is closest to that of E. coli but its gyrA is closer
to Klebsiella pneumoniae than that of E. coli. Again M. catarrhalis is not closest to
that ofN. gonorrhoeae whose sequence had been used for the primer design, but is, in
fact, closest to P. aeruginosa (PSEGAS, L29417).
This study has shown the direction in which some clinical bacterial isolates became
very highly resistant to fluoroquinolones. It is clear that point mutations at gyrA Ser-
83, Asp-87, parC Ser-83 and Gln-87 are the most important mechanisms used by
bacteria to overcome the fluoroquinolones. The greater the number of mutations in
these four positions, the higher fluoroquinolone resistance is. The type of substituting
amino acid in those mutations also play significant role in magnitude of resistance.
Either mutation in "gyrA 83 and 87" or "parC 83 and 87" is more pronounced from
one bacterium to another depending on whether DNA gyrase or topoisomerase IV is
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their primary target of fluoroquinolones. There is a unique nucleotide sequence found
in form of silent mutation, of E. coli from Malaysia and Thailand. It is assumed that
Malaysia and Thailand had high levels of fluoroquinolone resistance and they both
shared the same clinical bacterial reservoir, especially in case of E. coli. The gyrA
sequence ofM. catarrhalis's is closer to that of P. aeruginosa rather than that of N.
gonorrhoeae, and this relation may well apply to their parC sequence. The gyrA
sequence of C. freundii and E. sakazakii is closer to that of K. pneumoniae
(KPGYRA) rather than that ofE. coli.
When the aim of the research is to find out the mutations that are responsible for the
fluoroquinolone resistant mechanisms, it is recommended that not just gyrA genes, but
also parC genes, are sequenced. Wide-scale resistance to quinolones is expected soon
to develop further if existing fluoroquinolones are used irrationally. The main causes
of the drug resistance are wide including careless use of the drugs, and that not being
used to their maximum potential. There are potential solutions. In chemotherapy, it is
perhaps necessary to combine one or two more appropriate drugs of different classes
whenever a single agent of fluoroquinolones is needed in order to preserve, for the
future, the antibacterial potency of fluoroquinolones especially against MRSA S.
aureus and P. aeruginosa. To alleviate the future serious problem of antibiotic
resistance, modification of antibacterial policies and specific measures to counteract
the spread of such strains, inappropriate public attitudes towards the use of antibiotics
in some countries like Thailand should be changed. Furthermore, much more attention
should be paid to infection control.
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MUTUAL ANTAGONISM OF CIP BY CM AND RIF
The accepted perception of the bactericidal action of the fluoroquinolones has been
the biphasic dose response demonstrated by Smith (1986). This study shows that
ciprofloxacin had a similar biphasic dose response with E. coli NCTC 10418 as had
been demonstrated previously with E. coli KL16 (Smith 1986). The results of this
study demonstrated that E. coli KL16 did not give a biphasic dose response. The
reason for this discrepancy with the previous literature is unclear but probably results
from failure in maintaining strain integrity. Nevertheless, the results for E. coli NCTC
10418 were as expected and this strain was used throughout the result of the study.
The results with Staphylococcus aureus NCTC 6571 showed that ciprofloxacin was
unable to produce a biphasic dose-response curve and that this Gram-positive strain,
like others Gram-positive, did not follow the classic dose-response profile of
ciprofloxacin challenge (Lewin & Smith, 1989; Smith & Lewin, 1988). Whether all
other Gram-positive bacteria respond in the same manner is unknown.
The traditional method of examining the bactericidal response is to determine the kill-
rate at the maximum bactericidal concentration (Smith, 1986). When E. coli NCTC
10418 was challenged at this concentration (0.64 mg/L), the action of the drug could
be antagonised by the subsequent addition ofCm or Rif. This is exactly the same as
that reported by Smith et. al. (1984a) and has been interpreted that there are two
bactericidal mechanisms (A and B). Mechanism A is that part of the killing process
that requires protein synthesis and is thus inhibited by Cm (protein synthesis inhibitor)
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or Rif (RNA polymerase inhibitor). Mechanism B is that part which was deemed as
protein synthesis independent.
Much of the previous work had concentrated on adding the inhibitors 30 minutes after
ciprofloxacin. The initial studies in this thesis added the inhibitors at 60 minutes. The
effects of these inhibitors appeared correspondingly less effective than those in the
published literature (Smith, 1986; Smith et. al., 1988). In other words, the inhibition
ofprotein synthesis seemed less important. Therefore, was the kill at this stage due to
Mechanism B?
When Cm was added earlier in the experiment it had a greater effect. The results
adding Cm at 30 minutes after Cip showed marked similarities with published
literature (Smith, 1986). Addition of Cm at the same time as Cip showed an even
greater effect and if Cm was added 30 minutes before Cip, the effect was to reduce
significantly the bactericidal effect of Cip. The earlier the Cm was added, the more
prominent was the effect of Mechanism A and the less influence of Mechanism B.
TThis suggests that protein synthesis occurs immediately on Cip challenge and any
interference with this significantly reduces the bactericidal effect of this
fluoroquinolone.
This experiment was extended so that Cip was added up to 120 minutes after Cm.
The net result was that Cip was then incapable ofproducing a bactericidal effect. The
conclusion from this must be that all killing by ciprofloxacin needs protein synthesis at
some stage. This questions the role or existence of protein synthesis-free
fluoroquinolone-induced death or mechanism B. When the RNA polymerase
173
inhibitor, Rif, is added at the same time intervals before Cip challenge, the same
results are found, confirming that both transcription and translation are required to kill
the cell with Cip.
The inhibition of protein synthesis is reversible. When Cm is added before Cip, then
washed out of the cells and ciprofloxacin added, then the fluoroquinolone kills the
bacteria. In marked contrast the antagonism by Rif vanished on the 30 min Rif-
exposed E. coli as the bactericidal activity of Cip remained unchanged between Cip
alone and Cip with Rif; there were the same number of survivors throughout the rest
of 150 mins of experiment. It might be that the antagonism caused by Cm is
reversible, but it is not by Rif. Nevertheless, we can no longer assume that Rif
antagonises bactericidal activity ofCip in E. coli in all situations.
The conclusion from this section is that protein synthesis is required for all death with
ciprofloxacin. It is known that SOS repair is needed (Howard, Pinney and Smith,
1993b) and this requires active protein synthesis. However, these results show that
long-term protein synthesis is required not only to initiate cell death but some
continued protein synthesis is required to sustain it. It is likely that there is more than
one direct mechanism of action, perhaps the dual targets of the GyrA and ParC
proteins may set off different death cascades. However, all these death cascades
require protein synthesis, at some stage.
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APPENDIX
catenane: A complex of two or more circular nucleic acid molecules interlocked like
links in a chain (Singleton & Sainsbury. 1988).
catenate: (1) (verb) To interlock circular nucleic acid molecules to form a catenae
(hence noun catenation). (2) (adj.) Of e.g. spores: formed in chains (Singleton
& Sainsbury. 1988).
chloramphenicol: An antibiotic produced by Streptomyces venezuelae and also made
synthetically. It is bacteriostatic for a wide range of Gram-positive and Gram-
negative bacteria; it also inhibits vegetative growth and sporulation in certain
fungi. The antibiotic binds to the 5OS subunit of prokaryotic and mitochondrial
ribosomes. it inhibits peptidyl transferase and hence protein synthesis.
Resistance to chloramphenicol is commonly due to a plasmid-specified
enzyme, CAT, which catalyses an acetyl-CoA-dependent acetylation of the
antibiotic at the C-3 hydroxy group to form a compound with little or no
antibiotic activity. Chloramphenicol antagonizes those antibiotics (e.g.
penicillins ) which inhibit only actively growing and dividing bacteria. Its
clinical usage is limited by its toxicity (Singleton & Sainsbury. 1988).
rifampicin: A semisynthetic antibiotic of a family of highly substituted macrocyclic
antibiotic (ansamycins) produced by Nocardia mediterranei. Rifempicins
specifically inhibit eubacterial DNA-dependent RNA polymerase, binding to
the P subunit and inhibiting inintiation of transcription. They do not inhibit
mammalian RNA polymerase or bacterial primase (Singleton & Sainsbury.
1988).
(DNA) topoisomerase Any enzyme which converts one topological isomer of
cccDNA to another; for example, most or all topoisomerases can alter the
linking number (a) of a cccDNA molecule (thus altering its degree of
supercoiling), and some can form and resolve knots and catenanes (i.e., the
reaction may be inter- or intramolecular). All such topological conversions
must involve transient breakage of DNA strands (Singleton & Sainsbury.
1988). There are two type of topoisomerases; TYPE I and TYPE II.
Type I (DNA) topoisomerases A topoisomerase I (also called untwisting, relaxing, or
nick-closing enzymnes or swivelases) that break only one DNA strand; in a ds
cccDNA molecule, the unbroken strand is passed through the break before
resealing, thus changing a in steps of one. An example of a type I
topoisomerase is the co (omega) protein (DNA topoisomerase I) of
Escherichia coli (E. coli topoisomerase I or 'topo I'); this enzyme efficiently
relaxes negatively (but not positively) supercoiled DNA, can introduce
topological knots into ss cccDNA, and can convert complementary ss
cccDNA circles into completely base-paired ds cccDNA. The o protein is
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necessary e.g.for chromosomal DNA replication (Singleton & Sainsbury.
1988).
Type II (DNA) topoisomerase A topoisomerase II that break both strands of a ds
cccDNA molecule; a (double-stranded) segment of DNA from elsewhere in
the molecule is then passed through the break (without strand rotation) before
re-sealing : this leads to changes in a in steps of two. Enzyme of both types
have been found in prokaryotic and eukaryotic cells. Type II topoisomerases
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